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CHAPTER 1.
General introduction
Aims and Outline
*The title of the drawing is ‘café-au-lait’; 
so called ‘café-au-lait’-spots are a distinguishing feature of NF1
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Alexander* is a boy who is 14 years old when he comes to see the pediatrician and the pediatric neurologist 
of the outpatients’ clinic for neurofibromatosis type 1 (NF1).  Since he was 1 ½ years old, his parents and 
medical specialists thought he could have NF1, which was genetically confirmed when Alexander was six. 
Next to medical help in an academic hospital, he already had physical therapy, speech/language therapy, 
and psychological support. At the age of seven, psychological assessment points out he has average 
intelligence and a year later, autism with some characteristics of ADHD (attention-deficit/hyperactivity 
disorder) is being diagnosed at the psychiatry department of the hospital. A rehabilitation physician sees 
Alexander to treat his chronic complaints of fatigue and pain.  
Alexander comes with his parents to the NF1 Expertise Center of the Erasmus Medical Center 
(Erasmus MC) Sophia children’s hospital because, in the other hospital, the specialists feel they do not have 
enough experience in dealing with NF1 in association with autism. In the neuropsychological evaluation, his 
limitations in processing speed, executive, and sensorimotor functions appear to affect his motivation, his 
activity level, and his all-over performance at school. To discuss these limitations and their impact on the 
daily life of Alexander and his family, Alexander and his parents see the psychologist of the expertise center 
for consultations every two months. Alexander is now 20 years old.   
Merel* is a 16-year-old girl who wants to join a psychosocial intervention she has heard of at a meeting of 
the NF1 patients’ association. She knows she has NF1 since she was 12 years old, but apart from a plexiform 
neurofibroma (a painful bump on the back of her right arm) and some fatigue, she is quite happy and she 
does not experience any other complaints. She is curious to find out how other people experience NF1. 
When meeting other people with NF1, she thinks, “They all look rather normal, just like me.” During the 
intervention, she learns that her motor ‘clumsiness’ could be seen as a part of NF1. Merel is capable of 
looking at NF1 from a distance, and in spite of her young age, some of her thoughts about NF1 are very 
striking and are being used in a brochure for young people with NF1. One of her quotes is, “I think it is hard 
to explain NF1 in one sentence. There are all kinds of things that go together with NF 1, like back pain and 
learning problems. You need an extensive story to explain all that. I feel like I fall in between everything, but 
there is no middle way.”  
Alexander and Merel are two of the about 6000 people in the Netherlands having NF1. They are different in 
many ways: their age, sex, their jobs, the age at which they discovered they had NF1, and the extent to 
which NF1 is a burden for them. Since they both have NF1, it is also interesting to find similarities: They are 
both adolescents and they live with their parents, they both experienced problems in learning and they 
both experience more fatigue than their peers do.  
*Names are fictitious, written informed consent obtained from persons involved  
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Background: The ENCORE expertise center 
 
Since 2010, the Expertise Center for genetic neurocognitive developmental disorders Rotterdam 
Erasmus Medical Center ENCORE (Dutch acronym for Erfelijke Neuro-Cognitieve 
Ontwikkelingsstoornissen Rotterdam Erasmus MC: ‘Genetic neurodevelopmental disorders 
Rotterdam Erasmus Medical Center’) is combining the care for children with genetic disorders with 
both clinical and fundamental research. The outpatients’ clinic for children with Neurofibromatosis 
type 1 was already present in the Erasmus MC Sophia Children’s Hospital since 1985, mainly led by 
pediatrician Arja de Goede-Bolder and in 2012, it became part of the ENCORE expertise center for 
neurodevelopmental disorders that was founded by neuroscientist Ype Elgersma and pediatrician 
Henriette Moll. ENCORE is an effort to translate findings from research to care and daily life of 
persons with NF1, but also of other monogenetic neurocognitive (neurogenetic) disorders such as 
Tuberous Sclerosis Complex (TSC), Angelman syndrome, Fragile X syndrome, Sturge-Weber 
syndrome, Costello syndrome, and Cardio-Facio-Cutaneous syndrome (CFC).  One of the aims of 
ENCORE is to contribute to the understanding of these syndromes, from a somatic, genetic, and 
psychological perspective. Since the start of ENCORE, a multidisciplinary team aims to help parents 
and patients in understanding their problems and in finding the right treatment for these patients.  
From the start of ENCORE, one of the ways to optimize assessment of children with 
neurocognitive developmental disorders is the VOLG program (Dutch acronym for Vroegtijdige 
Onderkenning Leer- en Gedragsproblemen: ‘Early recognition of problems in learning and 
behavior’). This program aims to standardize assessments of these children by neuropsychological 
and psychiatric assessments for all neurocognitive disorders on standardized ages, at 3, 6, 11, 15, 
and 18 years old. These are the ages at which, generally, decisions need to be made about the 
next step in education. This follow-up program facilitates longitudinal research aiming to reveal 
the natural history of learning and behavior in this population.  
Follow-up is not the only way to ameliorate the understanding, assessment, and treatment 
of neurogenetic syndromes. Fundamental research and translating findings from this research to 
targeted treatment for cognitive and behavioral problems are important ways to provide insight in 
the underlying molecular, physiological, genetic, neurological, and psychological mechanisms of 
these syndromes. This translational research is an important part of the work of ENCORE1-3. The 
combination of multidisciplinary clinical practice with clinical and fundamental research has led to 
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the recognition by the Dutch federation of university hospitals (Nederlandse Federatie van 
Universitair Medische Centra: NFU) of ENCORE as a national expertise center in 2015.  
 
Behavioral phenotyping in neurocognitive disorders 
Genotype is described as the genetic make-up or code of cells or of an organism. Together with 
epigenetic factors and non-inherited environmental factors, it determines one's phenotype.4 The 
phenotype (In ancient Greek, φαίνω (phaino) means ‘to appear or to show’, τύποςs (typos) means 
‘type’) of an organism is the composite of the observable characteristics or traits, including 
morphology (physical form and structure), developmental processes, biochemical and 
physiological properties, and behavior.5 A behavioral phenotype includes cognitive, personality, 
and behavioral patterns. Some behavioral phenotypes may characterize psychiatric disorders or 
syndromes. This more narrow definition of a behavioral phenotype is suggested to be ”a behavior, 
including cognitive processes and social interaction style, that is consistently associated with, and 
specific to, a syndrome which has a chromosomal or genetic etiology ”.6  For patients with 
neurogenetic disorders and their parents, the diagnosis of a neurogenetic disorder itself is of 
limited use without a description of the somatic, cognitive, psychosocial, and behavioral features 
that usually accompany such a disorder. In neurogenetic disorders, some of these features are 
coined as ‘endo-phenotypic’ characteristics or as intermediate phenotype. Endophenotypes are 
thought to be more easily quantifiable and more reliable than the clinical phenotype. This term is 
used in psychiatric genetics7 in order to bridge the gap between behavioral symptoms and genetic 
characteristics. 
In clinical assessment, treatment, and research of neurogenetic disorders, specialists 
cooperate in the somatic, the cognitive, and the psychosocial domains. The nature, severity and 
the natural history of somatic processes can have a large impact on cognitive and psychosocial 
processes. Neurocognitive and psychosocial assessments can provide a profile of strengths and 
weaknesses, a behavioral phenotype of the cognitive, sensory, motor, educational, behavioral, 
social, and emotional characteristics of patients8.  
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Neurofibromatosis type 1 (NF1) 
Neurofibromatosis type 1 (NF1) is a monogenic autosomal dominant neurodevelopmental 
disorder caused by heterozygous mutations in the NF1 gene on chromosome 17q11.2.9 This gene 
encodes for neurofibromin, a protein which is involved in modulating the rat-sarcoma (Ras) 
signaling pathway.10 Possible mechanisms underlying learning and behavioral problems in NF1 are 
increased release of the inhibitory neurotransmitter GABA and impaired plasticity (LTP: long-term 
potentiation) in the hippocampus, as is shown in Nf1+/- mice 11-13.  
Estimates of prevalence rates of NF1 vary between 1:2,052 (95% confidence interval (CI): 
1:2,176 – 1:1,941)14, 1:2,996 (95% CI 1:2,260 to 1:3,984),15 and 1:4,56016. Estimates of the 
proportion of new (de novo) mutations in NF1 vary between 40% and 75%, leaving the other 
patients with familial or germline mutations.16, 17 NF1 leads to symptoms such as café-au-lait 
macules, cutaneous, and subcutaneous neurofibromas but also to an increased susceptibility to 
various benign and malignant tumors. The major disease features of NF1 involve the nervous 
system, the skin, and the bones. Resulting complications are numerous, unpredictable, and vary 
even within families.18 To enable and harmonize diagnostics, criteria were set by an NIH (National 
Institutes of Health) committee in 198719 (Table 1).  
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Diagnostic criteria for neurofibromatosis type 1 are met if  
two or more of the below criteria are found: 
 Six or more café au lait macules (>0.5 cm in children or > 1.5 cm in adults) 
 Two or more cutaneous or subcutaneous neurofibromas or one plexiform 
neurofibroma 
 Freckling in axillary or inguinal regions  
 Optic pathway glioma 
 Two or more Lisch nodules (iris hamartomas seen on slit-lamp examination) 
 Bony dysplasia (sphenoid wing dysplasia, bowing of long bone +/– 
pseudarthrosis) 
 First-degree relative (parent, sibling or offspring) with NF1 
 
Table 1. Diagnostic criteria for neurofibromatosis type 1 
 
Café au lait patches and cutaneous neurofibromas occur in almost 100% of the cases and 
mainly have cosmetic effects. Subcutaneous and plexiform neurofibromas are less frequent (20-
44%) and can lead to neurologic deficits and malignant change.20  Plexiform neurofibromas21 can 
cause neurological deficits and pain. Malignant peripheral nerve sheath tumors (MPNST) can occur 
from 5 years on and individuals with NF1 have a 7-13% lifetime risk of developing an MPNST.18 
MPNSTs and cardiovascular problems are the primary causes of an 8-15 years reduction in average 
life expectancy in both men and women with NF1.22 Other frequent somatic symptoms are: 
macrocephaly (45%), small stature (below 25th percentile, 30%), scoliosis (10%), optic pathway 
glioma (15%), epilepsy (6-7%), precocious puberty (2-3%), and cerebral glioma (2-3%).20  
The severity of NF1 is commonly scored by a physician who is specialized in NF1. The Riccardi 
scale is one of the instruments used to estimate NF1-severity.23 In adults, sex and age do not seem 
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to be associated with NF1-severity, but there appears to be an association with general quality of 
life.24 The Riccardi scale was also used in studies to find associations between severity of the 
somatic phenotype and the behavioral phenotype. To do this, the scale is modified by excluding 
cognitive or behavioral symptoms into the categories:  
 Minimal NF1 (no features that compromise health, that is, only harmless cosmetic 
features such as café-au-lait maculae, freckling, and Lisch nodules), 
 Mild NF1 (minor complications such as small stature or discrete plexiform 
neurofibroma), 
 Moderate NF1 (complications that are a significant compromise to health, such as 
paravertebral neurofibromas or hypertension), and  
 Severe NF1 (medical history with malignancy).25  
Some studies found an association of severity of NF1 with didactic and neuropsychological 
tests in children.25 NF1 is a progressive condition of which prognosis and cause are hard to predict. 
Some symptoms (café-au-lait spots, pseudarthrosis, and specific plexiform neurofibromas) are 
present in the first year of life. Mostly, freckling, optic gliomas, and scoliosis occur at school-age. 
MPNST’s and some other plexiform neurofibromas generally occur in adulthood.26  A relatively 
new factor is the information that comes to most people through the internet. When searching for 
NF1 with a web-browser, next to objective information, subjective and personal information and 
pictures of generally severely affected patients can be found by people of almost all ages. The 
unpredictable nature of NF1 and the impact of unfiltered information from the internet may have 
severe effects on the well-being of individuals with NF1. Although the diagnostic criteria are 
largely somatic and the physical symptoms are serious and impressive, cognitive deficits and 
behavioral problems are the most common complications of NF1 during childhood.18, 27, 28  
 
Behavioral phenotyping of NF1 
In the last decades, several reviews have described the behavioral phenotype of individuals with 
NF1.29-32 With increasing knowledge, this gives a developing  picture of the strengths and 
weaknesses on a diversity of domains: cognitive domains such as intelligence, language, 
visuospatial functioning, and executive function, behavioral domains such as emotional and social 
competence, and effects of NF1 on achievement and daily life.32 As is the case with somatic 
symptoms, cognitive and behavioral profiles of children with NF1 are highly variable within and 
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between families.  Below, the behavioral phenotype of NF1 is described from the perspectives of 
cognitive and behavioral problems and their effects on daily life.   
Cognitive problems 
In psychological assessment, intelligence is being used as a way to give an impression of general 
mental capabilities or cognitive abilities. The average full-scale intelligence quotient (IQ) of 
children with NF1 is lower than the IQ in the general population, in different studies varying from 
86.2 (Standard deviation (SD) = 15.3) to 90.6 (SD= 13.3).25, 28, 33, 34  In general, this indicates a left-
shift of the normal distribution of 10 to 15 points (SD 0.6- 1.0). A left-shift is also visible when IQ 
scores of children with NF1 are compared with those of their siblings.28, 34 Consequently, 
intellectual disability is twice as common in NF1 and there are more individuals with NF1 who have 
an IQ below 70 (6-8%, compared to 2% in the general population).32, 33 Results regarding the 
intelligence profile mainly direct toward the conclusion that there is no significant difference 
between scores on verbal tasks and scores on performance tasks.32  Figure 1 shows the 
distribution of intelligence scores measured with Wechsler scales in children aged 6-16 years old 
using density plots of total, verbal, and performance IQ scores.35  
 
 
Figure 1. Distribution of intelligence scores in children with NF 
   (picture permission of the author: Myrthe Ottenhof) 
 
Speech and language problems, such as delays in speech and language development, 
articulation disorders, have been found in toddlers, school-age children, and adults with NF1.36, 37 
38 These language abilities affect functional communication, social interaction, and social skills 
development. 37 Some authors look at language development in the light of general cognitive 
development and suggest that pure language-based learning disabilities are rare in NF1 and are 
copied with the  
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often part of a more general delay in development. Speech impairments seem to show a more 
distinctive profile in adults with NF1, with hypernasality and abnormal rate, volume, pitch, and 
articulation.39, 40  
Since long, visuospatial and visuoconstructive deficits have been considered an important 
feature of the cognitive phenotype of NF1.28, 32, 34, 41 Although scores on several instruments (RCFT: 
Rey Complex Figure Test and JLO: Judgment of Line Orientation) are below 1 SD compared to 
population means, some authors suggest these tests not only measure visuospatial functioning 
but also tap into executive functioning.42, 43 Executive functions (EF) refer to a family of top-down 
mental processes facilitating the adaptation to novel situations: inhibition, working memory, and 
cognitive flexibility.44   These functions are also affected in NF1 and are sometimes referred to as a 
core feature of the cognitive profile of children with NF1.45 Different studies found deficiencies in 
EF, also after correcting for IQ.46 Children with NF1 score lower than controls on tasks for cognitive 
flexibility, planning, and working memory.46, 47 The association of scores on direct measures for EF 
with scores on measures for functional EF (i.e. the BRIEF, a parent-rated questionnaire for EF in 
daily life) is not always consistent.48 Scores on the BRIEF mainly indicate problems in working 
memory, self-monitoring, and planning and organization.48  A methodological problem is the use 
of a diversity of tests for different executive functions in different studies.31, 49  
Attention (focused, sustained, or divided) as a construct overlaps with executive 
functioning44 and seems to be one of the most consistently affected abilities in NF1, both when 
using direct measurements in neuropsychological assessments and when using indirect measures 
such as parental rating scales.28, 48, 50 Attention problems are highly prevalent in NF1, although not 
all people with NF1 will meet the full criteria for ADHD.51 
Motor problems may be affecting performance on tasks for executive function, 
visuospatial, or visual motor skills in NF1.42 Both fine and gross motor skills are affected in 30-50% 
of children with NF1; 28, 42 almost 30 % of children with NF1 had had occupational therapy and 
over 40% had remedial teaching for these problems in school.25   
Finally, studies focusing on memory problems in NF1 reported mixed results. Several 
studies did not find any selective memory problems.1, 28, 52 Some small studies suggested problems 
in verbal memory but not in spatial memory53 or in nonverbal memory.54   
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The distinction between cognitive and behavioral problems is arbitrary because many 
behavioral problems have cognitive aspects: Individuals with ADHD suffer from a lack of inhibition 
or other executive functions and problems in social interaction often occur due to deficits in social 
cognition. The most important emotional, behavioral, and social problems in NF1 are discussed 
below. 
Behavioral problems 
Behavioral problems in children are mainly assessed using parental rating scales. The majority of 
the problems found in NF1 concern emotional (also called ‘internalizing’) problems such as 
anxiety, depression, and social withdrawal. This may be associated with the social deficits and the 
self-image of individuals with NF1.55 At preschool age, the amount of parent- and teacher-rated 
emotional and behavioral problems in NF1 is stable.56 It is unclear what the natural history of 
these problems at school age is due to a lack of longitudinal studies. The most common behavioral 
disorder in NF1 is ADHD. In the general population, ADHD affects around 5% of the children and 
2.5% of the adults.57 The incidence of ADHD among children with NF1 is probably between 30 and 
50%, although a formal diagnosis of ADHD is not always made in individuals with NF1 who do fulfill 
the criteria for ADHD.28, 58-61 ADHD is more common in children with NF1 than in their siblings or 
their parents.62 Interestingly, ADHD in NF1 seems to occur as frequently in boys as in girls, 
whereas the male: female ratio in the general population is 3:1.28, 63 
 Children with NF1 have poorer social outcomes than their siblings without NF1 have and 
they have significantly poorer social skills in comparison with normative data. They are frequently 
teased and rejected by their peers.64 Children with NF1 and ADHD have the poorest social skills 
and social outcomes when compared to children with NF1 only or to children with NF1 and 
learning difficulties.65 Severe social problems are observed in children with autism spectrum 
disorder (ASD). Although the estimated ASD prevalence in the general population is 0.8%, 66 ASD 
frequency estimates in children with NF1 range from 11 to 30%, depending on sampling method, 
country, and diagnostic instruments used.63, 67, 68 Ideally, ASD classification is based not only on 
screening instruments but also on both observation scales and anamnestic information. Next to 
this, prevalence estimates must be based on large unselected groups of children with NF1. For this 
reason, the prevalence of ASD in NF1 is closer to 11 than to 30.68 In addition, in a British 
population-based study an estimated 25% of the children met questionnaire criteria for both 
ADHD and ASD.63  
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Effects on daily life 
Knowledge about the behavioral phenotype is mainly useful if this knowledge has a connection 
with the problems of individuals with NF1 in daily life. Making this connection is a way to validate 
this knowledge and the assessments that are necessary to acquire this knowledge. The World 
Health Organization (WHO) provides a framework for measuring health and disability. The 
International Classification of Functioning, Disability, and Health (ICF) is a classification of health 
and health-related domains in the context of an individual.69 The ICF model is shown in Figure 2. In 
2007, the WHO published the ICF for children and youth (ICF-CY).70 The ICF is a framework that 
helps to identify the consequences of conditions such as NF1 not only in terms of functions and 
symptoms but also in terms of the effects in daily life. In this model, ‘body functions and 
structures’ refers to the different body systems and their specific roles. Activity is defined as the 
execution of a task or action or how an individual performs. Participation is defined as the 
involvement in a life situation or as what an individual does in daily life. In addition, the model 
includes contextual factors, referring to personal and environmental factors. Personal factors 
include features related to the individual, such as sex, age, education, fitness, coping abilities, and 
social and economic background. Environmental factors finally, concern physical, social, and 
attitudinal aspects of the environment of people that affect access to services, health benefits, 
opportunities, and information.71 
Looking at the ICF model, it becomes clear that most of the above-cited research concerns 
effects of NF1 on the level of functions and activities, meaning there is a need to also describe 
effects of NF1 (and of limitations in functions and activities) on participation and to describe the 
interaction between these effects and contextual factors.  
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Figure 2. The WHO International Classification of Functioning, Disability, and Health (ICF)69 
 
Many NF1-related complications (pain, anxiety, depression, cognitive issues, and organic 
sleep pathology) may interfere with sleep quality and cause sleep disturbance.72 This is the case 
for both adults72 and children.58, 73 In children, the association with behavioral problems is 
inconclusive: one study found an association with conduct problems, hyperactivity, and emotional 
problems,58 another did not find a relation with ADHD, cognitive impairment, nor stimulant 
medication use.73 In children, sleep problems are associated with problems with school 
performance,74 in adults, it is associated with unemployment status.72  
One of the effects of cognitive and behavioral problems is the effect on academic skills and 
school performance. The majority of children (75%) perform one SD below their grade peers in 
spelling, mathematics, technical reading, or reading comprehension.25 Visuospatial and motor 
problems can result in problems in handwriting, which are frequent in children with NF1.28, 75 
Children with NF1 repeat a grade in primary school significantly more often than children in the 
general population.25, 76 Motor problems can limit participation at school and in play, sports, and 
peer-group activities, but they may also affect social and emotional development.77 Most children 
with NF1 need additional support, for example, special education and/or remedial teaching. 
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Many NF1-related complications (pain, anxiety, depression, cognitive is ues, and organic 
sleep pathology) may interfere with sleep quality and cause sleep disturbance.72 This is the case 
for both adults72 and children.58, 73 In children, the association with behavioral problems is 
problems,58 another did not find a relation with ADHD, cognitive impairment, nor stimulant 
medication use.73 In children, sleep problems are associated with problems with school 
performance,74 in adults, it is associated with unemployment status.72  
One of the effects of cognitive and behavioral problems is th  effect on academic skills 
school performance. The majority of children (75%) perform one SD below their grade peers in 
spelling, mathematics, technical reading, or reading comprehension.25 Visuospatial and motor 
problems can result in problems in handwriting, which are frequent in children with NF1.28, 75 
Children with NF1 repeat a grade in primary school significantly more often than children in the 
general population.25, 76 Motor problems can limit participation at school and in play, sports, and 
peer-group activities, but they may also affect social and emotional development.77 
with NF1 need additional support, for example, special education and/or remedial teaching. 
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On a systemic level, NF1 has its effects on relations, families, and communities. Children 
with NF1 have lower social competence, they have a reduced ability to get along with siblings, 
difficulties forming friendships and they have fewer friends.64 Mothers of children with NF1 report 
higher levels of parental stress.78 Possible reasons for this elevated stress are the emotional and 
behavioral problems of children but also difficulty coping with the uncertainty about the long-term 
prognosis of NF1.79  
Only a few studies addressed participation in association with NF1. Children with NF1 were 
found to participate in a wide range of activities but showed an overall lower level of participation 
in activities compared to children from a normative sample with the lowest participation in skill-
based and active physical activities.64, 80  
Although patients with NF1 are at risk of significant clinical illness, most patients are only 
mildly affected and lead healthy and productive lives.81 In spite of this, (health-related) quality of 
life (QoL) is lower for specific age groups in specific domains. In young children, parental 
perceptions of general health, growth, and development, and emotional impact were the most 
severely affected domains. Especially parental QoL scores about children with evident 
complications were very low, mainly in association with bodily pain.82 Also in older children, 
adolescents, and in adults, QoL was found to be reduced across the majority of domains, both in 
proxy- and in self-ratings.55, 83 Both visibility, specific symptoms and complications of NF1 and the 
variability and uncertainty about the course of NF1 seem to contribute to QoL.84  
 To summarize the areas of research and function in NF1 as a neurodevelopmental disorder 
using the ICF framework, Figure 3 shows the biological, somatic and functional domains where 
problems occur in NF1, where research is being conducted and where more research is needed. 
The icons of the eyes   at the top of the figure indicate the direction in which research 
attempts to connect domains: 
1. The first eye from the left looks from Biology towards Tissue, Function, Activity, and 
Participation. This research, for instance, studies the effects of genotype on phenotype. 
2. The second eye looks from Tissue towards Function, Activity, and Participation. This 
includes studies that look for the effects of somatic symptoms such as in Chapters 2 to 6. 
3. The third eye looks from Function towards Activity and Participation. Almost all studies in 
this thesis also look for the associations between function/impairment and 
activity/disability 
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4. The fourth eye looks from Activity towards Participation. Mainly Chapters 5 to 8 contain 
studies that involve associations between activity/disability, participation, and quality of 
life. Instruments that measure the quality of life usually make a connection between 
activities and participation. For this reason, quality of life is not indicated in this figure.  
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Gaps in research of the behavioral phenotype in NF1 
Since NF1 is a relatively rare disorder, many studies used small sample sizes, focused on a specific 
age group, and were performed in a selection of mainly Western societies (i.e. Western Europe, 
Australia, or North America). Studies to date vary widely in design, measures used, and participant 
groups. Consequently, generalizability over the NF1 population is often limited. Since clinical 
follow-up of NF1 patient-cohorts has become more common, research can focus on larger groups 
using data from multiple countries and cultures and broader age-groups. Because the majority of 
studies were observational cross-sectional studies, there is a need for more longitudinal studies 
that provide insight into the natural history of NF1 in both children, adolescents, and adults. 
 Another problem in the assessment of the behavioral phenotype is the wide variety of 
instruments used to measure specific cognitive and behavioral problems in NF1. For instance, 
motor proficiency can be assessed using tests targeting only parts of the motor domain and 
therefore do not show the full range of motor problems in children with NF1.32 Broader test 
batteries for both fine and gross motor skills were only used in a limited number of smaller 
studies.60, 85 For this reason, there is a need for studies that use broader test batteries measuring 
broad concepts such as cognition, behavioral problems, and motor proficiency. 
 Also, the selection of outcome measures in studies leads to distinct limitations. For 
instance, to measure emotional or behavioral problems in children with NF1, rating scales are 
often completed by proxies, e.g. parents and teachers, without taking the view of children or 
adolescents themselves into account.29, 52, 65 Using self-rating scales as well could be an important 
contribution to the current knowledge about these emotional and behavioral problems. Next to 
this, selecting direct outcome measures (i.e. neuropsychological tests or observation) versus 
indirect measures (rating scales) has an effect on the outcome of a study and can yield different 
views and different conclusions, as is the case when comparing the direct neuropsychological 
assessment of executive functions with the outcome of parental ratings of executive functions.48 
Several studies in this thesis use information from multiple sources: ratings from parents, 
teachers, patients themselves or they use both indirect and direct outcomes.  
 
  
Chapter 1
24
  
 
25 
 
Aims  
This thesis aims to supplement the above gaps and to contribute to the knowledge about NF1 on 
cognitive, behavioral, emotional, and social domains of the behavioral phenotype and on the 
effects of this phenotype on daily life. The results of these studies can guide the direction of future 
follow-up programs, inspire future assessment and treatments, and improve intervention trials. 
Next to this, an intervention study targeting cognitive deficits and daily life functioning studies the 
efficacy and safety of simvastatin treatment. The overall aim is to improve the care for and the 
quality of life of individuals with NF1.  
 
Outline 
In the first chapters, knowledge about the behavioral phenotype is expanded with regard to 
motor, emotional, behavioral, and cognitive problems, fatigue, and participation. Knowledge 
about the behavioral phenotype is applied in the design of three studies, the SPOT study, the 
SIMCODA study, and a qualitative study regarding worries and care needs.  
 Chapter 2 focuses on the prevalence and severity of motor problems of children with NF1 
and possible predictors.  
 Chapter 3 is a longitudinal study about the development of emotional and behavioral 
problems of young children with NF1 in association with their intellectual and language 
development.  
 Chapter 4 describes a cross-sectional study, defining the emotional and behavioral problems 
of a large group of children and adolescents with NF1.  
 Chapter 5 focuses on finding predictors for mental quality of life of adolescents and young 
adults with NF1 using the baseline measurement of the SPOT NF1 study (Dutch acronym for 
‘Social and Psychological support Of people with NF1 in their Teens or twenties’).  
 Chapter 6 is an intervention study: the translational randomized placebo-controlled NF1-
SIMCODA-trial (Simvastatin for cognitive deficits and daily life functioning), an RCT that 
studied the efficacy and safety of simvastatin treatment in a group of school-aged children 
and adolescents with NF1.  
 Chapter 7 evaluates the cognitive and behavioral outcome measures used in the SIMCODA 
trial in order to find how appropriate the selection of these measures was.  
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25
1
  
 
26 
 
 Chapter 8 studies the worries in daily life and the needs for care of adults with NF1 using a 
qualitative design.  
This thesis is concluded with a discussion, summarizing and combining the findings, but also 
formulating implications and recommendations for future follow-up, treatment, and research. 
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Abstract 
Background and aim 
Children with the neurogenetic disorder neurofibromatosis type 1 (NF1) often have problems with 
learning and behaviour. In both parent reports and neuropsychological assessment, motor 
problems are reported in approximately one-third to one-half of the children with NF1 1-3. Studies 
using broad motor performance test batteries with relatively large groups of children with NF1 are 
limited. The aim of this cross-sectional observational study was to describe the severity of motor 
problems in children with NF1 and to explore the predictive value of demographics, intelligence, 
and behavioural problems. 
Methods 
From 2002 to 2014, 69 children with NF1, aged 4 to 16 years (age = 9.5 + 2.8 years; 29 girls) had a 
motor, psychological, and neurological evaluation in an NF1 expertise centre. Data were collected 
about (1) motor performance (M-ABC: Movement Assessment Battery for Children), (2) 
intelligence, and (3) emotional and behavioural problems as rated by parents. 
Results 
Sixty-one percent of these children scored within the clinical range of the M-ABC. In ordinal logistic 
regression analyses, motor problems were associated with symptoms of Attention-Deficit/ 
Hyperactivity Disorder (ADHD), symptoms of Autism Spectrum Disorder (ASD), and externalising 
behavioural problems. Motor outcome was not predicted by age, intelligence, scoliosis, hypotonia, 
nor hypermobility. 
Conclusions 
Motor problems are among the most common comorbid developmental problems in children with 
NF1 and these problems do not diminish with age. Because of their impact on daily functioning, 
motor problems need to be specifically addressed in diagnosis, follow up and treatment of NF1.  
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Background 
Neurofibromatosis type 1 (NF1) is an autosomal dominant neurogenetic disorder with an 
incidence of at least 1:2,700.4 Although NF1 is defined by cutaneous and neurological symptoms 
such as café-au-lait spots and neurofibromas, the most common complications in childhood are 
deficits of cognition and of social and emotional development.5 The prevalence of 
neuropsychiatric problems such as Attention-Deficit/ Hyperactivity Disorder (ADHD) and Autism 
Spectrum Disorder (ASD) is much larger than in the general population.6 In both parent reports 
and neuropsychological assessments, motor problems are reported in approximately one-third to 
one-half of the children with NF1. 2, 3 Almost 30% of children with NF1 had received occupational 
therapy 1 and over 40% receive remedial teaching for motor problems at school.7 NF1 related 
skeletal and muscular abnormalities, such as scoliosis, pseudo-arthrosis, decreased bone strength, 
and reduced muscle strength may be associated with motor problems in NF1.3 Motor problems 
can hinder a child’s participation at school, and in play, sports, and peer-group activities but they 
may also affect social and emotional development8. In our expertise centres for NF1, motor 
problems are amongst the most common complaints, which is the reason for the structural 
assessment of motor skills presented in this study. 
Previous studies on motor skills in NF1 have often used selective tests, targeting only parts 
of the motor domain.5, 9 Studies using a small selection of motor or constructional tests do not 
show the full range of motor problems in children with NF1. Broader test batteries for both fine 
and gross motor skills have been used in a limited number of smaller studies 3, 10 or when focusing 
on young children.2, 11 Recently,9 a broad test battery (the BOT-2) was used with 46 children, from 
7 to 17 years old, to establish correlations between problems in motor and cognitive domains. In 
this study, cognition was associated with balance, gait, running speed and agility in children with 
NF1. A shared abnormal neurodevelopmental process underlying cognitive and motor abilities in 
NF1 was hypothesized.9  
A study on a large group of children and adolescents with NF1, using a broad test battery 
for motor performance, could inform health care professionals not only about the association 
between motor problems and cognitive development but also about the association with the 
emotional and behavioural problems often present in NF1. Our cross-sectional study aims to 
describe the presence and severity of motor problems in children and adolescents with 
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Neurofibromatosis type 1 (NF1) and to explore the associations between these motor problems 
and background variables, intelligence, and emotional and behavioural problems. 
 
Methods 
Procedure and Patients 
The Kempenhaeghe Centre for Neurological Learning Disabilities (CNL) is an expertise centre for 
children with neurological learning disabilities such as NF1. At school age, a paediatric neurologist 
evaluates all patients at least once. Patients are offered additional evaluations by a 
neuropsychologist and a physiotherapist. Patients without any complaints about motor 
performance were not included in this study. Next to this, we did not re-evaluate the motor 
performance of patients who already had serious motor problems according to a recent 
evaluation by a physiotherapist using the Movement- ABC in a different institute. The selection 
process is depicted in Figure 1. We used medical and psychological patient files from 2002 to 2014 
of 4 to 16 year old patients who met the National Institutes of Health (NIH) diagnostic criteria for 
NF1,12 and who were evaluated by a physiotherapist using the Movement Assessment Battery for 
Children version 113 or 214 (M-ABC-1 or 2). Exclusion criteria were: segmental NF1, symptomatic 
pathology of the CNS, deafness or severely impaired vision, pseudarthrosis, insufficient command 
of the Dutch language, or an IQ below the range covered by the Wechsler Intelligence Scale for 
Children, third edition, Dutch version (WISC-III-NL15; Total IQ below 48). 
Clinical data were registered by a paediatrician of Erasmus Medical Centre, Sophia 
Children’s Hospital during annual follow-up, by a paediatric neurologist from CNL, and by 
psychologists from both centres. All children were evaluated according to a standardized protocol, 
routinely applied to all children with NF1 visiting the expertise centre. Familial or sporadic NF1 was 
determined from family history. In clinical assessments by the paediatric neurologist and the 
psychologist, the presence of neurologic, orthopaedic or neuropsychiatric problems such as 
hypotonia, hypermobility, and scoliosis were recorded. Classifications of ADHD and ASD were 
based on neuropsychological assessment and on information from parents and teachers, using 
DSM-IV16 criteria. Writing problems were reported by parents. Socio-economic status (SES) was 
derived from the zip code of the child’s home address using a standard Dutch classification system 
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17. For the participating patients, a formal review and waiver was given by the medical ethical 
human research ethics committees of both the Erasmus Medical Centre and the CNL. 
 
Figure 1. Flow chart of participants and outcomes 
 
* M-ABC Normal score: > P15; Borderline score: P5 to < P15; Clinical score: < P5 
 
Instruments 
The Movement ABC,13, 14 an instrument measuring the presence and severity of motor 
problems, is one of the most frequently and widely used standardized assessments of motor skills, 
also used in diagnosing DCD. To assess motor performance, the physiotherapist administered the 
M-ABC-113 (2002-2010) or 214 (2010-2014). The M-ABC assesses three components: manual 
dexterity, ball skills (catching and throwing), and balance (static and dynamic). The M-ABC is 
designed to identify and describe impairments in the motor performance of children and 
adolescents aged 4 to 12 (M-ABC-1) or 3 to 16 (M-ABC-2). The M-ABC-2 is an updated version of 
the M-ABC-1: not only the age range but also the sample size, have been expanded and more 
information on psychometric qualities has been acquired. Results on both tests are expressed in a 
Motor problems in children with NF1
39
2
  
 
40 
 
score, with any child scoring below the 6th percentile of the normative sample being recorded as 
falling within the clinical range indicating serious movement difficulties. Scores from the 6th to the 
15th percentile (approximately between 1.5 and 2.0 SD below average) are labeled as borderline, 
indicating that the child is at risk of motor problems. Above the 15th percentile, the child is unlikely 
to have movement difficulties. Additionally, the M-ABC-2 also provides norm-referenced 
standardized scores for the component and the total scores. The M-ABC-2 has good reliability (ICC 
= .95 to .98). 
Intelligence was measured with the Wechsler Preschool and Primary Scale of Intelligence- 
Revised, Dutch version (first WPPSI-R18, from 2010 WPPSI-III-NL19) or the WISC-III-NL15. These are 
intelligence tests for children, the first for those aged 2 years and 6 months to 7 years and 7 
months, and the second for children aged 6 to 17 years. The tests consist of several subtests 
resulting in a Full-Scale IQ, Verbal IQ, and Performance IQ.  
To assess emotional and behavioural problems, parents completed the Child Behavior 
Checklist (CBCL) using either the preschool version, the CBCL/1½-520, or the school-aged version, 
CBCL/6-1821. Scores were converted to T scores (mean 50, SD 10), with higher scores 
corresponding to more problems. Summed scores result in three broad-band scales for 
Internalising, Externalising, and Total Problems. The Internalising Problems scale comprises 
anxious/depressed behaviour, withdrawn/depressed behaviour, and somatic complaints. The 
Externalising Problems scale comprises rule-breaking behaviour and aggressive behaviour. The 
Total problems scale is a combination of both the Internalising and Externalising Problems scales, 
together with scales for Social Problems, Thought Problems, and Attention Problems. T scores 
between 59 and 62 fall within a borderline clinical range, whilst T scores of 63 and higher fall 
within the clinical range. All tests were administered in their Dutch versions, using Dutch 
normative samples. 
Statistical analysis 
All data were analysed using SPSS, version 2122, and R.23  Proportions of groups were compared 
using chi-square (χ2) tests. Effect sizes were calculated using Cohen’s d,24 when comparing the NF1 
sample with the test manual normative sample, with .20 interpreted as a small effect size, .50 as 
medium, and .80 as large.  
Since the common outcome for both versions of the M-ABC was the classification into 
three consecutive categories (normal, borderline, or clinical), ordinal logistic regression analysis 
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was performed to find predictors of these three categories of motor outcome. For this, a two-
phase strategy was followed. In phase 1, all separate variables from Table 1 were tested in 
univariable ordinal regression analyses with M-ABC classification as the dependent variable. Since 
this phase served as an initial, broad selection of potential predictors, α in phase 1 was set at .2025. 
In phase 2, multivariable ordinal regression models were constructed for every block of variables 
from Tables 1 and 2, containing all significant variables from phase 1. Blocks were defined as 
demographics, neuropsychiatric problems, emotional and behavioural problems, and cognition. 
Variables shown to be significant contributors in the final models were regarded as the final 
predictors of M-ABC motor outcome (α in phase 2 was set at .05; stepwise backward elimination 
procedure).  
 
Results 
Patient characteristics 
From 2002 to 2014, 159 children with NF1 aged 4 to 16 years old visited the expertise centre. 
Ninety (57% of 159; 46 girls and 44 boys) were not referred to the physiotherapist, of which 31 
(34% of 90) had a previous assessment outside our institute, indicating serious motor problems, 
according to M-ABC-scores in the clinical range. Of the other 59 (66% of 90), parents and children 
did not have any complaints about motor performance before or during their visit to our institute. 
In the flow chart of Figure 1, we have visualized the distribution of the sample. For this study, 69 
children (43% of 159) with NF1 were included for PT evaluation in our institute, 29 girls, and 40 
boys. This group is indicated in the box ‘Referred to PT assessment’ in Figure 1. Ages ranged from 
4 years to 15 years and 11 months, with a median age of 8 years and 8 months (IQR= 4y 1mo) 
(Table 1). Sixty-seven children were right-handed.  
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Table 1. Characteristics of children with NF1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Median (interquartile range) bAverage SES in 2010 = 0.17; higher scores indicate higher SES 
  
Variable                                                                                       n = 69 
Demographic characteristics Frequency (%) 
Age 8.7 (4.1)a 
Gender  
  Male 40 (58) 
  Female 29 (42) 
Type of education  
  Regular education 48 (70) 
  Special education 21 (30) 
Social Economic Status b 0.34 (1.29)a 
Mode of inheritance NF1 
De novo mutation 39 (57) 
Familial mutation 29 (42) 
Unknown 1 (1) 
Neuropsychiatric problems 
Attention-Deficit/ Hyperactivity Disorder (ADHD) 
  ADHD combined type 25 (36) 
  ADHD inattentive type 11 (16) 
  ADHD hyperactive/impulsive type 2 (3) 
  Total 38 (55) 
Using stimulant medication 18 (26) 
Autism spectrum disorder (PDD-NOS) 7 (10) 
Neurologic and orthopaedic problems 
Hypotonia 14 (20) 
Hypermobility (Beighton criteria) 13 (19) 
Scoliosis 7 (10) 
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Eighteen out of 38 of the children with a DSM-IV-TR classification of ADHD (47%) used stimulant 
medication. Seven children had an ASD classification, all of them with a comorbid ADHD 
classification. Intelligence, emotional and behavioural problems, and standard scores of the M-
ABC-2 are presented in Table 2. 
Twenty-four children (41%) had emotional and behavioural problems scores within the 
clinical range, with large effect sizes for internalising problems and medium effect sizes for 
externalising problems. Parents of 11 children (16%) did not return CBCLs. These children were left 
out of analyses using CBCL scores as predictors. Compared to the normative sample, the 
distribution of intelligence scores was shifted approximately one SD to the left, and total IQ scores 
ranged from 58 to 123. Effect sizes were large for performance IQ and medium for verbal IQ 
compared to the normative population. Effect sizes for all motor scales were large. 
Motor problems 
 Thirty-five of 69 children (51%) were assessed with the M-ABC version 1, 34 (49%) with 
version 2. The comparison between children tested with these two versions showed no significant 
differences in the distribution of scores between the percentile classification categories for the 
total scores (χ² (2) = 3.08, p = .21), nor for distributions of Hand, Ball or Balance scale scores. For 
the purpose of ordinal regression analyses, both groups were combined. Figure 2 presents the 
distribution of the classifications in all motor scales. Overall, 42 (61%) children with NF1 scored 
within the clinical range (below 6th percentile) of the M-ABC. 
In ordinal regression analysis, age was found not to be a significant predictor of motor 
outcome. The proportion of children scoring in the ‘borderline’ or ‘clinical’ range of the M-ABC 
was 67% of children from 4 to 6 years old, 82% of children from 7 to 11 years old, and 79% of 
adolescents from 12 to 16 years old. 
In univariable ordinal regression analysis (Table 3; phase 1 with α set at .20 ), a higher 
probability of borderline or clinical motor problems was predicted by type of education, 
classifications of ADHD or ASD, hypermobility, Performance IQ, Total IQ, and CBCL Internalising, 
Externalising, and Total Problems. In all univariable models, the test of parallel lines failed to reach 
significance, meaning that effects of all separate variables were the same for normal versus 
borderline and borderline versus clinical scores.  
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Table 2. Scores and frequencies for emotional and behavioural problems, intelligence and motor 
performance 
a SD = Standard Deviation b BCR/CR: Percentage of scores in borderline clinical range/clinical range  
c ES: effect size (Cohen’s d); Significance compared to normative sample *p <.05; **p <.01; ***p <.001 
d T scores (population mean = 50; SD = 10; higher scores reflect more problems) 
e IQ scores (population mean = 100; SD = 15; higher scores reflect better performance) 
f M-ABC Normal score: > P15; Borderline score: P5 to < P15; Clinical score: < P5) 
g Standard-scores (population mean = 10; SD = 3; higher scores reflect better performance) 
 
In multivariable ordinal regression analyses (Table 4; phase 2 with α set at .05), single 
variables within one block (type of education and hypermobility) had p values above α = .05 and so 
could not be used in multivariable models. In three blocks, final models yielded a limited amount 
of significant predictors. Since all seven children with an ASD classification scored within the 
Domain Number Mean SDa BCRb 
(%) 
CRb (%) ESc 
Parent-rated emotional and behavioural problemsd  
  Internalising problems 58 59 10 19 37 0.9*** 
  Externalising problems 58 55 12 8 27 0.5** 
  Total problems 58 61 11 10 41 1.0*** 
Intelligencee  
  Verbal IQ 68 92 15   0.5*** 
  Performance IQ 68 88 14   0.8*** 
  Total IQ 69 89 13   0.8*** 
Movement ABC-1 and 2 (n= 69)       
  Classification Normalf 15 (22%)      
  Classification Borderlinef 12 (17%)      
  Classification Clinicalf  42 (61%)      
Movement ABC-2g (n = 34)       
  Manual dexterity 34 5.8 3.3   1.3*** 
  Ball skills 34 6.7 3.6   1.0*** 
  Balance 33 5.7 3.0   1.4*** 
  Total 34 4.8 3.2   1.7*** 
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clinical range, the odds ratio of having borderline or clinical M-ABC scores could not be calculated 
and so ASD was left out of multivariable analyses. Also, the multivariable ordinal regression of 
ADHD and ASD could not be performed because all seven children with ASD classifications also 
had an ADHD classification. We compared the distribution of the M-ABC classification between the 
groups without ADHD or ASD versus the group with only ADHD versus the group with both ADHD 
and ASD using a Chi-squared test. This distribution did not differ significantly (χ2 (4, N=69) = 7.53, 
p= .11), indicating that all three groups contributed independently to the distribution of motor 
problems.  
The Externalising Problems scale was approaching significance as a predictor of motor 
outcome (p = .063). With low scores for Externalising Problems, the probability of a clinical score 
on the M-ABC was low. Children without externalising problems on the CBCL only had a 23% 
chance of a clinical score on the M-ABC, whilst children with externalising problems scores in the 
clinical range had an 81% chance, as is shown in Figure 3. Finally, intelligence (i.e. Performance IQ) 
was not found to be significantly associated with total motor problems.  
Exploratory univariable linear regression analyses, with motor outcome on the M-ABC-2 as 
a continuous dependent variable (n = 34), found significant associations with independent 
variables: Internalising Problems scale (F (1,26) = 5.21; p =.031; R2 = .17; β = -.13); Externalising 
Problems scale (F (1,26) = 6.99; p = .014; R2 = .21; β = -.12); and Total Problems scale (F (1,26) = 
6.15; p = .020; R2 = .19; β = -.13), again indicating that an increase in emotional and behavioural 
problems is associated with a decrease in motor proficiency. Residuals for these regressions were 
normally distributed.   
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Figure 2. Classification of motor problems based on Movement ABC percentile scores (n= 69) 
 
 
Clinical: Percentage of children with movement difficulty- scores below 6th percentile 
Borderline: Percentage of children with scores from 6th to 15th percentile 
Normal: Percentage of children with no movement difficulty- scores above 15th percentile 
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Table 3. Univariable ordinal logistic regression with separate variables predicting motor outcome 
(Movement ABC total scores; n=69) 
 
Variable 
  
B (SE) 
95% CI of Odds Ratio  
Wald 
 
R² 
 
   p Number lower OR upper 
Age 69 0.08 (0.09) 0.77 0.93 1.12 4.31 .01 .429 
Gender 69 0.56 (0.49) 0.22 0.57 1.49 1.31 .02 .253 
Type of education 69 0.84 (0.58) 0.14 0.43 1.35 2.08 .04 .135# 
Social economic status 69 -0.10 (0.19) 0.77 1.10 1.59 0.29 .01 .595 
Mode of inheritance 69 -0.42 (0.49) 0.59 1.53 3.95 0.76 .01 .383 
ADHD 69 1.01 (0.49) 0.14 0.36 0.96 4.22 .07 .038* 
Using stimulant medication 69 -0.35 (0.54) 0.49 1.41 4.05 0.41 .01 .523 
Autism spectrum disordera 69 - - NA - - .12 .035** 
Hypotonia 69 0.28 (0.60) 0.23 0.76 2.47 0.21 <.01 .644 
Hypermobility 69 0.98 (0.70) 0.10 0.38 1.49 1.94 .04 .140# 
Scoliosis 69 0.25 (0.79) 0.28 1.28 5.97 0.10 <.01 .755 
Writing problems at school 69 -0.20 (0.50) 0.46 1.22 3.25 0.16 <.01 .694 
CBCL Internalising problems 58 - 0.04 (0.03) 0.99 1.04 1.09 2.23 .04 .134# 
CBCL Externalising problems 58 - 0.04 (0.02) 0.10 1.04 1.09 3.30 .07 .063# 
CBCL Total problems 58 -0.05 (0.03) 1.00 1.05 1.10 3.65 .08 .051# 
Verbal IQ 68 0.01 (0.02) 0.96 0.99 1.02 0.41 .01 .519 
Performance IQ 68 0.03 (0.02) 0.94 0.97 1.01 2.43 .04 .115# 
Total IQ 69 0.03 (0.02) 0.94 0.97 1.01 2.10 .04 .141# 
R² = Nagelkerke pseudo R2  p-values of likelihood ratio chi-square; #p <.20; *p <.05; **p <.01 
a As there were no cases in cells with normal M-ABC-scores for children with an ASD classification, the estimate was 
minus infinity 
  
Motor problems in children with NF1
47
2
  
 
48 
 
Table 4. Multivariable backward ordinal logistic regression with variables from separate blocks predicting 
motor outcome (Movement ABC total classification; n=69) 
 
Variables 
  
B (SE) 
95% CI of OR  
Wald 
 
R² 
 
p-value Number lower OR upper 
Neuropsychiatric problems         
ADHD 69 1.01 (0.49) 0.14 0.36 0.96 4.22 .07 .038* 
Autism spectrum disordera 69 - - NA - - .12 .035* 
Emotional and behavioural problems       
Model 1 58      .07 .168 
Internalising problems  -0.01 (0.03) 0.95 1.01 1.08 0.10  .757 
Externalising problems  -0.04 (0.03) 0.98 1.04 1.10 1.44  .235 
Model 2 58        
Externalising problems  -0.04 (0.02) 0.10 1.04 1.09 3.30 .07 .063 
Intelligence         
Model 1 68      .04 .289 
Performance IQ  0.03 (0.03) 0.91 0.97 1.04 0.71  .401 
Total IQ  0.001 (0.03) 0.94 1.00 1.07 0.001  .973 
Model 2 68        
Performance IQ  0.03 (0.02) 0.94 0.97 1.01 2.43 .04 .115 
 
OR = Odds ratio; NA = Not Applicable R² = Nagelkerke pseudo R2  p-values of likelihood ratio chi-square; 
*p <.05; **p <.01 
a As there were nog cases in cells with normal M-ABC-scores for children with an ASD classification, the estimate was 
minus infinity 
 
Discussion 
Our study shows that motor problems frequently occur in our group of children with NF1: 61% of 
these 69 children have serious motor problems and another 17% score within the borderline 
range. In the part of our cohort not evaluated in the expertise centre (n=90), 31 were already 
identified as having motor problems, resulting in an overall 46% (73/159) with serious motor 
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problems. The distribution of these groups and outcomes is visualized in Figure 1 in the Box with 
‘Total number clinical score’. Previous studies using broad motor test batteries found smaller or 
comparable proportions. One study in a comparable age range found 54% (14 out of 26 children) 
scoring between one and two standard deviations below average and another 27% (7/26) scored 
below 2 SD.3 When comparing studies, one should realize that the cut-offs of the P5 and the P15 
correspond to z-scores of 1.65 and 1.04 below average in the standard normal distribution.  
 
Figure 3. Relationship between cumulative percentages of classification of total motor scores and scores on 
CBCL Externalising problems scale
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Next to ADHD26 and ASD symptoms27, motor problems seem to be among the most 
common comorbid developmental problems of children with NF1. We found motor problems in a 
broad range of domains, comparable to the problems found in DCD.8  
 In our attempt to find predictors of motor outcome we did not find a significant 
contribution of demographic characteristics such as age, gender, or SES. A previous comparable 
study in a smaller sample did not find effects for age or gender either. 3 We also did not find 
associations with neurological and orthopaedic problems such as hypotonia, hypermobility, or 
scoliosis. Given the broad variability in these characteristics within our population (Table 1), we 
think our study population had sufficient power to detect potential associations if they existed. 
There was a limited association between (performance) intelligence and motor performance. 
Previous research 1 found that motor coordination and motor speed contributed to the 
performance on some subtests of the WISC. However, in our study we used a broader motor test 
battery such as the M-ABC and children were found to have serious motor problems in general, 
regardless of their overall intelligence. Since a previous study 9 found that poorer balance skills 
were associated with a reduced perceptual reasoning index, we performed an additional 
univariable ordinal logistic regression to specifically find out whether balance skills on the M-ABC 
were associated with performance IQ. Only a weak association was found with an odds ratio of 
0.97 (95%CI, 0.93 to 1.00), Wald χ2 (1) = 3.774, p = .052). Whether this finding is a reflection of an 
abnormal neurodevelopmental process underlying these abilities in children with NF1, may be a 
subject for future research.  
Recent studies do provide evidence for a relation between motor experience and cognitive 
development in the first three years of life when at the same time this relation becomes less clear 
in older children. 28 The fact that we did not find a significant effect of age on motor performance, 
may presumably be caused by the fact we included children from 4 to 16 years old.   
 Externalising behavioural problems might be associated with motor outcome. This 
association was found to be significant in additional explorative analyses with standard scores of 
the children tested with the M-ABC-2. Also, ADHD was a significant predictor of motor outcome, 
and all children with an ASD classification had severe motor problems. Previous studies also found 
that motor problems often occur in children with emotional, behavioural, and pervasive 
developmental disorders.29, 30 The co-occurrence of motor and behavioural problems could be an 
indicator of a more severe neurologic phenotype.31 It is, however, unclear what the direction of 
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the association between behavioural and motor problems is. Longitudinal and treatment studies 
could elucidate this issue. Neuropsychiatric and motor problems have a large impact on 
participation in daily life, even more so when these problems occur simultaneously. 
Limitations 
Although NF1 is relatively rare, we succeeded in gathering data on the motor performance of 69 
children over a 12-year period. However, our sample size is still small considering the number of 
variables incorporated into the regression analyses of this study. For this reason, there is a risk of 
overfitting, and care should be taken when drawing conclusions regarding the predictive value of 
variables. To avoid unnecessary assessments, we did not evaluate the motor performance of 
children who recently had such an assessment. In addition, since the assessment of motor 
performance was on a voluntary basis, children without any motor complaints were not required to 
visit our physiotherapist. For these reasons, we cannot exclude selection bias. We tried to correct 
for this bias by calculating the total amount of children scoring in the clinical range (Figure 1).  
The cross-sectional design limits interpretations regarding the effect of age on motor 
performance. Probably, longitudinal research will be able to express this relationship in a more 
decisive way. 
During the time period of this study, there was a move by physiotherapists in the 
Netherlands from using the first version of the Movement-ABC to the second version. For this 
reason, we were dependent on the categorical classification of motor problems as a primary 
outcome measure. This is a consequence of continuous sampling over a long period of time. One 
should be careful when combining data from both tests since the M-ABC-2 is an elaboration of the 
M-ABC-1, resulting in differences between both instruments. 32 Because the age range of the M-
ABC was the starting point of this study, we used the two age-appropriate versions of the Wechsler 
scales and of the CBCL. Although the correlation between both versions is high, 19, 20 future research 
in larger groups could benefit from the selection of smaller age ranges.  
For this study, we collected data from medical records. This resulted in missing information 
(as is shown in Table 2), particularly regarding emotional and behavioural problems, most likely 
because some parents failed to return questionnaires. Since all children were assessed using a 
standardized protocol, other data are relatively complete.  
Motor problems in children with NF1
51
2
  
 
52 
 
The proportion of children with ADHD symptoms is comparable to that in other studies,26 
but the percentage of children with ASD symptomatology in our study (10%) is somewhat lower 
than former prevalence estimates (21-40%).33 In the group with ASD, all children appeared to have 
severe motor problems. Although this may suggest clinical relevance, we interpret this observation 
with care, due to the small sample size.  
Clinical implications and recommendations 
Developmental motor problems are frequently overlooked in clinical practice, yet they can have a 
considerable impact on children’s lives.34 Using a broad motor assessment in a large cohort of 
children with NF1, we showed a high prevalence of serious motor problems. These problems seem 
to be independent of age or intelligence. When children with NF1 show serious motor problems, 
the diagnosis of DCD might be considered as a comorbid problem. This is especially important in 
helping to recognise the impact of motor problems on daily life, and in allocating the correct 
treatment. Although the DSM-IV-TR16 states that in DCD, ‘the disorder is not due to a general 
medical condition’, to our opinion NF1 does not have to be regarded as such. DCD could be used in 
practice as a descriptive diagnosis stressing the impact of motor problems on daily life.  
Concerning participation in daily life, children with NF1 often experience problems with 
writing.1, 35 It is important to find out whether people with NF1 experience further such difficulties 
in daily functioning such as in activities of daily living, play, sports, or with driving. This is of great 
importance since a decrease in participation could not only affect the practice of motor skills but 
also the development of social skills and quality of life in general.   
Assessment and treatment of motor problems in NF1, especially in children with 
behavioural and social problems, should be considered at a young age, using a broad motor 
assessment battery. Early motor intervention can have a beneficial effect on behavioural 
problems, as is indicated by a study showing that in ADHD, 36 motor-affected children receiving 
physiotherapy presented less frequently with comorbid emotional and behavioural problems. The 
impact of physiotherapy and psychological therapy on motor functioning, motor participation, and 
emotional and behavioural problems in children with both NF1 and motor problems is unknown. 
However, considering the larger potential for plasticity at a young age, referral to both a 
physiotherapist and a psychologist could be considered at a young age in children with NF1.  
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Conclusion 
More than half of the children with NF1 in this sample had severe motor problems. These 
problems seem to be independent of age or intelligence. Next to ADHD and ASD, motor problems 
are among the most frequent comorbid developmental problems in children with NF1. In this 
study, ADHD and ASD-symptomatology, and externalising behavioural problems are associated 
with motor problems. The combination of both motor and behavioural problems might result in a 
more severe phenotype of NF1. Because of their impact on participation in daily life, motor 
problems need to be specifically addressed in diagnosis, follow up and treatment of children with 
NF1.  
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Abstract 
This retrospective longitudinal study in young children with neurofibromatosis type 1 (NF1) aimed 
to identify if, and how early problems in behavior, intelligence, and language development are 
associated with later behavioral problems. At the first assessment at preschool age, we evaluated 
language skills, intelligence, and emotional and behavioral problems as reported by parents. The 
second assessment at school-age we evaluated intelligence, and emotional and behavioral 
problems as reported by parents and teachers. Association of baseline assessments with 
secondary assessment was evaluated using multivariable linear regression analysis. 
Of the 61 patients (25 males, 36 females; mean age 4;5 years [SD 1;1 years]) with NF1 who had a 
first assessment, 38 children (21 males, 17 females; mean age 7;11 years [SD 2;1 years]) had a 
second assessment after a mean period of 3;5 years. Longitudinal data on behavioral problems 
were collected for 23 of these children. Intelligence and language development were not 
associated with internalizing problems. Parent-rated internalizing behavioral problems 
significantly increased with age in this subgroup. Baseline internalizing problems predicted later 
internalizing problems (adjusted R2=0.33, p=.003). The presence of these problems at pre-school 
age may be predictive of internalizing problems at a later age. 
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Introduction 
Neurofibromatosis type 1 (NF1) is an autosomal dominant disease with an estimated birth 
incidence of 1 in 2,700 1. As a neurocutaneous disorder, NF1 presents with readily visible features 
such as café-au-lait spots and neurofibromas, but cognitive and behavioral problems are also 
central to the disorder 2. Cognitive deficits include below-average IQ (intelligence quotient) scores3 
and impairments in attention, executive functioning, visuospatial skills, motor skills, and language 
2. Behavioral problems in children with NF1 consist mainly of emotional and social problems 4, 5. 
Parents mainly report internalizing problems, which encompasses social withdrawal, somatic 
complaints, anxiety, and depression 6, 7. Speech and language problems, such as delays in speech 
and language development, articulation disorders, and expressive and receptive language 
development disorders, affect toddlers and school-aged children, as well as adults with NF1 8-13. 
Longitudinal studies in neurogenetic disorders are relatively scarce 14. A study in 19 
children 15 , initially between 6 and 13 years old, concluded that children with NF1 scored lower on 
cognitive tests than their unaffected siblings, but over time, their patterns of growth were not 
different from those of their siblings. In a follow-up study in 11 children with NF1 from 12 to 20 
years old, Hyman et al. 16 observed no overall change in general cognitive ability. A longitudinal 
study in 43 children under eight years of age 17 found an increase with age of the number of areas 
of delay. Recently, longitudinal studies following patients with NF1 over a period of several years, 
focused on MRI data and general cognition as outcome measures 18, 19. The first study followed 67 
children aged 6 to 17 years over a three-year period; the second study retested 18 patients aged 8 
to 33 years over an 18-year period. Both studies observed improvement of IQ with age in the 
group of patients with discrete MRI T2 hyperintensities. A recent study by Lorenzo et al 20 followed 
39 toddlers from 21 to 40 months of age and found no change in parent rated behavioral scores 
between children of 21, 30 and 40 months old. 
In the general population, the proportion of parent- and teacher-rated emotional and 
behavioral problems is stable at preschool age and a predominantly internalizing profile only 
emerges at 6 years 21. Children with parent- or teacher rated internalizing problems at school 
entry (aged 4-5 years) have a greater chance of internalizing problems at preadolescence (aged 
10-11 years). The same applies for externalizing problem behavior 22.  
Development of emotional and behavioral problems in young children
59
3
  
 
60 
 
The aim of this longitudinal study in children between 4;5 and 7;11 years old was to 
identify whether problems in behavior, intelligence, and language development are associated 
with later behavioral problems, to inform future planning of interventions. 
 
Materials and methods 
Patients and moments of assessment 
In the Erasmus MC, Sophia Children’s Hospital in Rotterdam, the Netherlands, patients with NF1 
visit the outpatient clinic yearly. All patients with NF1 between the ages of 2 years 3 months and 6 
years 3 months are routinely referred for a first neuropsychological assessment and speech and 
language evaluation (at time point 1; T1). At primary school (T2), the same patients were offered a 
second neuropsychological evaluation in the outpatient clinic of the Erasmus MC or in the 
Kempenhaeghe Centre for Neurological Learning Disabilities (KCNL). The children who participated 
in the second evaluation were evaluated by a pediatric neurologist and a neuropsychologist.  For 
this study, we included all patients who were evaluated between 2002 and 2010 and met the 
National Institutes of Health diagnostic criteria for NF1 23. Clinical and demographic data for this 
study were obtained from patient records, as registered by the pediatrician of the NF1 team. 
Familial or sporadic NF1 was determined from family history. According to a standard evaluation 
of hearing abilities by an audiologist, no child had a hearing loss greater than a slight, temporary 
impairment 24.  
This study was approved by the Medical Ethical Committee of Erasmus MC, Sophia 
Children’s Hospital. 
Outcome measures 
Emotional and behavioral problems were the main outcome at both time points. Additionally, we 
report outcomes on intelligence and language development at the first assessment (T1) and on 
intelligence at the second assessment (T2). Because of the importance of detecting early problems 
in language development, cognition was evaluated by testing language development and non-
verbal intelligence separately at T1. Receptive language was tested with the Dutch version of the 
Reynell Developmental Language Scales (RDLS) 25. Expressive language was evaluated using the 
Dutch version of the Schlichting Expressive Language Test (SELT)26. Both tests are designed for 
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children aged 14 months to 6 years 3 months. The word development part of the SELT measures 
expressive vocabulary skills by asking the child to name objects or pictures. The sentence 
development part evaluates the level of grammatical skills (syntactic and morphological) by using 
functional imitation as an elicitation technique. Both RDLS and SELT provide norm-referenced 
scores, based on typical language levels for normally developing children. The RDLS yields a 
language comprehension quotient (LCQ). Scores on the SELT word development scale and on the 
sentence development scale are expressed in a word development quotient (WDQ) and a 
sentence development quotient (SDQ).  
Intelligence at T1 was assessed with the Snijders-Oomen Non-verbal revised intelligence 
scale for young children (SON-R 2½-7; 27) a non-verbal intelligence scale suitable for all children 
from age 2 years 3 months to 7 years 3 months. It is particularly suited for children with hearing 
impairments and/or language or verbal communication deficits and consists of six subtests 
resulting in a Total IQ, a Performance Scale IQ, and a Reasoning Scale IQ.  
At T2, intelligence was measured with the Wechsler Preschool and Primary Scale of 
Intelligence- Revised, Dutch version (WPPSI-R)28 or the Wechsler Intelligence Scale for Children, 
third edition, Dutch version (WISC-III-NL; 29. The WPPSI-R and the WISC-III-NL are intelligence tests 
for children, the first for children aged 2 years 6 months to 7 years 7 months, the second for 
children aged 6 to 17 years. The tests consist of several subtests resulting in a Full-scale IQ, Verbal 
IQ, and Performance IQ. All intelligence and language tests have a population mean of 100 and an 
SD of 15.  
At both T1 and T2, parents completed age-appropriate version of the Child Behavior 
Checklist (CBCL) to assess emotional and behavioral problems, either with the preschool version, 
the CBCL/1 ½-5 30, or with the school-aged version, CBCL/6-18 31. These both forms differ in items 
and scales but both report summary scales for internalizing, externalizing and total problems. At 
T2, teachers were asked to complete the Teacher’s Report Form 31. Scores were converted to T 
scores (Mean 50, SD 10), where a higher score corresponds to more problems. Summed scores 
result in three broad-band scales for Internalizing, Externalizing, and Total Problems. On these 
scales for Internalizing, Externalizing, and Total Problems, T scores from 60 to 62 are considered to 
fall in a borderline clinical range, whilst T scores of 63 and higher are considered to fall within the 
clinical range.  
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All data were analyzed using SPSS, version 20 32. Two-sided independent t-tests were used for 
comparisons of group means within one time point for continuous, normally distributed variables. 
Two-sided paired samples t-tests were used for comparisons between two time points (T1 versus 
T2). Wilcoxon signed ranks test for two related samples was used for non-normally distributed 
data and for small samples. Effect sizes were calculated for all t-tests using Cohen’s d. Effect sizes 
were considered small from 0.2 to 0.5, moderate from 0.5 to 0.8, and large if >0.8 33. The Shapiro-
Wilk test was used to control for normal distribution. 
Correlation analyses with the use of the Pearson correlation coefficient or Spearman’s ρ for 
non-normally distributed data were performed to describe the association between outcome 
measures. 
Multivariable linear regression models were constructed to analyze independent factors 
predicting outcomes with the largest difference between T1 and T2. In preparing analyses, we 
used the ‘rule-of-thumb’: one variable for every 10 participants 34. The cut-off level for significance 
was set at α=.05. 
 
Results 
Patients 
Sixty-one patients visited the outpatient clinic between 2002 and 2010 at time point 1 (T1) for 
evaluations by the speech/language therapist and the neuropsychologist (Table 1). The mean age 
of the children at T1 was 4;5 years (SD=1;1, range 2;3 to 6;3 years). At time point 2 (T2) 38 children 
(62%; mean age 7;11 years (range 5;0–13; 6 years; SD=2;1 years) had a second neuropsychological 
evaluation, including an intelligence test. Between T1 and T2 the mean interval was 3;5 years 
(range 1;1–7;10 years; SD=1;10 years). A flow chart of included patients is presented in Figure 1.  
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Table 1. Characteristics of children with NF1 at baseline (T1) and follow-up assessment (T2)  
 No. % No. % 
Demographic characteristics Time point 1 (n=61) Time point 2 (n=38) 
Mean age in years (SD) 4;5 (1;1) 7;11 (2;1) 
Male gender 25 41 21 58 
Familial NF1a 27 44 21 58 
Special educationab 3 5 11 29 
Speech-language therapy at T1 14 23 10 26 
a Leaving out 1 child with incomplete file 
b Attending a special school for children with learning and/or behavioral problems 
 
Figure 1. Flowchart of patient inclusion 
Abbreviations: 
NF1 : Neurofibromatosis type 1 
NPA : Neuropsychological assessment 
CBCL : Child Behavior Checklist 
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Language development, intelligence, and behavioral problems at T1 (Table 2 and 3) 
Scores on measures for language, intelligence, and behavior did not differ between boys and girls. 
Comparing the group with familial NF1 to the non-familial group, scores differed significantly on 
the three subtests for language development: RDLS LCQ (t58=2.381, p=.021), SELT WDQ (t51= 2.030, 
p=.048), and SELT SDQ (t51=2.039, p=.047), with lower scores for the familial NF1-group with 
moderate effect sizes (0.62, 0.56 and 0.56). There was no significant difference between these two 
groups for intelligence and behavioral scores. The receptive language development (RDLS LCQ) of 
three children (5%) was below 70, possibly indicating severe problems in this area. Expressive 
language development was below 70 for three children on the SELT test for word development. 
No children scored below 70 on the test for sentence development. However, seven children 
(11%) could not complete the language assessment because of limited attention span or an 
inability to imitate. Fourteen children (23%) had speech and language therapy before assessment. 
After this assessment, all these children were advised to continue therapy and another 20 children 
(33%) were advised to start therapy.  
Seven children (11%, different from the seven above) were evaluated for intelligence with 
intelligence tests or developmental screenings other than the SON-R. The average IQ of these 
children (M= 83.7; SD=17.1) did not differ significantly from the IQ of the other 54 children (M= 
88.4; SD=16.3).  
 According to the scores on the CBCL parent rating scale, 25% of the children (11/44) scored 
within the borderline or clinical range with their Total Problems score. Fifteen percent (7/48) of 
them also scored within this range for the Internalizing Problems score and 23% (11/48) for the 
Externalizing problems score. There was no significant difference between Internalizing and 
Externalizing Problems scores at T1 (p=.158).  
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Table 2. Scores on intelligence and language tests at baseline (T1) and follow-up (T2) assessment 
 
 T1; n=61 
Mean age 4;5 
(SD = 1;1) 
T2; n=38 
Mean age 7;11 
(SD = 2;1) 
 n Mean SD n Mean SD 
SONa Total IQb 54 88.4 16.3    
SON Reasoning IQ 55 93.5 16.0    
SON Performance IQ 54 86.8 16.1    
RDLS LCQc 61 92.9 14.5    
SELT WDQd 54 92.5 15.3    
SELT SDQe 54 92.7 11.4    
Full scale IQf    38 85.3 15.0 
Verbal IQf    36 88.1 16.8 
Performance IQf    36 85.2 15.9 
 
a SON: Snijders-Oomen Non-verbal intelligence test 
b All cognitive and language tests compared to normative population (M = 100; SD = 15) 
c Reynell Developmental Language Scales- language comprehension quotient 
d Schlichting Expressive Language Test- word development quotient 
e Schlichting Expressive Language Test- sentence development quotient 
f Wechsler Preschool and Primary Scale of intelligence, Revised Dutch version or Wechsler Intelligence Scale for Children, third version for the 
Netherlands
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Table 3. Scores on emotional and behavioral problems at baseline and follow-up assessment 
 T1; n=61 
Mean age 4;5 (SD=1;1) 
T2; n=38 
Mean age 7;11 (SD=2;1) 
 n Mean SD n (%) scoring 
in borderline 
or clinical 
rangea 
n Mean SD n (%) scoring 
in borderline 
or clinical 
rangea 
CBCLb Total Problems 44c 51.5 11.8 11 (25) 23e 60.8 12.7 12 (50) 
CBCL Internalizing 48d 49.8 11.3 7 (15) 23e 60.7 11.2 14 (58) 
CBCL Externalizing 48d 51.2 11.5 11 (23) 23e 55.2 12.8 10 (42) 
TRFf Total Problems     21 57.7 8.7 10 (48) 
TRF Internalizing     21 56.9 9.4 9 (43) 
TRF Externalizing     21 53.0 9.3 6 (29) 
 
a Behavioral Problems scores within the borderline clinical range (T score >59) 
 b Child Behavior Checklist; all behavioral questionnaires compared to normative population (M = 50; SD = 10).  
c Total problem scores of 4 participants were not reported in patient records.  
d Of these 48, 3 parents completed the CBCL/ 1 ½ -5 and 45 completed the CBCL/ 6-18 
e Of these 23, 2 parents completed the CBCL/ 1 ½ -5 and 21 completed the CBCL/ 6-18 
f Teacher Report Form 
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Intelligence and behavioral problems at T2 
Twenty-three parents (61%) and 21 teachers (55%) completed and returned the CBCL/TRF 
questionnaires. These 23 children had a mean age of 4;5 years at T1 and of 8;5 years at T2. Within 
this group, half of the children had familial NF1 (50% for CBCL and 52% for TRF). There were no 
significant differences between the scores for boys or girls, or between the groups with familial or 
non-familial NF1. The 23 patients in the final group with a CBCL at T1 and T2 did not differ from 
the 15 patients without a CBCL at T2 in any of the demographic scores nor in IQ-scores. 
Correlations between parent and teacher ratings were significant for Internalizing (r=0.69, p=.001) 
and for Total Problems scores (r=0.53, p=.019), but not for Externalizing Problems scores.  
Comparison between T1 and T2 
The group which participated in the assessments at T1 but not at T2 (n=23) was compared to the 
group which participated at both time points (n=38). Both groups neither differed in any of the 
scores nor in demographic variables, except for mode of transmission (familial or sporadic NF1). 
The group which had an assessment at T2 consisted of more children with familial NF1 (55%) 
compared to the group which was not assessed at T2 (27%) (χ21=4.4, p=.04).  
Although the intelligence tests at T1 and T2 differed, no significant difference was observed 
between Total IQ scores on both tests in children who had assessments at both T1 and T2. Scores 
on the SON-R as a non-verbal test at T1 also did not differ from Performance IQ at T2. The most 
striking difference is an increase in Internalizing Problems scores at T2 (M=61.3, SD=11.1) 
compared to T1 (M=52.6, SD=11.4) (Z=237.5, p<.001) in the scores of these 23 children, with a 
moderate effect size (0.77). With post-hoc power calculations based on this effect size and a 
sample size of 23, we found the power (1- beta) to be .93. Over a mean period of 3.4 years, the 
Internalizing Problems score increased with more than one standard deviation (10.9 points). 
Consequently, Total Problems scores differed significantly between T1 and T2 (p=.02, moderate 
effect size 0.77). Externalizing Problems scores did not change significantly as indicated by a small 
effect size (0.09). In a single linear regression model, baseline internalizing problems predicted 
later internalizing problems (adjusted R2 = 0.33, p = .003). Individual changes in CBCL Internalizing 
T-scores are presented in Figure 2. 
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Figure 2. Individual differences in T scores on the CBCL Internalising Problems scale between baseline (T1) and follow-
up (T2) (n=23). Decreases (light grey arrows) and increases (dark grey arrows) arranged in order of magnitude of 
change. The solid line represents population mean (T score=50), dashed line indicates lower limit of borderline scores 
(T score=60), dotted line indicates lower limit of clinical scores (T score=63). 
 
Multivariable linear regression 
Because particularly the Internalizing Problems score increased from T1 to T2, this variable was 
selected as the main dependent variable in regression analyses. To explore the predictive quality 
of each predictor separately, each of the variables at T1 from Tables 1 and 2 and length of follow-
up time were entered into a linear regression model (backward method), with Internalizing 
Problems scores at T2 as dependent variable, controlling for Internalizing Problems scores at T1. 
None of the variables at T1 contributed significantly to the regression equation. Also IQ at T2 was 
not found to be of predictive value. This corresponds with the low, non-significant correlations 
between Internalizing Problems scores and intelligence at T1 (N=34) and T2 (N=23).  
 
Discussion 
The present study investigates the development over time of parent-reported behavioral 
problems in young children with NF1 and the influence of intelligence, language development, and 
early behavioral problems. In accordance with other studies 35, we did not find an elevated level of 
behavioral problems in young children (mean age 4;5 years), but we did find more internalizing 
Chapter 3
68
  
 
69 
 
problems at a later age (mean age 7;11 years), compared to a normative sample. Higher rates of 
internalizing problems indicate more anxious, withdrawn and depressed behavior and/or more 
somatic complaints. Other, non-longitudinal studies also found more internalizing than 
externalizing problems in children with NF1 7, 8, 36. Our most prominent finding is a significant 
increase of parent-reported internalizing problems with age, as opposed to Lorenzo et al.20, who 
found no differences over time in younger children (1y 9mo to 3y 4mo). Considering their findings, 
this would imply that changes in internalizing behavior in these children with NF1 occurred at 
kindergarten-age but possibly not before.  
In our study, gender, age, non-verbal intelligence, and language development at T1 did not 
contribute significantly to behavioral problems at T2. In addition, intelligence scores at T2 did not 
correlate significantly with internalizing or externalizing problems at T2. This is in line with 
previous research 37 in which internalizing and externalizing behavioral problems did not correlate 
significantly with IQ-measures. In our study, only pre-existing internalizing problems at T1 
predicted internalizing problems at a later age in children with NF1. Verhulst and Van der Ende 38 
suggested that internalizing problems appearing in preschool children tend to persist over time. In 
our study, the internalizing problems not only persisted, but in 19 out of 23 children, these 
problems increased. The scores of most of these children moved into the clinical range, as shown 
in Figure 2. This increase is hard to explain when only relying on the current dataset. Only 
expressive grammatical language development had a possibly meaningful but nonsignificant 
contribution to the effect of initial internalizing problems (adjusted R2 increased from .35 to .44 
with CBCL at T1: standardized beta= .52; p= .01 and SELT SDQ at T1: standardized beta= -.31; p= 
.10). Possibly, a delay in expressive language development affects social and emotional 
development, worsening internalizing behavioral problems 39, 40.  In addition, internalizing 
problems in young children may remain unnoticed and thus untreated 41 leading to an increase of 
these problems. 
Intelligence and the rate of familial versus non-familial patients in this group are 
comparable to those in former samples of children with NF1. Non-verbal IQ at T1 and Full Scale IQ 
at T2 were in accordance with the Full Scale IQ of 86 in children with NF1, found by Krab et al.3. In 
our study, 33 of the children at T1 (55%) had a de novo mutation, which falls between the 
estimates of de novo mutation rates by Evans et al. (1; 42%) and Van Minkelen et al. (42; 74%). 
Having familial NF1 appeared to be a significant factor in language development, since these 
children scored lower on all language scales. Having a parent with NF1 might influence language 
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development. Whether this could be explained by genetic or sociocultural transmission is unclear 
and possibly a subject for further study.  
Strengths and limitations 
In neurogenetic disorders such as NF1, systematic follow-up is not obvious and sample sizes of 
longitudinal studies are generally small. This retrospective, longitudinal study follows the 
development of a sample of children with NF1. Because of the voluntary nature of the 
assessments offered, only 38 out of 61 children were assessed at two time points and out of these 
38, 23 CBCL’s were available. This loss to follow-up may affect the representativeness of this 
sample and so the generalizability of the results and the conclusions of this study. The decrease in 
sample size could result in attrition bias: maybe particularly parents with children who have more 
severe (behavioral) problems return for a second evaluation. Since the intelligence scores at T1 
and T2 are comparable and similar to the scores previously found in children with NF1 in our 
center 3, we assume that results are not biased by a selection in cognition. The dropout on T2 
because of unavailability of CBCL’s is another point of concern. We tried to estimate its effect by 
comparing the groups with and without CBCL on all available variables and did not find any 
differences. One could argue that mainly parents of children with severe or increasing 
(internalizing) problems returned for an evaluation at T2. Next to this, there is a wide variability in 
the length of follow-up time. This however did not contribute to the observed differences in 
internalizing problems scores. 
 The difference in questions and scales of the CBCL/1 ½-5 and the CBCL/6-18 could be 
regarded as another limitation. In the first, subscales of the Internalizing Problems scale are 
Emotionally Reactive, Anxious/Depressed, Somatization, and Withdrawn. In the second, these are 
Anxious/Depressed, Withdrawn, and Somatic problems. Most preschool scales have a clear 
counterpart in the school-age scales. The correlation between the Internalizing Problems scales of 
the preschool and the school-age forms is between .39 and .61 43. Unfortunately, we did not have 
the scores on all the subscales, so we could not point out which of the subscales made the 
difference. Since former research did not show a difference between the scores on the separate 
subscales for Internalizing Problems 8, 36, we expect that the difference could be an effect of an 
increase in scores on all these subscales.  
Measuring internalizing problem behavior in young children in an objective way is difficult 
and the validity of parental report could be disputed. However, there is no gold standard in 
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assessing behavioral problems in children, and  both CBCL and TRF discriminate well between 
referred and non-referred populations 44. Although it seems hard to measure this construct, test-
retest reliability of the CBCL for young children is .81 and the internal consistency of the 
Internalizing scale is .94 45. Because the data in this study were retrieved from patient records, 
only the scores on main scales of CBCL and TRF were available, but not on items or syndrome 
scales. Future research could focus on the nature of internalizing problems in young children and 
on variables that are predictive of later behavioral problems such as family functioning, ADHD and 
ASD (Autism Spectrum Disorder) behavior, and social economic status.  Particularly the 
development of ASD symptoms is of interest. A recent cross-sectional study found an increase of 
social difficulties when comparing children with NF1 before and after the age of 8 years 46. 
Internalizing problems as found in our study include withdrawn behavior. These behaviors could 
be related to social problems such as autism at a later age. 
Clinical implications 
In the general population, early preschool internalizing problems are predictive of DSM-IV 
diagnoses at school age 47. More specifically, internalizing behavior such as anxious and depressed 
behavior is predictive of later mood disorders 48. The risk of mood disorders increases in early 
adolescence. In the light of our findings, caregivers should be sensitive to psychopathology in 
children and adolescents with NF1, especially to those that showed early problems in this area.  In 
early and regular evaluations of emotional and behavioral problems in children with NF1, 
internalizing problems such as anxiety and depression should be a major point of concern. Both 
externalizing and internalizing problems can cause severe stress in families and schools. Early 
behavioral and psychosocial interventions should aim to support children and their parents and to 
reduce emotional and behavioral problems in children with NF1. Fortunately, internalizing 
problem behaviors are generally responsive to treatment 49. 
Next to this, especially children with familial NF1 should have an assessment of language 
and cognition at preschool. To confirm our observations from this incomplete follow-up, we are 
currently evaluating the development of children with neurocognitive genetic disorders over a 
broad age-range, at fixed ages, with a fixed battery of neuropsychological tests, facilitating 
comparability between constructs and ages.  
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Conclusions 
This study suggests a risk of increasing parent-reported internalizing behavioral problems in 
children with neurofibromatosis type 1. These problems seem to increase between the ages of 
four and eight years. Early internalizing problems at preschool may be determinants of 
internalizing problems at a later age. This underlines the importance of behavioral assessment at a 
young age. Future prospective research will help to identify risk factors to guide the focus of 
intervention programs. 
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Abstract  
To assess emotional and behavioral problems in children and adolescents with neurofibromatosis 
type 1, parents of 183 individuals aged 10.8 ± 3.1 years (range 6 to 17) completed the Child 
Behavior Checklist (CBCL). Also, 173 teachers completed the Teacher’s Report Form (TRF), and 88 
adolescents (children from 11 to 17 years) completed the Youth Self-Report (YSR). According to 
parental ratings, 32% scored in the clinical range (above the 90th percentile). This percentage was 
much lower when rated by teachers or adolescents themselves. Scores from all informants on 
scales for Somatic complaints, Social problems, and Attention problems were significantly 
different from normative scores. Attentional problems were associated with lower verbal IQ, male 
gender, younger age, and ADHD-symptoms. Disease-related factors did not predict behavioral 
problems scores. Substantial emotional and behavioral problems were reported by parents, 
teachers, and to a lesser extent by adolescents with NF1 themselves. Possibly, a positive illusory 
bias affects the observation of behavioral problems by adolescents with NF1.  
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Introduction 
Neurofibromatosis type 1 (NF1) is a common genetic disorder, with a birth incidence of at least 1 
in 2,700 1. NF1 is mainly characterized by various progressive neurocutaneous manifestations, 
including café-au-lait spots, skinfold freckling, and neurofibromas. The most frequent 
complications of NF1 in children are deficits in cognition and behavior 2. Neuropsychological 
deficits include a lowered average IQ, as well as problems with academic skills, visuospatial skills, 
social competence, and attention 3. Up to 75% of NF1 children have learning disabilities and the 
majority of children need additional support, e.g. special education and/or remedial teaching 4. 
Parental behavioral reports using the Child Behavior Checklist (CBCL) tend to reveal problems 
predominantly in the internalizing domain, encompassing anxiety, depression, social withdrawal, 
and somatic complaints 5, 6. 
So far, assessments of the behavioral phenotype of children with NF1 have mainly focused 
on reports by proxies 7-9. The addition of children’s perspectives could help guide future 
consultation. Former studies used small numbers of NF1-patients, whereas larger samples might 
facilitate the identification of predictors of behavioral problems. 
This study aims to (1) describe emotional and behavioral problems in a large group of 
children with NF1 as identified by parent and teacher reports versus self-reports and (2) identify 
demographic, cognitive and disease-related factors contributing to these problems. 
 
Method 
Procedure 
Patients were recruited from the NF1 outpatient clinics of two national referral centers: the 
Erasmus Medical Center, Sophia Children’s Hospital (Rotterdam, the Netherlands), and the Centre 
for Human Genetics of the University Hospitals of Leuven (Belgium). These were supplemented 
with baseline data of participants from two randomized controlled trials 10, 11. When children had 
more than one evaluation, the most recent one was used. Inclusion criteria for this study were: 
NF1 diagnosis according to the criteria of the National Institutes of Health 12, age 6 to 18 years, and 
informed consent from parents and from adolescents aged 12 years and older. For the purpose of 
this study, patients were included if at least one parent questionnaire (Child Behavior Checklist: 
CBCL) was completed between 2005 and 2013. Exclusion criteria for all children and adolescents 
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were: segmental NF1, symptomatic CNS pathology (including cerebral tumors or symptomatic 
optic pathway gliomas requiring treatment), deafness or severely impaired vision, use of anti-
epileptic medication, inefficient production/ comprehension of the Dutch language, and an IQ 
below the range covered by the WISC-III-NL (Total IQ below 48). An additional exclusion criterion 
for one of the trial groups 10 was the use of stimulant drugs. In total, 183 children and adolescents 
were included. This study was approved by the Medical Ethical Committee of Erasmus MC, Sophia 
Children’s Hospital and the Medical Ethical Committee (MEC) of the University Hospitals of 
Leuven. For data of all trial participants informed consent was received and for patients in clinical 
follow-up, a formal review and waiver of the MEC was given. 
Instruments 
Parents completed the Child Behavior Checklist to assess emotional and behavioral problems with 
the CBCL/6-18 (120 items). Teachers completed the Teacher’s Report Form (TRF, 120 items) and, 
as is customary, adolescents from 11 to 17 years old completed the Youth Self-Report (YSR, 119 
items)13, 14. These three questionnaires contain the same eight ‘syndrome scales’, enabling cross-
informant comparison: Anxious/Depressed, Withdrawn/Depressed, and Somatic complaints 
(together: Internalizing or emotional problems); Rule-breaking behavior and Aggressive behavior 
(together: Externalizing or behavioral problems); and Social problems, Thought problems, and 
Attention problems. All questionnaires consist of a problem section with items rated 0 (never 
true), 1 (somewhat or sometimes true), or 2 (often or always true). Raw scores are converted to T 
scores (mean 50, SD 10), with higher scores corresponding to more problems. Sum-scores result in 
three broad-band scales for Internalizing, Externalizing, and Total problems. Test-retest reliability 
in the Dutch population is sufficient to good for the broad-band scales (Pearson’s r =0.82- 0.94) 
and acceptable for the syndrome scales (r = 0.72- 0.92)14. T scores on the broad-band scales 
between 59 and 64 (84th to 90th percentile) are considered to fall within a borderline clinical range, 
whilst T scores of 64 and higher fall within the clinical range. For syndrome scales, these cut-off 
scores are 65 for the borderline range and 70 for the clinical range (93rd and 97th percentile)14. 
Scores were compared with those of the full normative sample of the Dutch version of the CBCL, 
TRF, and YSR questionnaires. These norms are from a randomly drawn sample, regarded as 
representative of the total Dutch population.  
Physical disease severity was scored using the Riccardi Scale 15, modified to exclude 
cognitive aspects of NF1 11 into Minimal NF1 (patient has no features that compromise health, i.e. 
Chapter 4
80
  
 
81 
 
only harmless cosmetic features such as café au lait maculae, freckling, and Lisch nodules), Mild 
NF1 (patient has minor medical complications such as small stature or discrete plexiform 
neurofibroma), Moderate NF1 (patient has complications that are a significant compromise to 
health, such as paravertebral neurofibromas or hypertension), and Severe NF1 (medical history 
with malignancy). After reviewing the data, the severity groups ‘moderate’ and ‘severe’ were 
merged, because only four children were in the ‘severe’ group.  
Intelligence was measured with the Wechsler Intelligence Scale for Children, third edition, 
Dutch version (WISC-III-NL)16. The WISC-III-NL is an intelligence test for children aged 6 to 16 years. 
The test consists of several subtests resulting in a Total IQ, Verbal IQ, and Performance IQ, with a 
population mean of 100 and an SD of 15.  
Participants 
Clinical data were prospectively registered by a pediatrician experienced in NF1. Socioeconomic 
status was determined from highest parental occupation and was divided into low, middle, or 
high, modified from the Dutch standard occupation classification 17. Children with an ADHD 
classification regardless of subtype (inattentive, hyperactive/impulsive or combined) were 
identified independently from CBCL-scores by a retrospective chart review using DSM-IV criteria. 
Statistical analyses 
Data were analyzed using SPSS 21. In behavioral rating scales, data are usually non-normally 
distributed, as is the case in our sample. Therefore, we used nonparametric tests for comparisons 
(independent samples Mann-Whitney U-tests or independent-samples Kruskal-Wallis tests). 
Although Table 2 reports T scores to communicate clinically relevant data, all comparisons and 
regressions in other tables were performed using raw scores. Spearman’s ρ correlations were 
calculated to measure agreement between parent-, teacher-, and self-ratings, with correlations 
between .10 and .29 representing a small association, .30-.49 a medium association, and above 
0.50 a large association.18 Effect sizes were calculated using Cohen’s d, with .20 interpreted as a 
small effect size, .50 as medium, and .80 as large 18. When comparing scores on syndrome scales 
with those of the Dutch normative sample of CBCL, TRF, and YSR, the level of significance was 
adjusted for multiple testing with a Bonferroni correction. Since all three questionnaires contain 
eight syndrome scales, 𝛼𝛼 was set at .025/(3*8) = .001.  
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In regression analysis, a two-phase strategy was followed for each of the outcome 
measures. In phase 1, all separate prediction variables from Table 1 were tested in univariable 
analyses on those CBCL, TRF, and YSR syndrome scales on which scores were significantly different 
from the normative sample for all three informants. Since this phase served as an initial, broad 
selection of predictors, α in phase 1 was set at .10. The final model in phase 2 contained all 
significant variables from phase 1. Variables shown to be significant contributors in the final model 
were regarded as the final predictors of CBCL, TRF, and YSR outcomes (α in phase 2 was set at .05; 
backward elimination procedure).  
 
Results 
Patient characteristics 
We included 183 children and adolescents, 129 from the Netherlands and 54 from Belgium. 
Seventy percent of the children (N=128) were participants from randomized controlled trials, 24 
percent (N=44) from the first trial 11, 46 percent (N=84) from the second 10, the other thirty percent 
(N=55) were patients from outpatient clinics. General, cognitive, and disease-specific NF1 
characteristics are shown in Table 1. Teachers of 173 children (95%) completed the TRF and 88 of 
these children (48%) completed a YSR (i.e. 90% of those eligible for self-report). As to our 
knowledge, missing data were due to the fact that some teachers or adolescents did not return 
the forms that were sent or given to them. The age-range of all children was 6 to 17 years. Thirty-
six percent (n=66) attended a school for special education. ADHD classifications were present in 53 
children (33%), of whom 19 used behavioral medication: 18 used stimulants and one used anti-
psychotic medication. Of the children without ADHD classification, one used anti-psychotic 
medication. The distribution of Total IQ scores was shifted to the left while retaining a Gaussian 
distribution and ranged from 51 to 125. Not all information from patient records was found to be 
complete. Particularly information on ADHD, IQ, microdeletion status and parental profession was 
not routinely collected in the outpatient clinics and were missing in 7-20% of the patients.  
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Table 1. Characteristics of the Children with NF1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data represented as number/sample size and percentage unless stated otherwise. aMean (SD). 
  
Characteristic N (%) 
General characteristics (N=183)  
Age at time of CBCLa 10.8 (3.1) 
Gender  
  Male 100/183 (55%) 
  Female 83/183 (45%) 
Socio-Economic Status  
  Low 51/148 (34%) 
  Middle 49/148 (33%) 
  High 48/148 (32%) 
School Type  
  Regular 115/181 (64%) 
  Special 66/181 (36%) 
ADHD  
  Yes 53/161 (33%) 
  No 108/161 (67%) 
Cognitiona (N=158) 
Total IQ 
 
85 (16) 
Verbal IQ 87 (16) 
Performance IQ 86 (16) 
NF1 Characteristics (N=183)  
Mode of Inheritance  
  Familial 70/170 (41%) 
  Sporadic 100/170 (59%) 
NF1-Microdeletion  14/159 (9%) 
Severity   
  Minimal 84/179 (47%) 
  Mild 33/179 (18%) 
  Moderate 58/179 (32%) 
  Severe 4/179 (2%) 
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Behavioral problems in a large sample of children and adolescents with NF1 
Scores on the CBCL, TRF, and YSR questionnaires are shown in Table 2. Cronbach’s alpha’s as 
calculated for the CBCL (116 items; α = .956), the TRF (111 items; α =.933), and the YSR (115 items; 
α =.924) were excellent, indicating high internal consistency. We found no differences between 
the groups of data-origin (trial/outpatient clinics, Belgian/Dutch) on syndrome scale scores. Also, 
scores of the children from the second trial 10, where additional exclusion criteria were applicable, 
did not differ from scores from the other children. In addition, percentages of ADHD classifications 
were not different when comparing the children within this trial to children in the other groups (χ2 
(1, N= 161)=.672, p=.412)). Overall, parents scored behavioral problems in the clinical range more 
frequently than teachers or children, illustrated by the overall rating on the Total problems Scale, 
with scores of parent ratings in the clinical range for 58 children (32%), compared to 35 (20%) 
according to teachers and only six (7%) according to adolescents themselves, as is shown in Figure 
1. For comparison of groups, we looked at those individuals (N=81) from whom all three 
questionnaires (CBCL, TRF, and YSR) were present and found proportions of adolescents scoring in 
the clinical range that did not differ substantially: 31%, 21%, and 7% respectively. Associations 
between informants on syndrome scales are all small to medium-sized and comparable to those 
found in the general population. Associations of parent-teacher ratings range from .25 to .47 in 
the NF1 group and from .21 to.44 in the normative sample 14. Associations between parent- and 
self-ratings range from .17 to .51 for NF1 and from .29 to .53 in the normative sample. Between 
teacher- and self-ratings, associations range from .004 to .28 for NF1 and from .01 to .36 in the 
normative sample.  
As shown in Table 3, raw scores on most scales differed significantly from those of the 
normative sample. After adjusting for multiple comparisons, all three informants reported 
significantly more problems on the broad-band scale for Internalizing problems and on the 
syndrome scales for Somatic complaints, Social problems, and Attention problems, compared with 
the normative sample. Effect sizes of parent ratings were generally larger than those of teacher- 
and self-ratings. Parents reported significant problems, with medium to large effect sizes on four 
out of eight syndrome scales: Somatic complaints (d = .54), Social problems (d = 1.19), Thought 
problems (d = .52), Attention problems (d = 1.02). According to teacher-ratings, Social problems 
had a medium effect size (d = .67). For self-ratings, Social problems (d = .73) had a medium effect 
size. All other effect sizes were below medium. The lowest scores were on the Rule-breaking 
behavior scale.  
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As shown in Table 3, raw scores on most scales differed significantly from those of the 
normative sample. After adjusting for multiple comparisons, all three informants reported 
significantly more problems on the broad-band scale for Internalizing problems and on the 
syndrome scales for Somatic complaints, Social problems, and Attention problems, compared with 
the normative sample. Effect sizes of parent ratings were generally larger than those of teacher- 
and self-ratings. Parents reported significant problems, with medium to large effect sizes on four 
out of eight syndrome scales: Somatic complaints (d = .54), Social problems (d = 1.19), Thought 
problems (d = .52), Attention problems (d = 1.02). According to teacher-ratings, Social problems 
had a medium effect size (d = .67). For self-ratings, Social problems (d = .73) had a medium effect 
size. All other effect sizes were below medium. The lowest scores were on the Rule-breaking 
behavior scale.  
Predictors of emotional and behavioral problems 
When comparing disease characteristics of subgroups, there were no differences in scores on 
broad-band problem scales between children with a familial or sporadic mutation, between 
children with or without a microdeletion, nor between those with minimal, mild, or 
moderate/severe disease severity. 
Single linear regression analysis (phase 1; Table 4) revealed possible predictors for three 
selected syndrome scales: Somatic complaints, Social problems, and Attention problems. In 
multivariable regression analyses (phase 2; Table 5), significant predictors were found for parent- 
and teacher-rated Attention problems. Models for the other scales identified no significant 
predictors. Total IQ was not entered in the regression analyses because verbal IQ accounted for 
the significant contribution of total IQ.  
Parent-reported Attention problems were predicted by ADHD and lower verbal IQ. 
Teacher-reported Attention problems were predicted by younger age, male gender, ADHD, and 
lower verbal IQ. 
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Table 5. Multivariable Backward Regression Analyses showing significant predictors of scores on syndrome 
scales for Somatic complaints, Social problems, and Attention problems from CBCL (parent rating), TRF 
(teacher rating), and YSR (adolescent self-rating) 
 
 
*p <.05. **p <.01. ***p <.001.
Predictor and Outcome 
Variables 
df F R2 Adjusted 
R2 
Constant Unstandardized 
coefficient β 
SE Standardized 
coefficient β 
CBCL         
Social problems         
Model 1 157 2.69 .03 .02 9.61    
Gender      -.71 .57 -.10 
Verbal IQ      -.03 .02 -.15 
Model 2 157 3.81 .02 .02 8.69    
Verbal IQ      -.03 .02 -.15 
Attention problems         
Model 1 137 4.75** .13 .10 12.11    
Gender      -.56 .68 -.07 
School type      .16 .84 .02 
ADHD      2.11 .72 .24** 
Verbal IQ      -.05 .03 -.20* 
Model 3 137 9.21*** .12 .11 11.81    
ADHD      2.22 .70 .26** 
Verbal IQ      -.05 .02 -.22** 
TRF         
Attention problems         
Model 1 126 11.30*** .27 .25 35.14    
Age      -.59 .25 -.19* 
Gender      -5.85 1.4
5 
-.32*** 
ADHD      5.02 1.5
5 
.26** 
Verbal IQ      -.10 .04 -.19** 
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Discussion 
In this study, not only parent- and teacher-ratings in children with NF1 were taken into account, but 
also adolescent’s self-reports of emotional and behavioral problems. Parents, teachers, and 
adolescents reported significantly elevated scores for emotional and behavioral problems in a large 
group of children and adolescents with NF1. Children and adolescents with NF1 differed from children 
and adolescents from a normative sample on most of the broad-band scales and syndrome scales. In 
parent ratings, a high percentage of children (32%) displayed clinically significant problems. Teachers 
and adolescents reported fewer problems in the clinical range. Parents reported more severe 
problem behaviors over a wider range of areas than teachers, and teachers reported more problem 
behaviors than adolescents themselves.  
Adolescents with NF1 reported fewer behavioral difficulties than their parents, whereas self-
reports of adolescents from reference populations in various countries report more problems than 
their parents 19. Notably, even ADHD was not predictive of self-rated attention problems. The 
tendency towards a more positive self-report seen in our study is reminiscent of the pattern seen in 
children with NF1 reporting rather positively on their academic performance compared to objective 
measures 20 or on their quality of life compared to their parents 21. In children with ADHD, children 
with learning disabilities 22, and in children with NF120, this ‘positive illusory bias’, serving as a self-
protective mechanism, is regarded a possible explanation for these discrepancies.  
In the general population, the agreement between informants is typically modest 23, 24. 
Discrepancies between informants may be determinants of poor outcome. For instance, a CBCL-YSR 
discrepancy on the rating of attention problems in a clinical sample predicted disciplinary problems at 
school some four years later 23. Since this discrepancy is clearly present in this group of adolescents 
with NF1, caregivers should pay attention to the views of both parents and adolescents. Although the 
agreement between parents, teachers, and adolescents can be low, all different perspectives 
contribute to a more complete view of children and their problems. Also, the psychological treatment 
of adolescents with parent and teacher-rated emotional and behavioral problems will be different 
when the adolescents themselves do not agree with their parent’s and teacher’s reports. In that case, 
the motivation for treatment may need to be addressed before starting treatment. Creating 
awareness for another’s perception of behavior could be an important focus in therapy.  
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Children with NF1 differed significantly from a normative sample on most broad-band and 
syndrome scales. However, not all of these differences had a large effect size. There was a strong 
agreement between all informants regarding high scores on the Social problems scale. This underlines 
the presence and severity of social problems in children and adolescents with NF1. Previous research 
in smaller groups 7, 9, 25 reported the social problems and the lack of social skills in children with NF1, 
particularly in those with comorbid ADHD 9 or ASD 26-28. Unfortunately, we did not find any significant 
predictors of these social problems. Other studies found an elevated risk of poor social functioning 9 
and social competence problems in children with elevated ADHD symptoms 28. Possibly, our sample 
did not show this effect due to a lower severity of ADHD symptoms as a result of the exclusion of 
children with ADHD using stimulant medication in one of the trials 10, containing 46% of the children. 
A different explanation for this decreased association of social problems and ADHD in NF1 could be 
that the NF1 mutation itself is responsible for limitations in social learning, next to other factors that 
impact on social learning, such as ADHD and ASD 29.  
ADHD and a lower verbal IQ independently predicted more parent- and teacher-rated 
attentional problems. Young age and male gender were additional independent predictors of teacher-
rated attentional problems. The association between ADHD, male gender and attentional problems is 
not new, in this respect, children with NF1 do not differ from children in the general population. 
Males, in general, are more likely to meet the criteria for ADHD, confirming this association between 
gender and attentional problems 30. Although the prevalence of attentional problems generally does 
not decrease with age in children in this age range 30, this is the case in our group. The association 
between lower verbal IQ and attentional problems is of interest, as it adds new evidence to the 
suggested link between verbal IQ and ADHD in NF1. A recent study suggested a link between verbal IQ 
and both ADHD and ASD symptoms 31. In our study, we did not assess ASD symptoms but we did find a 
high level of social problems. Although in the current study, the association between verbal IQ and 
social problems did not reach significance, the triad of social, attentional, and verbal problems may be 
a point of concern in children and adolescents with NF1 and warrants further investigation. In NF1, 
male gender, ADHD, young age and low verbal IQ should not only be regarded as predictors of 
attentional problems at school but also as risk factors for developing these problems. 
In none of the final regression models, disease-related factors such as disease severity, NF1-
microdeletion status, and familial inheritance were significant predictors of behavioral outcome. 
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Although disease characteristics such as severity of NF1 do have an effect on the perceived quality of 
life in adults 32, this is not the case for behavioral problems in the current group of children and 
adolescents. Since NF1 is a progressive disorder and somatic problems tend to increase during life, 
the relationship between disease characteristics, behavioral functioning, and quality of life might not 
yet be established in or noticed by children. A study using the BASC-2 parent questionnaire 33 did find 
an association between disease severity and internalizing problems in 50 children.  Differences 
between the instruments used to measure disease severity, between the questionnaire items, or 
between the samples could be reasons why this association was found in the Martin et al. study and 
not in the study reported here. Future studies could benefit from using more comparable instruments 
for disease severity in NF1.  
There are several strengths and limitations to this study. In NF1, studies in large groups of 
patients are rare. We succeeded in gathering data on 183 children between 6 and 17 years old over a 
period of eight years. Since all children visited a university hospital, there is a risk of an academic 
selection bias, possibly including children with more severe problems. However, both centers are 
national referral centers in two geographically small countries and all children were offered a periodic 
follow-up. Since seventy percent of the children were recruited for randomized controlled trials, there 
is a possibility for ascertainment bias. However, these children did not differ in their behavioral scores 
from children in clinical follow-up. Although for a subgroup of children (46%), the use of stimulant 
medication was an exclusion criterion, the proportion of children with ADHD did not differ between 
the children in this subgroup and the other children in our study, nor was there a difference between 
this subgroup and the total group. Nevertheless, this selection could have biased the sample towards 
a less severe behavioral phenotype, limiting the generalizability of the results.  
Not all data in this study were complete. For instance, information on intelligence, NF1-
microdeletion status, and parental profession was not routinely collected in the group of outpatient 
children. However, the group with missing data did not differ significantly from the group that had 
complete data on any of the behavioral scale scores.  
 
Conclusion 
This study shows that in parent-ratings, almost one-third of the children with NF1 have severe 
emotional and behavioral problems. Most of these problems are in the internalizing domain but 
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adolescents themselves are less likely to report these problems. This might hinder the identification of 
these problems, especially for caregivers that have a less intimate relationship with the child. Whilst 
teachers and adolescents themselves report fewer problems than parents do, they also report 
different problems from ecologically different perspectives. Problem behavior might be tackled more 
effectively if multiple views are taken into account. Groups at risk for developing these problems are 
children with NF1 and a lower verbal IQ, boys, younger children (primary school age), and children 
with ADHD-symptoms.  
NF1 clearly predisposes to behavioral problems, and this is most likely not associated with the 
physical severity of the disease. Although animal studies have shed light on the molecular and cellular 
mechanisms underlying cognitive problems 34, the way these mechanisms lead to emotional and 
behavioral problems remains unclear. In the follow-up of children and adolescents with NF1, one 
should screen for a wide range of emotional and behavioral problems, using multiple informants. 
Whenever these screenings are positive, referral to mental health professionals is recommended.  
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Summary 
 
Background  
Neuroﬁbromatosis type 1 is a common genetic disorder characterised by neurocutaneous 
manifestations and cognitive and behavioural problems. Statins were shown to reduce analogous 
learning deﬁcits in a mouse model of the disease, but a short-term trial in humans was inconclusive. 
We aimed to assess the use of simvastatin for the improvement of cognitive and behavioural deﬁcits 
in children with neuroﬁbromatosis type 1 for 12 months. 
Methods  
In this randomised, double-masked, placebo-controlled trial, we recruited children with genetically 
conﬁrmed neuroﬁbromatosis type 1 aged 8–16 years from two national referral centres in the 
Netherlands and Belgium. Those with symptomatic CNS abnormalities or on neurotropic medication, 
including stimulants, were excluded. Eligible patients were randomly assigned (1:1) via a computer-
generated, permuted-block list to simvastatin (10 mg per day in month 1, 20 mg per day in month 2, 
and 20–40 mg per day in months 3–12) or placebo for 12 months. Investigators, participants, and 
parents were masked to treatment assignment. Primary outcome measures were full-scale 
intelligence (Wechsler intelligence scale for children), attention problems (child behaviour checklist, 
parent-rated [CBCL]), and internalising behavioural problems (CBCL). We did intention-to-treat 
analyses (of all patients who had outcome data) using linear regression of the 12 month outcome 
scores, adjusted for baseline performance. This trial is registered with the Netherlands Trial Register, 
number NTR2150. 
Findings  
We randomly assigned 84 children to a treatment group (43 to simvastatin, 41 to placebo) between 
March 9, 2010, and March 6, 2012. We did not assess outcomes in two patients in the placebo group 
because they needed additional drug therapy. Simvastatin for 12 months had no eﬀect on full-scale 
intelligence (treatment eﬀect compared with placebo –1.3 IQ points [95% CI –3.8 to 1.3]; p=0.33), 
attention problems (–1.6 T-score points [–4.3 to 1.0]; p=0.23), and internalising behavioural problems 
(–0.1 T-score points [–3.3 to 3.1]; p=0.96). 38 (88%) of 43 patients on simvastatin and 39 (95%) of 41 
patients on placebo reported adverse events, which were serious in two and four patients, 
respectively. 
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Interpretation  
12 month simvastatin treatment did not ameliorate cognitive deficits or behavioural problems in 
children with neurofibromatosis type 1. The use of 20–40 mg simvastatin per day for cognitive 
enhancement in children with neurofibromatosis type 1 is not recommended. 
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Introduction 
Neuroﬁbromatosis type 1 is a common autosomal-dominant disorder, with a prevalence of 1 in every 
2500–3000 births.1 It is caused by loss-of-function mutations in the NF1 gene, which encodes 
neuroﬁbromin, a negative regulator of rat-sarcoma viral oncogene homologue (Ras). 
Neuroﬁbromatosis type 1 is characterised by cutaneous café-au-lait spots, neuroﬁbromas, and 
cognitive and behavioural problems.2 Up to 80% of children aged 6–18 years with neuroﬁbromatosis 
type 1 present with moderate to severe impairment in one or more areas of cognitive functioning, 
and 40% attend special education.3,4 Moreover, 30–40% of children with neuroﬁbromatosis type 1 
fulﬁl criteria for attention deﬁcit hyperactivity disorder and up to 60% have problems with executive 
functioning.3,5 The average intelligence quotient (IQ) is 10–15 points lower in these children than in 
population or sibling control groups.3,6 Parents of children with neuroﬁbromatosis type 1 frequently 
report diﬃculties in their child’s social daily life activities and a high rate of internalising behavioural 
problems, such as anxiety or mood disorders.7 Taken together, cognitive and behavioural deﬁcits lead 
to lower academic achievement and loss of quality of life,4,8,9 persisting into adulthood.10 The learning 
and attention deﬁcits noted in patients with neuroﬁbromatosis type 1 are reported in the Nf1+/– 
mouse model,11–13 accompanied by a decrease in synaptic plasticity.11–13 These animal studies have 
shown that the plasticity and behavioural deﬁcits are reversed by reducing Ras activity.11,14 Ras 
activity requires farnesylation, which allows Ras to anchor to the plasma membrane where it can be 
activated by growth-factor receptors and their adaptor proteins. Since cholesterol is an obligate 
precursor of farnesyl, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
have been suggested as a potential therapy for neuroﬁbromatosis type 1. Indeed, lovastatin 
normalised Ras activity, rescued synaptic plasticity deﬁcits, and restored learning and attention 
deﬁcits in the Nf1+/– mouse model.14 Results of a small, open-label, single-arm study of lovastatin in 
children with neuroﬁbromatosis type 1 suggested that lovastatin improved memory and attention, 
and normalised default network functional connectivity measured with resting state functional 
MRI.15,16 
However, lovastatin is not approved or marketed in many parts of the world, including the 
European Union. The closest approved alternative, simvastatin, is similar in structure, 
pharmacokinetics, and blood–brain barrier permeability. Moreover, simvastatin is a slightly more 
potent inhibitor of HMG-CoA reductase and is better at reducing HMG-CoA reductase activity in 
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neurons than is lovastatin.17,18 Although ﬁndings of a randomised controlled trial reporting the short-
term eﬀect of simvastatin in children with neuroﬁbromatosis type 1 showed no eﬀect after 12 weeks 
on a set of primary outcome measures,6 a signiﬁcant improvement was reported for a secondary 
outcome measure, the object assembly subtask of the Dutch translation of the third edition of the 
Wechsler intelligence scale for children (WISC-III-NL).6 
Although this trial had an overall negative outcome, it had some limitations that might have 
aﬀected its results: children on stimulant- medication were not excluded, and 12 week treatment was 
short, with only 4 weeks at the highest target dose. A longer treatment duration would have allowed 
the assessment of the eﬀects on global cognitive functioning, daily life functioning, and behaviour, 
and might have been necessary to show clinical beneﬁts. 
Given the large amount of safety data in children6,19 and worldwide marketing authorisation of 
simvastatin, we aimed to improve upon the limitations of this previous trial by assessing the use of 
simvastatin for the treatment of cognitive and behavioural deﬁcits in children with neuroﬁbromatosis 
type 1 for 12 months. 
 
Methods 
Study design and participants  
We undertook this randomised, parallel-group, placebo-controlled trial in two national referral 
centres: Erasmus MC (Rotterdam, Netherlands) and UZ Leuven (Leuven, Belgium). We screened 
patients aged 8–16 years with genetically conﬁrmed neuroﬁbromatosis type 1 for eligibility. Genetic 
counselling and testing for neuroﬁbromatosis type 1 is part of routine care and was done 
independently of this trial. The rationale for genetic conﬁrmation was the substantial overlap in 
phenotypes between neuroﬁbromatosis type 1 and related disorders (e.g., Legius syndrome).20 
Exclusion criteria were: use of neurotropic medication, including stimulant, anti- psychotic, 
antiepileptic, antianxiety, and antidepressant drugs, or current simvastatin use; symptomatic CNS 
abnormalities; insuﬃcient comprehension of the Dutch language; severely impaired vision or 
deafness; segmental neuroﬁbromatosis type 1; or an IQ below 48. 
We obtained informed oral and written consent from parents and assent from children of 12 years 
and older. Local and national institutional review boards approved the protocol. The trial was done in 
agreement with the Declaration of Helsinki (version 2008) and Good Clinical Practice guidelines. 
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Randomisation and masking 
Eligible patients were randomly assigned (1:1) by the local hospital pharmacist to simvastatin or 
matched placebo according to computer-generated, permuted block randomisation lists (ten 
participants per block, stratiﬁed by centre) that were provided by the Department of Biostatistics, 
Erasmus MC, with medication numbers in the order of enrolment. All investigators, participants, and 
their parents were masked to treatment allocation. We achieved blinding by using capsules of 
identical colour, shape, size, weight, smell, and taste. 
Procedures 
Participants took 10 mg per day of simvastatin or matched placebo once daily in the morning during 
the ﬁrst month and 20 mg per day once daily in the morning during the second month. During months 
3–12, dosing was ﬁxed at 20 mg per day for children aged 12 years and younger and 40 mg per day for 
adolescents older than 12 years. We assessed efficacy outcome measures at baseline and at the end 
of month 12 of treatment. Since no standard measure exists to assess improvement of cognition in 
patients with neuroﬁbromatosis type 1, we included a broad range of validated tests and 
questionnaires that are sensitive to the cognitive and behavioural deﬁcits in this group of patients. 
Outcome measures included constructs that were similar to those that improved in mouse models 
receiving statins:14 visual-spatial memory and attention; improvements in daily life behavioural 
problems rated by parents; and global cognitive functioning. We used three primary outcome 
measures that are relevant to daily life functioning and academic achievement: full-scale intelligence 
(WISC-III-NL),4,6 parent-reported attention problems (child behaviour checklist [CBCL]21), and parent-
reported internalising behavioural problems (CBCL). The attention problems scale of the CBCL consists 
of items screening for problems in directing and sustaining attention, controlling impulsivity, and 
hyperactivity. Secondary outcomes were visual-spatial memory (Rey complex ﬁgure test–delayed 
recall),6 attention (Stroop colour–word interference test),6 teacher-reported school performance 
(teacher report form),21 parent-reported psychosocial quality of life (child health questionnaire–
parent form 50 [CHQ-PF50]),9 patient-reported internalising behavioural problems (youth self-report 
[YSR] form, completed by patients aged ≥11 years),21 and ﬁne motor coordination (grooved pegboard 
test).8 All neuropsychological tests were developed for children and were written or presented in 
Dutch. For most outcome measures, we used age-standardised scores. The mean average IQ for the 
general population is 100 (SD 15), with higher IQ WISC-III-NL test scores indicating higher intelligence. 
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For CBCL and YSR, data were represented as T scores, with a mean average of 50 and an SD of 10 in 
the general population, with higher scores indicative of more problems. The Rey complex ﬁgure test 
(for which a higher score suggests a better visual-spatial memory) and CHQ-PF50 (for which a higher 
score suggests a better quality of life) are presented using Z scores, with 0 representing the mean for 
the normal sample with an SD of 1. Teacher-reported school performance was calculated on a scale 
from 2 to 10, by summation of 5-point scores on topics of language and arithmetic, in which higher 
scores were given for greater ability in each area. For teacher-reported school performance, Stroop 
colour–word test (for which a lower score suggests better attention), and grooved pegboard test (for 
which a lower score suggests better ﬁne motor coordination), raw scores were used, since no 
appropriate normal groups are available for the entire age range. Measurements taken before and 
after administration of study drug were done by the same neuropsychologist (either ABR or EP). 
Adverse events and study compliance were monitored by monthly telephone contact and by visits to 
the outpatient clinic at baseline and at 1, 3, 6, 9, and 12 months. Adverse events were classiﬁed 
according to WHO adverse reaction terminology and graded according to the National Cancer 
Institute common terminology criteria for adverse events. Blood was drawn at baseline and at 1, 6, 9, 
and 12 months to measure: alanine aminotransferase, aspartate aminotransferase, and creatine 
phosphokinase to screen for laboratory adverse events; and total cholesterol, high-density lipoprotein 
(HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides to assess lower limits of 
lipid concentrations and to monitor compliance. Further details on procedures are presented in the 
appendix. 
 
Statistical analysis 
We used data from the intention-to-treat population—which consisted of all participants with 
outcome data—for all primary and secondary analyses, without imputation of missing values. Data 
from all patients were used for safety analyses—even those without eﬃcacy outcome data. We 
analysed primary and secondary outcome measures using linear regression for the eﬀect of treatment 
group on the score at 12 months, adjusted for baseline performance in the bivariable analysis and 
adjusted for baseline performance, age, and sex in the multivariable analysis. 
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Figure 1. Trial profile   
 
 
The cut-off level for signiﬁcance was set at p<0.05, ignoring multiple testing. We analysed lipid blood 
concentrations using the generalised linear mixed model procedure with the interaction of time and 
treatment as the variable of interest. Sample size calculation suggested that inclusion of 84 
participants (85% power; α=0.05) would be sufficient to detect a clinically relevant treatment effect of 
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7.5 full-scale intelligence points (0.5 SD), adjusted for baseline performance, and an increase or 
decrease of 5 T-score points (SD 0.5) for attention problems and internalising behavioural problems. 
Inclusion of 84 participants would lead to greater than 80% power on the co-primary outcome 
measures of attention problems and internalising behavioural problems. Because of low inclusion 
rates, the protocol was amended from 90% power and 106 participants to 85% power and 84 
participants in the second recruitment year, without outcome knowledge and with approval from 
review boards. We planned the analysis before unmasking according to the study protocol. All data 
were analysed using IBM SPSS Statistics for Windows (version 20.0). 
This trial is registered with the Netherlands Trial Register, number NTR2150. 
Role of the funding sources 
The sponsors of the study had no role in the conception and design of the trial, the collection, 
analysis, and interpretation of the data, the writing of the manuscript, or the decision to publish the 
results. All authors had full access to all of the data in the study, and EL, YE, and HAM had final 
responsibility for the decision to submit for publication. 
For the study protocol see http://www.erasmusmc.nl/nf1-simcoda  
 
Results 
We screened 343 patients for eligibility, of whom 221 were eligible. Between March 9, 2010, and 
March 6, 2012, we obtained informed consent from 84 patients or their parents. They were randomly 
assigned to 12 months of treatment with simvastatin (n=43) or placebo (n=41). Two patients in the 
placebo group were lost to follow-up before outcome could be assessed because they had 
behavioural problems that required drug therapy. Two participants in the placebo group discontinued 
study medication, but were available for outcome assessment (figure 1). Median compliance per 
patient was 96% (IQR 93–100), measured by counting returned capsules. Baseline demographic and 
disease characteristics were generally balanced between both treatment groups, although more 
patients in the simvastatin group were male than in the placebo group (table 1). At baseline, average 
full-scale intelligence was 83.3 points (SD 15.6) and 46 (55%) participants had attention problems 
scored on the CBCL of more than 1 SD above the mean of the general population. Median age was 
11.5 years (range 7.9–16.0). 12 months of simvastatin had no significant effect on full-scale 
intelligence (treatment effect –1·3 IQ points 
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Table 1. Baseline characteristics 
 Simvastatin (n= 43) Placebo (n= 41) 
Age, years 11·1 (9·2 – 13·0) 11·8 (10·2 – 14·7) 
Male sex 26 (61%) 13 (32%) 
Full-scale intelligence (WISC-III-NL)* 83·8 (16·1) 82·7 (15·3) 
Attention problems (CBCL), T-score† 61·1 (8·9) 62·8 (8·3) 
Internalizing behavioural problems (CBCL), T-
score† 
 
55·2 (10·7) 
 
56·7 (10·1) 
NF1 disease severity‡ 
 Minimal 
 Mild 
 Moderate  
 Severe 
 
18 (42%) 
7 (16%) 
17 (40%) 
1 (2%) 
 
21 (51%) 
4 (10%) 
15 (37%) 
1 (2%) 
Genetic mutation type 
 Truncating mutation 
 In-frame del-dup or missense mutation 
 Microdeletion 
 Unclassified variant 
 
24 (56%) 
18 (42%) 
1 (2%) 
0  
 
28 (68%) 
11 (27%) 
1 (2%) 
1 (2%) 
NF1 inheritance 
 Familial 
 Sporadic 
 Unknown 
 
22 (51%) 
21 (49%) 
0  
 
19 (46%) 
20 (49%) 
2 (5%) 
Education type 
 Regular 
 Special 
 
20 (46%) 
23 (54%) 
 
24 (58%) 
17 (42%) 
Parental Occupation§ 
 Lower 
 Middle 
 Higher 
 
18 (42%) 
13 (30%) 
12 (28%) 
 
13 (32%) 
15 (37%) 
13 (32%) 
Total cholesterol, mmol/L 4·17 (0·57) 4·30 (0·75) 
LDL cholesterol, mmol/L 2·33 (0·54) 2·41 (0·65) 
Dose group in months 3-12 
 20 mg/d or placebo 
 40 mg/d or placebo 
 
29 (67%) 
14 (33)% 
 
23 (56%) 
18 (44%) 
 
Data are median (IQR), number (%), or mean (SD). WISC-III-NL=Wechsler intelligence scale for children, third edition, Dutch translation. 
CBCL=parent-reported child behaviour checklist. NF1=neurofibromatosis type 1. LDL=low-density lipoprotein. *Higher is better. †Lower 
is better. ‡NF1 disease severity was scored according to the Riccardi scale, modified to exclude cognitive aspects of NF1.6 §Classification 
of parental occupation was done according to data from the Dutch central bureau of statistics (which uses a five-level scale), which we 
used to apply our own three-level scale. Doses were decided based on the patient’s age. 
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 [95% CI –3·8 to 1·3]; p=0·33), attention problems (–1·6 T-score points [–4·3 to 1·0]; p=0·23), or 
internalising behavioural problems (–0·1 [–3·3 to 3·1]; p=0·96) when adjusted for baseline 
performance (table 2). Additional adjustment for age and sex produced similar results (table 2). 
Simvastatin had no significant effects on any of the secondary outcome measures, including visual-
spatial memory and attention (table 2). Figure 2 shows the standardised treatment effects on primary 
and secondary outcome measures. 
After 1 month (10 mg simvastatin per day), mean total cholesterol in the simvastatin group 
had decreased by 0·78 mmol/L (95% CI 0·54–1·03) more than it had in the placebo group and LDL 
cholesterol decreased by 0·79 mmol/L (0·56–1·01). Cholesterol concentrations had decreased no 
further at 6, 9, or 12 months. HDL cholesterol and triglycerides remained stable over the course of the 
study (appendix). Most adverse events were mild or moderate and frequency was similar between 
groups (table 3). 38 (88%) of 43 patients in the simvastatin group and 39 (95%) of 41 patients in the 
placebo group reported at least one adverse event. No increased incidence of myalgia, myopathy, or 
rhabdomyolysis was reported in patients given simvastatin compared with patients given placebo 
(appendix). Serious adverse events occurred in six patients: two in the simvastatin group and four in 
the placebo group. These events included continuing growth of plexiform neurofibromas (in two 
patients receiving simvastatin and one patient receiving placebo) and progressive scoliosis (two 
patients receiving placebo), all requiring surgery, and hospital admission for gastritis (one patient 
receiving placebo). 
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Results of laboratory screens showed a few mild and transient increases in liver enzymes and 
creatine kinase in both groups (table 3); none led to cessation of treatment. No participants 
reached the predefined lower limits for total cholesterol, HDL-cholesterol, or triglycerides (non-
fasting). In the simvastatin group, seven children had one (n=3) or more (n=4) LDL cholesterol 
measurements below the predefined lower threshold, but no action was recommended by the 
data and safety monitoring board, since other values were within the normal range. Nine (53%) of 
17 girls receiving simvastatin advanced one or more Tanner stages of puberty during the trial, 
compared with 16 (67%) of 24 receiving placebo. 14 (54%) of 26 boys receiving simvastatin and 
seven (54%) of 13 receiving placebo advanced one or more Tanner stages. Two girls in the placebo 
group were not included in this analysis because they did not undergo post-baseline Tanner stage 
assessments.  
 
Figure 2: Standardised treatment effects. 
 
 
 
The effect of simvastatin on primary and secondary outcome measures, adjusted for baseline 
performance, age, and sex. Treatment effects have been converted to SD difference and are accompanied 
by the corresponding 95% CI. WISC-III-NL = Wechsler intelligence scale for children, third edition, Dutch 
translation. CBCL = parent reported child behaviour checklist. CHQ-PF50 = child health questionnaire–
parent form 50. YSR = youth self-report. 
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Discussion 
Here we present the outcome of our randomised, double-masked, placebo-controlled trial aimed 
at improving cognitive deficits in children with neurofibromatosis type 1. Our results showed that 
simvastatin treatment for 12 months had no effect on full-scale intelligence, attention problems, 
or internalising behavioural problems. Moreover, we found no indications of efficacy on a carefully 
selected range of predefined secondary outcome measures. Hence, this trial refutes a role for 
simvastatin in treatment of cognitive or behavioural problems in children with neurofibromatosis 
type 1. Unfortunately, despite the many promising drugs that have been identified in mouse 
models of cognitive disorders, translational studies with placebo-controlled trial designs are rare 
for cognitive disorders caused by single-gene mutations. This situation is also true for 
neurofibromatosis type 1 (panel). The absence of good clinical studies encourages off -label 
prescription, which is a major concern, particularly when the drug is readily available to the 
patient. In this study, the cognitive and behavioural profile of the study population at baseline 
(table 1) was fairly representative of the cognitive profile in the general neurofibromatosis type 1 
population.3–5,8 Sample size was adequate, because we could confidently rule out a positive 
change of more than 1.3 points in full-scale intelligence, a reduction of attention problems of 
more than 4·3 T-score points, and a reduction of internalising behavioural problems of more than 
3·3 T-score points (table 2). Furthermore, we achieved a low attrition rate and high medication 
compliance, which suggests that medium-term to long-term trials for cognitive dysfunction are 
feasible in this population. The dosing was based on the maximum recommended daily dose for 
treatment of children with familial hypercholesterolaemia.19 At least in the liver, maximal 
inhibition of the HMG-CoA reductase pathway was achieved in patients on simvastatin, shown by 
the substantial reduction of blood cholesterol concentrations after 1 month (appendix). Whether 
similar inhibition of the HMG-CoA reductase pathway was achieved in the brain is unknown. It is 
possible that higher doses are necessary to achieve biological effects in human beings. However, 
increasing the dose would increase safety concerns, including the risk of myopathy, which was 30 
times higher (0·9%) in adults on 80 mg per day of simvastatin than in those on 20 mg per day.23 
Although 12 months of simvastatin was not related to any adverse events, this study was not 
powered to detect rare effects.  
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Table 3: Adverse events 
 
 Simvastatin (n=43) Placebo (n=41) 
 Grade 1-2 Grade 3 Grade 1-2 Grade 3 
Adverse events by system organ class     
Gastrointestinal system disorders 23 (17) 0 25 (21) 1 (1) 
General, whole-body disorders 16 (16) 0 25 (20) 0 
Skin and appendage disorders 12 (10) 0 11 (10) 0 
Musculoskeletal system disorders 8 (7) 0 13 (11) 0 
Respiratory system disorders 12 (11) 0 5 (5) 0 
Central and peripheral nervous system 
disorders 
9 (8) 0 6 (6) 0 
Neoplasms (eg, aggravated 
neurofibroma) 
2 (2) 2 (2) 3 (2) 1 (1) 
Psychiatric disorders 2 (2) 0 4 (4) 0 
Urinary system disorders 2 (2) 0 4 (4) 0 
Secondary events (eg, postoperative 
pain) 
3 (3) 0 1 (1) 2 (2) 
Resistance mechanism disorders 4 (4) 0 2 (2) 0 
Vision disorders 1 (1) 0 3 (3) 0 
Other systems 1 (1) 0 3 (3) 0 
Laboratory Adverse Events     
Raised alanine transaminase 6 (6) 0 1 (1) 0 
Raised aspartate transaminase 3 (3) 0 5 (5) 0 
Raised creatine kinase (CK) 1 (1) 0 1 (1) 0 
 
Data are number of events (number of patients who had an event). Adverse events are grouped by system organ class 
according to WHO adverse reaction terminology. A complete list of adverse events is presented in the appendix. 
 
Of note, a lower proportion of girls receiving simvastatin advanced one or more pubertal stages 
than did those receiving placebo, which was non-significant and might simply be attributed to age 
differences between the groups. Nonetheless, future studies of statin treatment in other 
populations of normocholesterolaemic children and adolescents should monitor puberty 
development. 
We assumed 12 months of treatment was long enough to measure effects on full-scale 
intelligence. In support of this view, results of 1 year randomised studies showed that full-scale 
intelligence can improve in children with attention deficit hyperactivity disorder who receive 
stimulant medication24 and in healthy children taking music lessons.25 However, how much time a 
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model and patients.11,12,31 Nevertheless, in view of the results of our trial, further insight into the 
pathophysiology of neurofibromatosis type 1 will be necessary to explore other targetable disease 
mechanisms. 
 
Panel: Research in context 
Systematic review 
We did a systematic search of PubMed on July 8, 2013, for additional cognitive trials in 
neurofibromatosis type 1. Search terms included “neurofibromatosis”, “cognition”, “attention”, 
“behaviour”, and “clinical trial”. Of 25 articles found, four described three clinical trials in patients 
with neurofibromatosis type 1. A 12 week randomised placebo-controlled trial in 61 children with 
neurofibromatosis type 1 showed no effect of simvastatin on cognitive function and MRI 
abnormalities, with the notable exception of the significant effect on one secondary outcome 
measure: the object assembly subtask of the Wechsler intelligence scale for children.6 
Furthermore, results of a phase 1 single-arm open-label study of lovastatin in 23 children with 
neurofibromatosis type 1 suggested lovastatin improved memory and attention, accompanied by 
normalisation of default network functional connectivity measured with resting-state functional 
MRI in a subset of the participants.15,16 These seemingly encouraging results might be attributable 
to normal cognitive development, test–retest improvements, or placebo effects. A third study was 
a single-arm 1 year study of methylphenidate to treat attention problems in children with 
neurofibromatosis type 1 and comorbid attention deficit hyperactivity disorder, and results 
showed a decrease in attention problems in children who received the drug.22 
Interpretation 
In this 12 month trial, use of simvastatin provided no benefit over placebo on full-scale 
intelligence, behavioural problems, visual-spatial memory, attention, motor coordination, school 
performance, and quality of life. These findings are in contrast with results from the previous 
single-arm study,15,16 but largely consistent with the smaller randomised controlled trial that 
measured short-term effects of simvastatin on neuropsychological test scores and MRI 
abnormalities.6 We conclude that the number of trials is limited, and more studies are needed to 
identify effective treatments for cognitive and behavioural problems in children with 
neurofibromatosis type 1. 
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Supplementary methods (published Online) 
 
Participants, treatment and follow-up 
Patients were eligible for randomization when they were 8·0 to 16·0 years of age and had a 
genetic confirmation of NF1. Genetic counseling and testing for NF1 is offered routinely at our 
centers, minimizing selection. Informed oral and written consent was obtained from parents or 
guardians and oral and written informed assent was obtained from participants aged 12 years and 
older. Exclusion criteria were use of neurotropic medication or current simvastatin use; 
symptomatic central nervous system abnormalities; insufficient comprehension of the Dutch 
language; severely impaired vision or deafness; segmental NF1 and IQ below 48, which is the 
detection limit for Wechsler Intelligence Scales for Children.  
Study design and setting 
We performed an investigator-initiated randomized, parallel group, double-masked, placebo-
controlled, one-year clinical trial in children with NF1 between March 9, 2010 and March 5, 2013. 
This was a two-center study at Erasmus University Medical Center, Rotterdam, the Netherlands, 
and University Hospital Leuven, Belgium, both national referral centers for Neurofibromatosis type 
1. Approval was obtained from the Central Committee on Research involving Human Subjects (The 
Hague, The Netherlands) and the Ethical Committee of University Hospital Leuven (Belgium) and 
performed in agreement with Declaration of Helsinki (2008 version) and Good Clinical Practice 
guidelines. Full source data verification was performed and all data queries had been solved 
before unmasking. All authors subscribe to adherence to the study protocol. 
Intervention 
Participants were treated with simvastatin or identical placebo once daily in the morning. The 
doses were carefully selected at the maximal daily dose recommended for children with familial 
hypercholesteremia: 10 mg/d in the first month, 20 mg/d in the second month, and fixed at 20 
mg/d for children aged ≤ 12 years or 40 mg/d for adolescents aged 13·0 years and older in months 
3 – 12. Treatment group assignments were masked for participants, investigators, and outcome 
assessors. Simvastatin and placebo capsules were produced by the hospital pharmacy. Capsules 
were identical in color, shape, size, weight, smell, and taste. The simvastatin capsules contain the 
active substance, simvastatin (Spruyt hillen bv, IJsselstein, The Netherlands), and as excipients 
siliciumdioxide colloidal (as glidant), magnesium stearate (as lubricant, diluent), cellulose 
microcrystalline (as binder, diluent) and lactose (as volume filler). The placebo capsules contain all 
of the abovementioned components, except the active substance. They were dispensed by the 
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hospital pharmacy in containers consisting of 35 capsules per month, allowing some flexibility in 
the planning of follow-up visits. Left-over capsules had to be returned and counted for 
compliance. To avoid unmasking of investigators during the trial, the independent Data and Safety 
Monitoring Board (Drs. Hop, de Rijke, de Klerk, de Heus, Erasmus MC) reviewed cholesterol levels 
during the study and primary analysis phase. Randomization was generated by the department of 
Biostatistics at Erasmus MC (dr. Hop) and implemented by the local hospital pharmacist (Erasmus 
MC: dr. Zaal; UH Leuven: dr. de Gieter) using computer generated, permuted block randomization 
lists, using blocks of 10 participants stratified by center. Patients were assigned a medication 
number in the order of their enrollment. Treatment allocation was concealed from all participants 
and investigators. 
Sample size calculation indicated that inclusion of 84 participants had a power of 85% with an 
alpha of 0.05 of detecting a clinically relevant effect of 7.5 IQ-points (equivalent to 0.5 standard 
deviation) difference between simvastatin and placebo on the primary outcome measure. The 
before-after design of the trial allows for the incorporation of test-retest correlation. No data was 
available on the one-year test-retest correlation of the WISC-III-NL, but 2-year correlation is 0.91s1. 
We estimated correlation after one-year at a conservative 0.69. 
Outcome measures 
Outcome measures were assessed at baseline and after 12 months of treatment. All 
neuropsychological tests were developed for children and were administered in their Dutch 
versions. For most outcome measures, age standardized scores were used. Population average for 
IQ is 100 and the standard deviation is 15, with higher scores indicating better performance. For 
CBCL, and YSR, data were represented as T-scores, with a population average of 50 and standard 
deviation of 10, with a higher score indicating more problems. Teacher reported school 
performance was calculated on a scale from 2 to 10, by summation of five-point scores on topics 
of Language and Arithmetic. Higher scores indicate better performance. Health-related Quality of 
life (CHQ-PF50) and Rey complex figure test are presented using z-scores, with 0 indicating the 
mean for the norm sample with a standard deviation of 1. For teacher reported school 
performance, Stroop Color Word test and grooved pegboard test, raw scores are used, since no 
appropriate norm groups are available for the entire age-range. Before and after measurements 
were performed by the same neuropsychologist AR or EP. Any age or gender confounding effects 
in the estimation of treatment effects are accounted for by multivariable analysis. Harms were 
monitored during monthly contacts with the investigators. Outpatient visits were scheduled at 
baseline and after 1, 3, 6, 9 and 12 months. In the intervening months, harms and study 
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compliance were monitored by telephone interviews. Participants were provided with a diary in 
which they were instructed to note any deviations from treatment protocol and possible adverse 
events. At each consult, one of the study physicians recorded any adverse events and serious 
adverse events (adverse events that were life-threatening, causing disability, or requiring 
hospitalization) with a standardized checklist containing simvastatin associated sideeffects, 
supported by open questions and a review of the participant’s diary. Standard internal and 
neurological clinical exams were performed and blood was drawn by phlebotomy for laboratory 
examination at visits after 1, 6, 9 and 12 months of treatment. Hypothetically, cholesterol 
reduction could influence sex hormone production. Therefore, Tanner stages for puberty 
development were noted. Laboratory screening parameters were measured according to standard 
hospital laboratory protocol; alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
and creatine phosphokinase (CK) to screen for laboratory adverse events; total cholesterol (tChol), 
highdensity lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and 
triglycerides to assess lower limits of lipid levels and to monitor compliance. Criteria for 
discontinuation of study medication were a persistent increase of more than 3-fold the upper limit 
of normal (ULN) ALT or AST levels, more than 10- fold the ULN for CK levels with or without 
muscular symptoms, or 5- to 10-fold the ULN for CK levels with muscular symptoms. Lower limits 
of cholesterol in blood in children do not exist, but children would stop study medication if these 
levels decreased with 3x standard deviation of the population norms, as assessed by the 
independent Data and Safety Monitoring Board to avoid premature unmasking. Adverse events 
were categorized according to WHO-ART nomenclatures2, and tabulated. No significance testing 
has been performed on adverse events, since statistical power to detect significant differences is 
low. All adverse events are therefore displayed using counts. For puberty development, Tanner 
stage change was defined as any change during the study versus no change during the study. 
Logistic regression analysis was performed by adjusting for lowest baseline Tanner scale. Adjusting 
for lowest baseline scale, age and sex were used to reveal significant changes. Lipid blood levels 
were analyzed over the course of the trial using the generalized linear mixed model procedure 
with time x treatment as the variable of interest. The statistical analysis plan and any exclusion 
from the intention to treat set were finalized before unmasking. All reported adverse events were 
scored as being not drug related, possibly drug related, or definitely drug related prior to 
unmasking. 
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Statistical analysis 
No statistical testing was performed for baseline study group differences. Intention to treat 
analysis was performed for all participants of whom post-baseline data was available, without 
imputation of missing values. Primary and secondary outcome measures were analyzed using 
bivariable linear regression for the effect of treatment group on the score at 12-month visit, 
adjusting for baseline performance. Multivariable regression was performed by adjusting 
treatment effects for baseline performance, age and sex. We planned to determine effect 
modification of outcome parameters using interaction term of treatment and age and baseline, 
only if main effects were present. If interaction terms treatment x baseline score would have 
shown significant effect modification, subgroup analysis was planned for groups with -1SD lower 
scores at baseline. The analysis plan was determined before unmasking and compiled according to 
the study protocol. All data were analyzed using IBM SPSS Statistics for Windows, Version 20.0. 
Armonk, NY: IBM Corp. All authors had full access to all trial data and assume final responsibility 
for the decision to submit the manuscript for publication. 
Role of funding sources 
Non-commercial funding was provided by The Netherlands Organization for Health Research and 
Development (ZonMw), the Marguerite-Marie Delacroix Foundation and Research Foundation 
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sources had no role in the conception, design and analysis of the trial, the writing of the 
manuscript or the decision to publish the results. 
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Online supplementary figure 1: Estimated means for total cholesterol, LDL-cholesterol, HDL-
cholesterol and triglycerides. Black circles = placebo. White diamonds = Simvastatin. Error bars 
represent 95% confidence intervals. 
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Behavioral and cognitive outcomes for clinical trials in 
children with neurofibromatosis type 1
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Abstract 
Objective: Clinical trials for behavioral problems and cognitive deficits in Neurofibromatosis type 1 
(NF1) are emerging. This study aims to evaluate the appropriateness of outcome measures by 
analyzing the degree of deficits compared to reference groups, test-retest reliability, and how 
scores correlate between outcome measures.  
Methods: Data were analyzed from NF1-SIMCODA, a randomized placebo-controlled trial of 
simvastatin for cognitive deficits and behavioral problems in children with NF1. Outcome 
measures were compared with age-specific reference groups to identify domains of dysfunction. 
Pearson’s r was computed for before-and-after-measurements within the placebo group to assess 
test-retest reliability. Principal component analysis was used to identify the internal structure in 
the outcome data.  
Results: Strongest mean score deviations from the reference groups were observed for full-scale 
intelligence (-1.1 SD), Rey-complex-figure-test (RCFT) delayed-recall (-2.0 SD), Attention problems 
(-1.2 SD) and Social problems (-1.1 SD). Long-term test-retest reliability were excellent for 
Wechsler-scales (r > 0.88), but poor-to-moderate for other neuropsychological tests (r range: 0.52 
– 0.81) and Child-Behavioral-Checklist (CBCL) subscales (r range: 0.40 – 0.79). The correlation 
structure revealed two strong components in the outcome measures, “Behavior” and “Cognition”, 
with no correlation between these components. Scores on psychosocial-quality-of-life correlate 
strongly with behavioral problems and less with cognitive deficits.  
Conclusions: Children with NF1 show distinct deficits in multiple domains. Many outcome 
measures showed weak test-retest correlations over the one-year trial period. Cognitive and 
behavioral outcomes are not interchangeable. This analysis demonstrates the need to include 
reliable outcome measures on a variety of cognitive and behavioral domains in clinical trials for 
NF1. 
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Introduction 
Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder with a birth-incidence 
of 1:2,700, caused by mutations or deletions in the NF1 gene.1, 2 Clinical diagnostic criteria include 
multiple café-au-lait spots, skinfold freckling, various types of neurofibroma, NF1-specific bony 
dysplasia, optic pathway glioma and Lisch noduli of the iris.3 Learning disabilities, cognitive deficits 
and behavioral problems in various domains are reported in up to 80% of children with NF1, but 
similar to the somatic complications of NF1 cognitive and behavioral problems are highly variable. 
Full-scale intelligence is 10-15 IQ-points lower than in the population and in sibling controls. 
Thirty-three to fifty percent of children with NF1 fulfill criteria for Attention-deficit-hyperactivity 
disorder (ADHD)4-6 and Internalizing behavioral are frequently observed.6 Specific deficits in 
visuospatial memory and motor coordination are prevalent.6, 7   
Several promising therapeutic options are emerging from preclinical studies of the 
cognitive and behavioral deficits in NF1. Neurofibromin, the protein product of the NF1 gene, has 
a GTP-ase activating (GAP) domain which is involved in the regulation of p21-RAS, a proto-
oncogene implicated in tumor formation.8, 9 Increased RAS-signaling in inhibitory interneurons has 
a major role in the learning deficits in Nf1 mice. 10-12 Lovastatin, a cholesterol-lowering agent, 
improved learning deficits of Nf1 mice, potentially through RAS-inhibition.13 Other candidate drugs 
are L-dopamine and methylphenidate, both shown to be effective on attention problems in an Nf1 
mouse model in which neurofibromin was selectively knocked-out in neuroglial-progenitor cells.14, 
15 Another recent study found Lamotrigine to be effective in treating cognitive deficits in two 
separate Nf1 mouse models, through regulation of the excitability of inhibitory interneurons.16 
Six clinical trials aimed at treating cognitive deficits in NF1 are reported in literature, 
varying in design, size, treatment and treatment duration. Outcome measures that were used 
varied widely (table 1). Reasons for this lack of consensus may include the variability of the 
neuropsychological spectrum in NF1, the divergence of theories regarding the pathophysiology, 
the desire to select tests paralleling the mouse findings, and the absence of clear positive effects 
in preceding trials. The NF1-SIMCODA randomized controlled trial  
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Table 1. Cognitive clinical trials in Neurofibromatosis type 1 and their outcome measures 
 
 
NF1: Neurofibromatosis type 1; ADHD: Attention deficit/hyperactivity disorder; TOVA: Test of Variables of Attention; 
CBCL: Child Behavioral Checklist; Rey CFT: Rey complex figure test; MRI ADC: magnetic resonance imaging apparent 
diffusion coefficient; Stroop CWT: Stroop colour word interference test; JLO: judgement of line orientation; TEA-Ch: 
Test of Every-Day Attention for Children; CVLT: California Verbal Learning Test for Children; WRAML-2: Wide Range 
Assessment of Memory and Learning, Second Edition; TAP: Test of Attentional Performance; TMS: transcranial 
magnetic stimulation; PAS: paired associative stimulation; SICI: short interval cortical inhibition; sCPRS: simplified 
Conners’ Parent Rating Scale; CTRS: Conners’ Teacher Rating Scale; CDRs-R: Children’s Depression Rating Scale; CDI: 
Children’s Depression Inventory; STAIc: State-trait Anxiety Inventory for Children 
  
Reference Drug & Design n Age 
(years) 
Inclusion 
criteria 
Treatment 
duration 
Outcome 
measures 
Conclusions 
Mautner et 
al., 2003 37 
Methylphenidate 
Single arm 
20 Mean: 
10.7, 
SD 2.2 
Diagnosis of 
ADHD 
12 months TOVA 
CBCL 
Methylphenidate 
improves attention 
in children with 
NF1 and ADHD 
Krab et al., 
2008 18 
Simvastatin 
Randomized 
parallel-group 
placebo-
controlled 
61 Range: 
8-16 
No selection 12 weeks Rey CFT; 
Cancellation 
test; Prism 
adaptation;  
MRI ADC-
values; 
Stroop 
CWT; Block 
design; 
Object 
assembly; 
JLO 
Simvastatin similar 
to placebo on all 
outcomes, except 
for improvement 
on object assembly  
Acosta et 
al., 2011 38 
Lovastatin 
Single arm 
23 
 
Range: 
10-17 
IQ >80; 
history of 
learning 
disabilities  
12 weeks TEA-Ch 
CVLT 
WRAML-2 
Improvements in 
areas of verbal and 
nonverbal memory 
after lovastatin use 
Mainberger 
et al., 2013 
39 
Lovastatin (high 
dose) 
Cross-over 
placebo-
controlled 
10 Range: 
19-44 
No 
psychotropic 
medications 
4 days TAP 
TMS-
PAS/SICI 
Increased phasic 
alertness and 
synaptic plasticity, 
and decrease of 
intracortical 
inhibition 
Van der 
Vaart et al., 
2013 17 
Simvastatin 
Randomized 
parallel-group 
placebo-
controlled 
84 Range: 
8-16 
No 
stimulant 
medication 
12 months See 
introduction 
and table 2 
Simvastatin similar 
to placebo 
Lion-
Francois et 
al., 201440 
Methylphenidate, 
cross-over 
placebo-
controlled 
39 Range: 
7-13 
IQ between 
80 -120; 
anamnestic 
attention 
problems or 
school 
problems 
4 weeks sCPRS; 
CTRS; CDRs-
R; CDI; 
STAIc 
Methylphenidate 
improves attention 
in children with 
NF1 and ADHD 
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(acronym for “Simvastatin on Cognition and Daily life”) evaluated the effects of 12-month 
simvastatin treatment on cognitive functioning and behavioral problems in children with NF1 aged 
8 – 16 years. Simvastatin did not have any positive effect on cognitive functioning, behavioral 
problems or school performance.17 The outcome measures for NF1-SIMCODA were carefully 
selected based on earlier experience from our earlier trial with shorter (three-month) duration18 
and the notion that longer study duration of 12 months allows for better detection of changes in 
global cognitive functioning, everyday behavioral problems, and school performance. Therefore, 
the primary outcome measures in NF1-SIMCODA were full-scale intelligence measured with the 
Wechsler Intelligence Scales for Children-III (WISC-III), and the Attention Problems scale and the 
Internalizing Behavioral Problems scales of a parent-rated questionnaire, the CBCL.17 The 
relevance of the CBCL is demonstrated by its correlation with psychosocial quality of life in 
children with NF1.19 Regarding secondary outcomes, we included more specific 
neuropsychological tests: the RCFT, the Stroop Color Word interference task (Stroop CWT) and the 
Grooved pegboard test. Other secondary outcome measures were teacher-rated school 
performance, psychosocial quality of life by Child-Health questionnaire (CHQ), and self-reported 
Internalizing behavioral problems. 
This paper analyzes the scores on outcome measures used in the NF1-SIMCODA study. We 
investigated three main questions. 1) Which outcome measures were most affected in comparison 
to normative reference groups? Although previous studies have resulted in a set of tests that are 
reliably affected by NF1,6 uncertainty remains about the performance on these tasks in a clinical 
trial population. Tests on which children with NF1 score within the normal range are less suitable 
as outcome measure in a trial. 2) What is the one-year test-retest reliability of scores on the 
outcome measures used? Trials designed with before – after measurements using reliable tests 
reduce the number of subjects needed and increases power.20 3) How are the scores on the 
various outcome measures correlated? Scores for cognitive outcome measures and behavioral 
problems are correlated in the general population, where lower intelligence is correlated with 
increased incidence of emotional, behavioral, and social problems.21 It is unclear whether this is 
also true within the NF1 population. In addition, what outcome measures are correlated to health-
related quality of life? The questions above are important when selecting appropriate outcome 
measures in trials involving patients with NF1.  
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Method 
Patient population 
The data from 84 children who participated in NF1-SIMCODA trial were analyzed.17 The trial is 
registered with the Netherlands Trial Registry (www.trialregister.nl, NTR2150). The children had a 
median age of 11.5 years (range: 7.9 – 16.0), with 45 of them female (54%). Informed consent was 
obtained and local and national institutional review boards approved the protocol. 
Outcome measurements 
In addition to the pre-specified outcome measures (see introduction),17 we have added the 
following outcome measures to the current analysis: 1) cognition data, a distinction between 
verbal and performance intelligence on the WISC-III-NL; RCFT copy, although delayed recall is 
more heavily affected in children with NF1, scores for the direct copy might show already large 
effects, contributing to the deficit on the delayed recall; 2) behavioral data from questionnaires 
from parent, youth self-report and teacher questionnaires on total problems, attention problems, 
social problems, and internalizing emotional and behavioral problems (e.g. anxiety or depression-
like behavior).  
Data analysis 
Baseline scores were used from all included participants (n=84). To allow comparisons of the 
magnitude of baseline deficits between different scoring systems, outcomes with a standardized 
scoring system (e.g. IQ-score, Z-scores, or T-scores) were converted into standard deviation scores 
(SDS) by dividing the effect by the standard deviation in the reference group, such that 0 equals 
reference group average with a standard deviation of 1. Normality was checked using Shapiro-Wilk 
tests, and visual inspection of histograms. If any of these violated assumptions of normality, 
nonparametric tests were used. Differences between the NF1 group and the reference group were 
tested using independent t-tests for normally distributed data and one-sample Wilcoxon-Signed-
Rank tests for non-normally distributed data. Within the placebo group, paired sample t-tests 
were used to calculate significant before-after differences in normally-distributed data and 
Wilcoxon-Signed Rank tests for non-normally-distributed data. Differences were considered 
significant when p < 0.05. Data are presented as mean +/- SD, unless otherwise indicated.  Pearson 
product moment correlation analyses were used to examine associations between first and 
second measurements in the placebo group, as an indication of test-retest reliability and/or 
Chapter 7
156
  
 
 
159 
stability. Bivariate normality (linearity) was assessed by inspecting scatter plots.22 In this 
exploratory analysis, we did not correct the significance level for multiple testing, given the high a 
priori probabilities of multiple significant findings in this study and the interdependency of 
cognitive measures. Methods to control for multiple testing would unreasonably increase the risk 
of type II error. 
Principal component analysis 
Since it is likely that scores on certain outcome measures are differentially correlated to other 
outcome measures, we performed a principal component analysis (PCA). This way, the correlation 
between outcome measures can be grouped in components and the internal structure of the 
outcome data can be revealed. We performed PCA for those outcome measures that had 
complete cases in more than 75% of the sample. We excluded variables from the PCA for which 
Kaiser-Meyer-Olkin (KMO) measures were low: Stroop CWT (KMO=.50) and Grooved Pegboard 
test (KMO=.42). The final PCA therefore included outcome measures for behavioral problems 
(Internalizing behavioral problems, Attention problems, Social problems), cognitive functioning 
(total performance IQ, verbal IQ, RCFT delayed recall), and health related quality of life 
(psychosocial quality of life summary scale from CHQ). Principal component analysis was 
conducted on these seven selected outcome measures with oblique rotation (direct oblimin 
rotation). The KMO verified the sampling adequacy for the analysis, KMO = .73, and all KMO values 
for individual items were at least .59 (well above the acceptable limit of .5). An initial analysis was 
run to obtain eigenvalues for each component in the data. Two components had eigenvalues over 
Kaiser’s criterion of 1 and in combination explained 68% of the variance. The scree plot showed an 
inflexion that would justify retaining three components. Because this third component had an 
eigenvalue below .7 (Jollefei’s criterion) and the sample size is rather small, we retained two 
components. 
 
Results 
Children with NF1 (8-16 years) had a mean full-scale intelligence (WISC-III) of 83.3 IQ-points (SD 
15.6), which is 1.1 SD below population mean (table 1). The largest deviations from the reference 
group in the cognitive domain were seen on performance IQ (1.1 SD, or 16 IQ-points below 
population mean) and the RCFT delayed recall (2.0 SD below population mean). Stroop CWT, 
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Grooved Pegboard test and teacher ratings have incomplete or no Dutch reference groups, 
therefore the raw scores are displayed. Behavioral problems, as measured by the CBCL, were most 
prominent for Attention problems rated by parents: mean T score = 62, with a T score of 50  as the 
mean and 10 as the SD of the normative population and higher scores indicating more problems. 
Also, Social problems were commonly reported by parents: mean T score = 61. Behavioral 
problems that were less pronounced than could be expected from literature were Internalizing 
behavioral problems rated by parents (0.6 SD more problems than the healthy population), and 
Internalizing behavioral problems self-rated by children (0.5 SD more problems than the healthy 
population). All baseline group averages were significantly different from reference groups, except 
for psychosocial quality of life. The mean z-score for psychosocial quality of life, measured by the 
CHQ was  -0.1 (SD 0.7; p-value 0.22).  
One-year test-retest effects in the placebo group 
The placebo group of the trial (n=39) provides a unique opportunity to examine one-year 
longitudinal changes in scores on the outcome measures. Full-scale intelligence was significantly 
higher after 12 months of placebo-use (table 2). This is due to an average 5.5 IQ-point increase in 
performance intelligence. Verbal intelligence did not improve over time. Improvements were seen 
on Stroop CWT scores, which were lower after 12 months, and on the Grooved Pegboard test. This 
is not unexpected, as these two tests have no adequate age-corrected reference data. 
Psychosocial health-related quality of life was .2 z-scores higher after 12 months (p = 0.045). Small 
reductions in behavioral problems were observed on most domains, but these were not 
statistically significant.  
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Correlations between before and after measurements give an indication of test-retest 
reliability and/or the within-subject stability of the underlying construct.22 Poor before-after 
correlation coefficients would indicate that a higher number of subjects would be needed to find 
significant treatment effects in a randomized trial. Before-after correlations were good to 
excellent for Wechsler-scales (Verbal intelligence: r= .88, Performance intelligence: r = .90, Full-
scale intelligence r = .94), poor for RCFT delayed recall (r = .52), acceptable for Stroop CWT (r = .78) 
and good for Grooved Pegboard test (r = .81). Behavioral problems reported by parents had 
questionable correlation coefficients for Total problems and Social problems (r = .63) but 
acceptable correlations for internalizing behavioral problems (r = .79). Of note, before-after 
correlations were low for Attention problems (r = .40), a scale that was used as an outcome 
measure in NF1-SIMCODA. Youth Self-report before-after correlations (available for 24 subjects in 
the placebo-group) were low for Internalizing behavioral problems (r= .41) and Social problems (r 
= .19), and questionable for Total problems (r= .64) and Attention problems (r = .64). Behavioral 
problems reported by the teacher showed a poor before-after correlation (r range: .39 – .54). 
Importantly, the majority of children changed teachers over the one-year period. Psychosocial 
health-related quality of life had questionable before-after correlation (r = .65). 
Analysis of the correlation structure within the outcome data 
Next we analyzed the correlation structure between the scores at baseline on various outcome 
measures. We had to consider the total sample size of 83 complete cases, allowing for a limited 
number of variables to be included. We included those outcome measures that were evaluated in 
a sufficient number of children (see Methods section for selection criteria). Table 3 shows the 
correlation matrix of the selected outcome measures, together with the significance levels. Of 
note, parent-rated Attention problems had no significant correlation to scores on the Stroop CWT, 
which we included as a measure of attention. The principal component analysis of these 
correlations resulted in two components. Table 4 shows the component loadings after rotation. 
The outcome measures that cluster on the same factor suggest that component 1 represents 
behavioral problems, and that quality of life clusters together with these behavioral problems. 
Component 2 represents cognitive functioning. The correlation between the two components is 
low (-.123). These data suggest that the performance of children in the NF1-SIMCODA trial on the 
cognitive outcome measures was independent from the behavioral problems reported by parents. 
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In addition, it shows that psychosocial quality of life scores as reported by parents, correlate much 
higher with behavioral problems than with cognitive deficits.  
Table 3: Pearson correlations 
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Psychosocial quality of life -.597 -.406 -.583 1.000 .004 -.112 -.054 -.132 -.117 
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Total performance intelligence -.039 -.077 -.057 -.112 .650 1.000 .469 -.015 -.366 
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Stroop Color word test - interference .020 .080 .010 -.132 .049 -.015 .011 1.000 .317** 
Grooved Pegboard test .022 .079 .104 -.117 -.064 -.366 -.230* .317** 1.000 
* indicates p < .05; ** indicates p < .01, bold indicates p < .001. 
 
 
 
Table 4. Summary of principal component analysis for the seven outcome measures included (n = 83) 
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Figure 1. Component plot in rotated space. 
 
 
  
Chapter 7
162
  
 
 
166 
Discussion 
We analyzed the performance of a range of cognitive, behavioral and quality of life outcome 
measures in a real-life clinical trial population of children with NF1 in order to improve clinical trial 
design of future studies. 
This report confirms the broad range of cognitive deficits and behavioral problems in 
patients with NF1.4, 6 As expected, the participants scored poorly on full-scale intelligence and 
RCFT delayed recall. In the behavioral domain, parents frequently reported Attention problems, 
but Internalizing behavioral problems were less prevalent in our sample than expected from 
previous studies.6, 19, 23 Interestingly, social behavioral problems were a major issue in our study 
population, and were also correlated to loss of quality of life. Recently, much attention has been 
directed at the prevalence and characterization of autism spectrum disorder within the NF1-
population.24-27 One ongoing clinical trial is specifically designed to evaluate the effect of 
simvastatin on autism in children with NF1 (SANTA-trial, EUDRACT-number: 2012-005742-38). 
The test-retest reliability analysis we performed indicated that the most reliable tests 
include full-scale intelligence, performance intelligence, followed by neuropsychological tests. We 
found evidence for a poor test-retest reliability of scores on Attention problems rated by parents. 
This finding indicates that the symptoms of attention problems in a given child may fluctuate more 
strongly than other outcomes do. Our analysis cannot discriminate between test-retest reliability 
(the test being imprecise) and a true high variability of Attention problems over time.22 Attention 
problems are considered a key aspect of the neurocognitive profile of NF1 and have been targeted 
in all therapy trials so far. The low stability of Attention problems parent rating might reflect a 
poorly understood natural variability within the NF1-population that is not observed within the 
reference population. Test-retest correlations for the Attention problems scale measured weeks 
apart in the reference population are as high as .9028, and long-term stability spanning 2-3 years 
during school age are around 0.70.29 In a clinical sample of ADHD patients, stability of Attention 
problems over four years’ time was 0.53.30 Interestingly, Stroop CWT in our study has high stability 
over one year time and was not correlated to questionnaire-based attention problems. The 
indication that attention problems ratings have high intra-individual variability in NF1 warrants 
further prospective evaluation.   
In addition, we found that behavioral problems, but not cognitive deficits, were strongly 
associated with psychosocial quality of life on the CHQ-PF50. This is in agreement with a previous 
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study, where behavioral problems were associated with reduced quality of life, but school 
performance was not.19 There might be an overlap in constructs measured between the 
behavioral questionnaires and the quality of life questionnaire, explaining this correlation. 
Therefore, the CHQ-PF50 seems insensitive to issues these children face in cognition and academic 
achievement. Future research might focus on developing an NF1-specific health-related quality of 
life scale to include all items that are relevant to children with NF1, including academic 
achievement and cognitive performance. 
The correlation between cognitive outcome measures and behavioral problems in this 
population of children with NF1 was not significant. Some children displayed mainly behavioral 
problems, whilst some only had cognitive problems. Payne et al. investigated scores on 
neuropsychological tests for attention in correlation with parent-rated questionnaires on working 
memory and attention and found at best moderate correlations between tests and 
questionnaires.31 Pride et al. found that a behavioral diagnosis of ADHD predicts poorer academic 
achievement. 32 It is unclear at present what causes this heterogeneity. There might indeed be 
multiple pathways responsible for cognitive deficits and behavioral problems in children with NF1, 
with inter-individual differences in the relative contribution of these mechanisms.33 Since it is yet 
unpredictable which neurocognitive substrates or behavioral problems will respond to treatment, 
it seems justified to include a broad set of outcome measures in early clinical trials, covering 
cognition, behavior, and quality of life. 
Other researchers have commented that outcome measures should focus on transferring 
tasks from mouse models to humans.34-36 Paired-associate learning (PAL), a subtest of the CANTAB 
neuropsychological testing battery, has been implemented in a running clinical trial of Lovastatin 
in NF1, based on its supposed similarity to the visuospatial learning in the mouse model.35 
Although the NF1-population is indeed affected on this particular task, it remains unclear what the 
clinical relevance is of such tasks. In a similar fashion, it might be tempting to translate the Morris 
Water Maze task to a human maze-like test, as was done in one study.36 In our opinion, it is 
important to respect the ecological differences in behavior between mice and children. Drugs that 
improve performance of children on a visuospatial learning task, but do not improve clinically 
relevant patient-reported outcomes such as behavioral problems, academic achievement and 
quality of life, are of purely academic interest.  
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Although the results of the current analysis are specific for NF1, the approach of validating 
outcome measures for cognitive research can well be used in other disorders. It is important to 
scrutinize the few trials that have been completed in order to guide future clinical trial design. In 
conclusion, this study highlights the variability of the neurocognitive profile of NF1 and 
demonstrates the need to include outcome measures on a variety of cognitive and behavioral 
domains in clinical trials. 
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Abstract  
Neurofibromatosis type 1 (NF1) is a neurocutaneous disorder associated with lifelong tumor 
growth propensity and neurocognitive impairments. Although follow-up of adults with NF1 often 
focuses on tumor growth, follow-up of cognitive or social problems and other NF1-related 
comorbidity is often not a part of standardized care. In order to provide optimal care services for 
these patients, we explored the care needs of adults with NF1. A qualitative study was performed 
using semi-structured group interviews, exploring worries and care needs in medical, psychological 
and socioeconomic domains, also focusing on the transition from pediatric to adult care. Four 
focus groups were conducted, including young adult patients, patients over age 30, and parents of 
young adult patients. In total, 30 patients and 12 parents participated. Data were transcribed 
verbatim and analyzed by computerized thematic analysis. Themes were organized using the WHO 
International Classification of Functioning, Disability, and Health (ICF). Results indicated many and 
diverse worries and care needs both during the transitional period and in adulthood in medical, 
mental health, and socioeconomic domains. Worries could be categorized into thirteen themes. 
Parents reported high stress levels and difficulties with their parental role. Participants expressed 
the need for more information, access to NF1 experts, daily living support, care for mental health 
and socioeconomic participation, and closer communication between healthcare providers. In 
conclusion, worries and needs of patients and parents underline the importance of 
multidisciplinary follow-up and continuity of care during and after the transitional period. 
Additionally, parental stress requires more attention from care providers. 
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Introduction  
Neurofibromatosis type 1 (NF1) is a relatively common autosomal dominant neurocutaneous 
disorder with an estimated birth incidence of 1/2700 1. Approximately 40 to 50% of the cases are 
caused by a de novo mutation in the NF1 gene 1, 2. Clinical features of NF1 include multiple café-
au-lait spots, axillary and inguinal freckling, multiple cutaneous neurofibromas and iris Lisch 
nodules 3. Serious complications of NF1 include different types of tumor formation, such as central 
nervous system gliomas and plexiform neurofibromas, with a risk of evolving into malignant 
peripheral nerve sheath tumors (MPNST’s) 4 for which guidelines for neuro-oncological follow-up 
are available. However, although neuropsychiatric and psychosocial problems persist into 
adulthood, currently these are often not routinely addressed in adults.  
Learning disabilities occur in at least 50% of children with NF1, making cognitive problems 
the most common complication to affect the quality of life in this group 5. Attention-
deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and sleep disturbance are 
also highly prevalent 6-8 and can persist throughout life 9-11. Furthermore, patients with NF1 are at 
risk for psychosocial problems. In adolescence and adulthood, the dermatological and neuronal 
tumor phenotype can exacerbate in a period in which appearance, acceptance, and social 
inclusion are of great importance 12, 13. Additionally, the impaired socialization, low self-esteem 
and poor interpretation of social cues reported in children with NF1 14 may limit social 
participation in adulthood. Even when adults with NF1 receive care for the tumor growth 
phenotype, appropriate care for other NF1-related morbidity is often not part of standardized care 
15. 
For patients with NF1, international healthcare guidelines advise multidisciplinary follow-
up including evaluation of tumor growth, dermatological manifestations, and neuropsychiatric 
disorders 16, 17. Although pediatric patients often receive and adhere to this multidisciplinary care, 
studies show that young adults with NF1 may have poor access to healthcare, limited disease 
knowledge, and are often lost to follow-up. At the same time, they have a high complication rate 
and neuropsychiatric and socioeconomic problems persisted or worsened 18. Adult patients with 
NF1 experience decreased quality of life 19 and they require developmentally appropriate care 15.   
Thus far, limited data are available on the full scope of worries and health care needs of 
young adults and adults with NF1 and their parents. Previous qualitative studies have focused on 
the impact of NF1 in adulthood, for instance, addressing the effects of plexiform neurofibromas 20, 
health and well-being, quality of life, and transition to adult care 12, 21-23. The aim of the current 
Worries and needs of adults with NF1 and parents
173
8
  
 
 
176 
study was to provide more information on the full spectrum of worries and care needs in medical, 
psychological, social, and economic domains of adults with NF1 and parents of patients with NF1. 
Using patient-driven data, we formulate recommendations for health care providers (HCP) in 
order to optimize health care for this vulnerable patient group.  
 
Materials and methods  
A qualitative design with semi-structured group interviews was used to obtain in-depth data on 
worries and care needs of patients and their parents. The full spectrum of care needs was 
explored, including medical, psychological, social and societal domains, and contextual factors. 
The COREQ (Consolidated criteria for reporting qualitative studies) checklist was used as a 
reporting framework for this qualitative study 24.  
 
Participants 
Convenience sampling was performed in close cooperation with the NF1 patient association of the 
Netherlands (NFVN). Young adults (18-30 years) and older adults (30-67 years) with NF1 and 
parents of patients with NF1 were invited to join focus groups, which were conducted on April 16, 
2016, at a conference center in the Netherlands after the annual meeting of the NFVN. This annual 
meeting is generally visited by 50 to 100 patients, parents of patients and professionals. The 
invitation was part of the agenda that was sent to all members of this association. Inclusion 
criteria for the patients were that they must be 18 years of age or older, and have a diagnosis of 
NF1 (as stated by the participating members, not necessarily confirmed by DNA testing). The 
inclusion criterion for parents was having a child with NF1 who is now an adult. Participation of 
parents was not dependent on their child’s participation or vice-versa.  
Participants were divided into four focus groups: 1) patients aged 18 to 30 years, 2) parents 
of patients aged 18-30 years, 3 & 4) two groups of patients and parents of patients aged over 30. 
The cut-point of 30 years was based on the European Commission definition of ‘youth and young 
people’ 25, evidence that neurodevelopment continues up to the age of 30 years old, and clinical 
experience that the transitional period can be protracted in patients with neurodevelopmental 
disorders. Both groups 3 and 4 were mixed groups of parents and patients, who indicated they 
wanted to join the groups together. In total, 12 parents participated, including four fathers and 
eight mothers.  
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Data collection 
Focus groups were 90 minutes in length and were moderated by a pediatrician (RO), an 
intellectual disability physician (AE), and two psychologists (AR, JL). Moderators were specifically 
allocated to ensure they had no treatment relationships with participants. Prior to the focus 
group, moderators received training to ensure consistency across interviews. Two observers (HH 
and PB) joined the focus groups.  
Semi-structured interviews contained previously drafted questions and probes on worries and 
needs in medical, psychological, and socioeconomic domains (see Table 1). Participants were 
explicitly asked to discuss the transitional phase between pediatric and adult care. In the 
Netherlands, the transition from pediatric to adult health-care usually occurs at approximately 18 
years of age26.  
 
Table 1. Abbreviated interview guide 
 
Key questions: 
1) What are your worries about… 
2) What are your care needs for… 
 
 
Probes 
Transition from pediatric to adult care? Transition to adult health care, change in physician, transition to 
adult life, transition to work, independent living 
Medical issues? Symptoms, NF1-related care, medication, care consultations 
Psychological and behavioral issues? Sleeping problems, ADHD, ASD, depression, anxiety 
Social life? Friendships, romantic relationships, family, family planning, 
loneliness, sexuality 
Work and daily activities? Work, school, independence, finances, daily living 
Paramedical issues? Language problems, nutrition, motor skills 
 
 
Data analysis 
Focus groups were digitally recorded and transcribed verbatim. Transcripts were imported into the 
qualitative software package ATLAS.ti 6.2 27. Thematic analysis 28 was selected for its theoretical 
freedom and yield of rich and detailed account of data.  
All transcripts were reviewed and coded by a member of the research team (HH). Initial 
codes were based on the overall subject of a text fragment. During analysis, initial codes were 
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modified, expanded, or merged as new issues emerged. Decisions about the codes were made 
based on the most complete representation of the data. Subthemes were merged where possible. 
To enhance validity, the coding process and the emerging themes were continually discussed with 
two co-investigators (PB, AE), and in an additional meeting with other co-investigators themes 
were discussed until consensus was reached.  
 After obtaining a consensus on the open coding, worries and care needs were organized 
based on the ICF framework. The ICF is a classification of health and related domains, published in 
2001 by the World Health Organization 29, and describes impairments of body functions and 
structures, activity limitations, participation restriction, and environmental factors. It is used as a 
framework to express health and disability using individual and population measures and has been 
used for holistic evaluation and interpretation of NF1-related disabilities in pediatric patients 30. A 
valuable contribution of the ICF classification is the emphasis on the effects of health issues on 
activities and social and economic (socioeconomic) participation. Socioeconomic participation is 
defined as a person’s involvement in a life situation and the socioeconomic domain represents the 
societal perspective of functioning. The theme ‘parental stress’ was classified as an environmental 
factor for the patient, since parents are part of the environment they live in.  ‘Problems during 
transition phase’ were also considered an environmental factor since the current healthcare 
infrastructure appeared to contribute to these problems.  
The education of patients was classified according to the international classification of 
education (ISCED 2011) 31.  
Ethical approval  
This study was approved by the medical ethical review committee of the Erasmus Medical Centre 
(ref. MEC-2016-532). For all participants and recordings, informed consent was obtained and a 
formal review and waiver of the MEC was given.  
 
Results 
Participants 
Forty-two participants were included; 30 patients and 12 parents (see Table 2 for patient 
characteristics). The age of patients ranged from 18 to 67 years, while the age of parents ranged 
from 54 to 75 years. The NF1-mutation status of parents was unknown. After transcription and 
coding, 13 major themes were identified and classified using the ICF (Table 3 provides an 
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overview). The ICF-framework proved to be a useful tool in organizing the diversity of worries and 
needs ensuring an overview of both functional impairments and their consequences in daily life. 
Detailed results of the analysis of the transcript are provided below. The addition of new codes 
diminished greatly during analysis, suggesting data saturation.  
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Impairment of body functions and structures  
Mental health problems 
High levels of anxiety and stress were broadly discussed, such as fear of failure, social anxiety, and 
fears and worries about the future. Symptoms of depression were also discussed in all focus 
groups, as several patients reported needing antidepressants and psychological consultation. Both 
patients and parents noted problems with emotion and mood regulation, leading to anticipatory 
stress and frustration by family members.  
“Anxiety is always present, you know. Fear of new situations, and also fear of meeting new people. 
I see it in my son, even when he needs to go into a new store. So every time he goes somewhere 
new for the first time, he wants me to join him.”– Parent 18-30 
Difficulties with self-acceptance and coping with the disease were widely present. Especially 
patients in the 30+ focus groups, who mentioned that it would have been helpful if psychological 
care had been offered. Various patients noted that the disorder of NF1 itself limited their coping 
skills: fatigue, anticipatory stress, and a depressed mood made them feel less resilient.  
Worries about the future 
The unpredictable course of NF1 was a major concern of patients. Patients worried about future 
symptoms and prognosis, future loss of functions, future surgery, future aesthetic problems, 
malignant transformation of neurofibromas in the future, obtaining relationships, and achieving 
independence.  
“It is just that you don’t know how it will be. Really everything is worrisome.” – Patient 18-30 
Cognitive deficits 
Language and speech problems were mentioned and some adults received speech therapy. Not 
many cognitive deficits or learning problems were presented as worries, although their 
dependence on others was often mentioned. Some parents had the impression that cognitive 
development stopped or slowed during the transition period  because their children reached 
independence much later than their peers.  
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“... That’s where I have question marks. I wonder if development in those children, in young adults 
under age 30, if there is still progress.” – Parent 18-30  
Physical problems 
There was great diversity in the experienced physical problems. Sleeping problems, fatigue, 
headache, and limited motor skills often expressed as ‘clumsiness’ had a major impact on daily 
life. Fatigue and headaches had a large effect on the ability to work full time and to participate in 
as many activities as peers. Various sleeping problems were reported as a concern; difficulty falling 
asleep, difficulty staying asleep, difficulty waking up and need for sleep medication. Furthermore, 
the growth of neurofibromas was mentioned as a major cause of frustration, because of possible 
malignant transformation and changing appearance. Symptoms mentioned by a small group of 
patients were pain, back pain, and scoliosis. Limited motor skills had a more indirect impact on the 
lives of the patients, for instance being unable to cycle or swim. 
Visibility of disability  
Patients noted being watched, stared at, and/or insulted in public places because of their cosmetic 
problems. The visibility of the disease caused questions from outsiders which were perceived as 
annoying, for example, questions about contagiousness.  
“It was hinted that I had to leave the pool because others had problems with me being in the pool.” 
– Patient 30+ 
Particularly the younger patients were annoyed about NF1-portrayal in media, for example only 
the worst cases being shown on television or the internet, resulting in a false perception of NF1. 
“There was a documentary also about (person’s name), and it’s always about getting the worst, 
very worst, the worst of all ... and showing the most severe [cases]…” – Patient 18-30 
 
Activity limitations & participation restriction 
Limitation of independence 
Parents and patients mentioned their worries about achieving independence. Parents reported 
that their children with NF1 took little initiative. Young adults emphasized that achieving 
independence was delayed; some patients wanted to complete school before moving out of their 
Chapter 8
180
  
 
 
184 
parent’s house. Those who lived independently stated that they needed assistance in 
housekeeping, planning, and organizing. Patients had trouble asking for help, resulting in having to 
wait for people offering assistance. Additionally, patients encountered problems adjusting their 
lives to their limitations caused by NF1, for example planning too many activities while at the same 
time having limited energy.  
 “I’m having a hard time becoming independent, and it’s very scary to separate from my parents 
and to do it all by myself.” – Patient 18-30  
Many parents remained in the coordinating role regarding medical affairs and participated in visits 
with medical specialists, claiming that patients did not recognize and seek help for NF1 symptoms.  
Social deficits 
Loneliness and trouble initiating and maintaining social and romantic relationships were the main 
social problems. Some of the young adults stated to have had social skills training in the past. 
Furthermore, patients feared a lack of understanding of NF1 in new social contacts. Both patients 
and parents mentioned that friendships were complicated by limited understanding of the 
disorder in their environment.  
“Yes, obtaining friendships is difficult because she [my daughter] sometimes behaves a bit 
awkward.” – Parents 18-30 
Especially among patients between 18-30, feelings of insecurity and low self-esteem were 
reported. They felt that they were ‘different’ from others and wanted to be ‘normal’. Many 
patients were still trying to cope with bullying in their past and some patients even mentioned this 
prior bullying “still influenced their current social skills”.  
Family planning difficulties  
There were many worries regarding family planning. Patients appeared to be informed that they 
could pass NF1 to their offspring, but discussed their need for timely and adequate information 
and care on this issue. Some of the patients mentioned the desire to have children but felt 
uncertain about obtaining a relationship which would allow for that in the future. 
“I want children, but do not want to inflict upon them the life that I’m leading, […] so yes, you have 
to go into that trajectory, but who with, and how, and adopting is an option, but then you can’t 
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give birth, and yes, I’m twenty now and I do not have a partner, and I’m getting older…”Patient 18-
30 
Limitations with work  
For cognitively high-functioning patients (ISCED levels 5-7), fatigue was a large cause of problems 
at work. They felt unable to work full-time, but the reduction of working hours was not always 
allowed by their employers. Patients mentioned the need for assistance with employment 
matters, for example: obtaining a suitable job, obtaining a permanent contract, overestimation of 
abilities, lack of understanding of disabilities, and unequal treatment at work. A job coach or 
specific organizations were often deployed, but not always successfully. Parents indicated the 
need for involvement of health care providers in living and working arrangements.  
“Fatigue, headaches … there is zero understanding …” – Parents 18-30 
“Actually, in my view, a coordinating physician should refer to rehabilitation doctors earlier, or that 
for the home/work situation a medical advice is provided, about how to proceed with such a 
child…” – Parents 18-30 
Environmental factors 
Required support in daily life  
Parents and patients all mentioned the need for support and recognition, and many of them found 
this in peer groups of the national patient association. Also, they appreciated people in their direct 
networks showing interest in NF1, both in real life and in social media networks. 
“… in the peer group, we recognize each other there, fortunately, we are very happy with the 
patient foundation because we feel supported.” – Parents 18-30 
Problems during transition process  
Many of the patients declared that the transition to adult health care had been hampered by a 
lack of communication about the transition to adult care, lack of organization of adequate follow-
up, lack of consultation between physicians, and lack of referral to expert care. Often, patients 
were referred back to their general practitioner (GP) for adult care. Parents noted that counter to 
their expectations, care needs increased after becoming 18.  
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Limited access to adequate care 
A number of patients noted that they appreciated when their GP was closely involved.  Patients 
noted the lack of communication and consultations between physicians. Generally, it was very 
difficult to find physicians with knowledge and experience with NF1, and often second opinions 
were required. Patients from outside NF1 expertise centers were not referred to appropriate adult 
care by their GP’s or pediatricians. Psychological support during intensive treatments (for example 
facial surgery) was not often offered but mentioned as a care need by various patients. Parents 
felt that their child received inadequate care if parents were not involved.  
“Some physicians, they didn’t know the disorder and they had to sometimes ‘google’ during the 
consultation, and that I find absolutely unacceptable, personally.” – Patients 18-30 
Patients and parents indicated a need for one easily accessible contact person for NF1-related 
questions, surrounded by a multidisciplinary team. Also, they were in need of family planning care, 
social assistance and community support, and support for parents. During the focus groups, the 
question was raised about whether the expertise center could provide information about NF1 to 
employers, health insurance companies, and social security offices. These organizations have a 
lack of knowledge about NF1 and patients would benefit if they would have more information. 
Interestingly, parents noted that short-term thinking was helpful for their child, because of their 
slower development and the unpredictable course of NF1. As remarks about possible long-term 
effects of NF1 were not found to be useful and unnecessarily stressful, parents also advised 
professionals surrounding the NF1-patient to use ‘short-term thinking’ with short-term 
recommendations.  
NF1 related stress in parents 
Parents were particularly concerned about their children not recognizing NF1-related symptoms 
such as (growth of) neurofibromas, not seeking health care, not receiving proper transitional care, 
and losing their child to the complications of NF1. Parents worried about the slow development of 
independence and the vulnerability of their child (e.g. risking abuse). Many parents reported high 
stress and fatigue levels due to their persistent coordinating role in the lives of their children - 
spending much time with the planning, organization, and administration of daily life and medical 
issues. Some parents even acted as a legal representative. Consequently, by having the 
coordinating role, the question arose: “Who will take care of our child when we are no longer able 
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to do so in the future?” Parental concerns were generally not acknowledged or addressed by 
health care providers or people in their environment, leading to increased stress.  
“… Listen to us, really hear us, even when it seems exaggerated” – Parents 18-30 
 
Discussion 
This study offers patient- and parent-driven data on worries and care needs of adult patients with 
NF1, with an emphasis on the transitional period. Worries emerged from a broad spectrum of 
areas, ranging from physical and mental health to areas of social and occupational participation, 
and transition. This enabled us to formulate recommendations for transitional and adult care. 
 
Physical health 
Physical symptoms such as fatigue, headaches, sleeping problems, and pain had a large effect on 
daily life and were the cause of many worries and medical consultations. Most of these generally 
non-specific symptoms have been reported in children, adolescents, and adults with NF1 7, 32-34. 
Although tumor growth must be excluded, further clinical evaluation often indicates that these 
physical complaints may be associated with NF1, but also with mental health, lifestyle, or 
problems at work. Patients pointed out they wished to know whether these complaints were 
associated with NF1. Since these complaints have a great impact on quality of life, referral to 
psychological or occupational care is warranted to cope with these symptoms. Different levels of 
care may help to answer these questions regarding the role of NF1 in any of these problems. A 
healthcare model with an NF1 expertise center, coordinating NF1-specialists, and several regional 
treatment centers (a ‘hub-and-spoke’ model, the way complex NF1 services are organized in the 
United Kingdom) may facilitate close cooperation of GP’s with a center that offers the appropriate 
level of care.  
 
Mental health 
Although many psychological worries were reported, most participants noted a lack of routine 
assessment of these problems and experienced difficulties finding appropriate evaluation and 
treatment. Fears and worries about the future occurred very frequently on many different topics 
and potential growth of neurofibromas was especially worrisome to the participants. Symptoms of 
depression and anxiety are frequently found in patients with NF1 35, 36 which may be related to the 
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risk of development of malignancies, as is the case in patients at risk for breast and colon cancer 37, 
38. In NF1, MPNST is the most commonly found malignancy with a lifetime risk of 8-13% in NF139. 
In the current study groups, problems with self-acceptance, low self-esteem, and limited 
socioeconomic participation also seemed associated with the NF1 related cosmetic burden 19 and 
mental health problems. 
Although primary concerns with cognitive deficits were not reported, limited 
independence and poor social skills were worries of both patients and parents, and symptoms of 
ADHD and ASD were broadly described. Although more elaborately documented in children with 
NF1, neurocognitive deficits also result in significant limitations in adults with NF1 14 and our 
results underline the presence and burden of these deficits throughout life.  
 
Activities and participation 
Patients expressed frustrations about their inability to function independently, limiting their socio-
economic participation. Difficulties adjusting their life to the complications of NF1 and asking for 
help, problems with organizing and planning daily life, and problems with relationships and work 
were widespread. Poor social skills, reported in children 40 and adults with NF141, affect the lives of 
adult patients, manifesting as problems initiating and maintaining social and romantic 
relationships. Also, negative reactions from others to visible differences in appearance may affect 
self-esteem and the forming of these social and romantic relationships 22. Participants experienced 
problems with finding and maintaining work, and problems with employers. During the interviews, 
inadequate socioeconomic participation and loneliness appeared to be associated with 
psychological complaints - which has been reported before in teenagers and young adults with 
NF1 42, 43.  
Family planning was an important theme, especially for young adults, which is in line with 
previous research 44. Patients stated that they would want to have children without NF1 and that 
additional and timely education about genetics and reproduction was needed, although patients 
could not agree on the age at which this information should be given. This indicates that health 
care providers should make patient-specific decisions on the appropriate timing and level of detail 
of this information. 
 
Environmental factors  
Generally, adult patients and parents seemed to be well informed about NF1, but they often 
noticed a lack of knowledge in people in their direct environment. Both patients and parents 
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experienced limitations in their environment, such as lack of appropriate health care, lack of 
multidisciplinary care, lack of family care, and inadequate support from family, social networks, 
and employers. 
 
Parental stress 
 Parents of patients have previously participated in research to elucidate the impact 
of NF1 on their children 45, yet the impact on parents themselves has not been described yet. In 
our study, parents of young adults reported many worries, high stress levels, and little attention 
from health care providers for their complex parental role. Since the GP is often well informed 
about family issues, she/he may have a crucial role in referring to the appropriate type of support 
and mental health care in the community.  
Parental stress has been described in other pediatric cohorts with neurodevelopmental 
syndromes or autism 46-48. In children with NF1, mothers reported higher parenting stress than the 
mothers of typically developing children 49. The uncertainty of tumor progression may increase 
anxiety in both patients and parents of patients with NF1. In future research, the contributing 
factors to parental stress should be explored more fully, to identify parents at risk and to provide 
targets for prevention and treatment. In addition to parental stress, future research should also 
address the stress of other members of families with NF1.  
 
Implications for transitional care  
The transitional period from pediatric to adult care is known to be a challenging phase for patients 
with NF1 and their parents 12, 18, which was confirmed by our participants. For many patients, this 
transition did not proceed well. Although expert adult care for the tumor phenotype was often 
accessible, finding NF1 experts in other domains was difficult. The neuropsychological deficits that 
frequently occur in patients with NF1 may decrease their self-care and organizational capabilities, 
which puts them at risk for problems during the transition to adult care 12. At this age, as is also 
the case in our sample, differences between parent- and patient-reported worries underline that 
both parents and young adults should be involved in the transitional process.  
Previous studies on the transitional stage in patients with special needs, such as intellectual 
disabilities or chronic disorders, have shown that many adolescents experience significant 
problems with the continuity of care during the transition to adult health care 50-52. Often, after 
years of periodic check-ups by the pediatrician before adolescence, patients discontinued clinical 
evaluations or did not have contact with any health care professionals 18, 53. In our study, adult 
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patients expressed a need for well-informed, accessible, and multidisciplinary NF1 expertise in 
close communication with the patient’s local network and care providers. Continuous ‘chronic’ 
care before, during, and after transition 54 could be facilitated if these specialists could also be 
‘generalists’ in adult care for people with neurogenetic disorders in the way pediatricians are in 
pediatric care 55.  
 
Implications for adult care  
From the worries mentioned above, conclusions can be drawn regarding the organization and the 
content of care provisions. These findings expand on current recommendations for the 
management of NF1 56. Suggestions for clinical practice are listed in Table 4: ‘Addressing health 
care needs during NF1 consultation’.  
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 In all groups, next to a local network of health care professionals including a GP, a 
desire for multidisciplinary expertise on adults with NF1 was expressed, to obtain treatment and 
information on all domains. As our results suggest, this expertise team should communicate 
closely with local health care providers and would be responsible for diagnosis, timely follow-up, 
second opinions, education, and assistance for the patients, parents, and even the socio-economic 
network. Screening and follow-up for mental health problems should be included in routine 
follow-up, as this patient group is at risk for psychiatric morbidity 11, 35, 36, 41, 57. In practice, this 
implicates that individuals with NF1 should be offered structured care, including an accessible 
leading NF1-expert team who routinely screens for physical and mental health and for limitations 
in participation in social, occupational or other meaningful daily activities. Prevention and early 
intervention of mental health problems can be efficient and cost-effective 58 and will ultimately 
improve socioeconomic participation and quality of life.  
Since this study offered us a clear view of worries and care needs within patients with NF1 
and parents of patients with NF1, comparisons across different genetic neurodevelopmental 
syndromes might help to find common factors and to contrast these findings to neurocognitive, 
neurobehavioral, and environmental factors.  
The organization of multidisciplinary and multilevel care requires a method for severity 
assessment that includes the full impact of NF1 on all ICF domains, including limitations in 
activities and participation. Although the Riccardi scale for disease severity 59 has frequently been 
used to assess impairments 60-62, many worries and healthcare needs of our respondents are not 
addressed by this scale, since it mainly focuses on disease characteristics at a somatic level. This 
suggests there is a need for assessing the full impact of NF1 on all ICF domains, including 
limitations in activities and participation. In Tuberous Sclerosis Complex, another neurocognitive 
and tumor predisposition disorder, an attempt has been made to capture the burden of the 
disease by introducing the TAND checklist, encompassing ‘Tuberous sclerosis-associated 
neuropsychiatric disorders’. This could serve as an inspiration for such initiatives in the field of 
neurofibromatosis type 1 63. 
Strengths and limitations  
In a qualitative observational study, the subjects that are to be discussed can be standardized, but 
conversations themselves cannot be standardized. Given the sample size and the nature of this 
study, these differences cannot be explored in a quantitative way. Future studies with larger 
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sample sizes and a quantitative may focus on systematic differences between age groups, genders, 
or between parents and patients.  
Using focus groups as a means to explore worries and needs has the possible drawback of 
participants feeling limited in their ability to express feelings or concerns in the presence of other 
patients or parent. In our focus groups, the atmosphere was quite open and stimulating, and 
almost all participants actively joined the conversation. However, problems with more intimate 
matters such as sexuality, addiction, suicidal thoughts, and finance were hardly reported.  
All patients who participated in this study were members of the Dutch NF1 patient 
organization (NFVN). For this reason, our sample may be biased towards relatively well-informed 
patients with a higher level of education, and parents and patients may also have a more severe 
phenotype. The Netherlands is a high-income country in Western Europe. This should be taken 
into consideration when extrapolating our results and recommendations to other societies where 
limitations in care infrastructure, expertise, and finances may be more prevalent.  
Since a large part of the participants were adults over 30 years old, their reporting about 
the translational period could have suffered from ‘recall bias’. For some of them, this period was 
quite some time ago. Healthcare services probably may have changed in the past years. However, 
we do feel that the recommendations in this paper directly result from the information of both 
younger and older participants. 
The apparent data saturation during analysis suggests sufficient sample size and data 
quality. Other strengths of the study were the large age range, the range in level of education, and 
reports from both patients and parents. The ICF turned out to be an appropriate method to 
describe patient-related problems in almost all areas of life. The universal nature of the ICF and 
the apparent shortcomings of Dutch health care make our findings applicable to other countries 
where multidisciplinary care is not routinely offered.  
 
 
Acknowledgments 
We would like to thank all the participants, their family members, and the Dutch patient’s 
organization (Neurofibromatosis Vereniging Nederland) for their participation and support in this 
study. We are grateful to Alanna Jacobs, who helped to edit the final version of the manuscript.  
 
Worries and needs of adults with NF1 and parents
191
8
  
 
 
195 
References 
1. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone 
syndromes: estimates from a UK family genetic register service. Am J Med Genet A 
2010;152A:327-332. 
2. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999;89:1-6. 
3. NIH nioh. Neurofibromatosis. NIH Consens Statement 1987 Jul 13-15. 1987;6:1-19. 
4. Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. 
Handb Clin Neurol 2013;115:939-955. 
5. Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children 
with neurofibromatosis type 1. Neurology 2005;65:1037-1044. 
6. Hyman SL, Arthur Shores E, North KN. Learning disabilities in children with 
neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. 
Dev Med Child Neurol 2006;48:973-977. 
7. Leschziner GD, Golding JF, Ferner RE. Sleep disturbance as part of the neurofibromatosis 
type 1 phenotype in adults. Am J Med Genet A 2013;161A:1319-1322. 
8. Morris SM, Acosta MT, Garg S, et al. Disease Burden and Symptom Structure of Autism in 
Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT). 
JAMA Psychiatry 2016;73:1276-1284. 
9. Constantino JN, Zhang Y, Holzhauer K, et al. Distribution and Within-Family Specificity of 
Quantitative Autistic Traits in Patients with Neurofibromatosis Type I. J Pediatr 2015;167:621-626 
e621. 
10. Mautner VF, Granstrom S, Leark RA. Impact of ADHD in adults with neurofibromatosis type 
1: associated psychological and social problems. J Atten Disord 2015;19:35-43. 
11. Descheemaeker MJ, Plasschaert E, Frijns JP, Legius E. Neuropsychological profile in adults 
with neurofibromatosis type 1 compared to a control group. J Intellect Disabil Res 2013;57:874-
886. 
12. Van Lierde A, Menni F, Bedeschi MF, et al. Healthcare transition in patients with rare 
genetic disorders with and without developmental disability: neurofibromatosis 1 and Williams-
Beuren syndrome. Am J Med Genet A 2013;161A:1666-1674. 
13. Vranceanu AM, Merker VL, Park ER, Plotkin SR. Quality of life among children and 
adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol 
2015;122:219-228. 
Chapter 8
192
  
 
 
196 
14. Lehtonen A, Howie E, Trump D, Huson SM. Behaviour in children with neurofibromatosis 
type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child 
Neurol 2013;55:111-125. 
15. Farre A, Wood V, McDonagh JE, et al. Health professionals' and managers' definitions of 
developmentally appropriate healthcare for young people: conceptual dimensions and embedded 
controversies. Arch Dis Child 2016;101:628-633. 
16. Korf BR. Neurofibromatosis type 1 (NF1): Management and prognosis [online]. Available at: 
https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-management-and-prognosis. 
17. Rauen KA, Huson SM, Burkitt-Wright E, et al. Recent developments in neurofibromatoses 
and RASopathies: management, diagnosis and current and future therapeutic avenues. Am J Med 
Genet A 2015;167A:1-10. 
18. Oates EC, Payne JM, Foster SL, Clarke NF, North KN. Young Australian adults with NF1 have 
poor access to health care, high complication rates, and limited disease knowledge. Am J Med 
Genet A 2013;161A:659-666. 
19. Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adult patients with 
neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the 
literature. J Neurooncol 2013;114:257-262. 
20. Lai JS, Jensen SE, Patel ZS, Listernick R, Charrow J. Using a qualitative approach to 
conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform 
neurofibromas (pNF) across the lifespan. Am J Med Genet A 2017;173:79-87. 
21. Crawford HA, Barton B, Wilson MJ, et al. The Impact of Neurofibromatosis Type 1 on the 
Health and Wellbeing of Australian Adults. J Genet Couns 2015. 
22. Barke J, Harcourt D, Coad J. 'It's like a bag of pick and mix--you don't know what you are 
going to get': young people's experience of neurofibromatosis Type 1. J Adv Nurs 2014;70:1594-
1603. 
23. Draucker CB, Nutakki K, Varni JW, Swigonski NL. The health-related quality of life of 
children, adolescents, and young adults with neurofibromatosis type 1 and their families: Analysis 
of narratives. J Spec Pediatr Nurs 2017;22. 
24. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research 
(COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007;19:349-
357. 
Worries and needs of adults with NF1 and parents
193
8
  
 
 
197 
25. European-Commission. Inclusion strategy of the "Youth in Action"programme (2007-2013) 
[online]. Available at: https://www.salto-youth.net/downloads/4-17-
1294/InclusionStrategyYiA.pdf. Accessed 22nd July 2017. 
26. van Staa A, van der Stege HA, Jedeloo S, Moll HA, Hilberink SR. Readiness to transfer to 
adult care of adolescents with chronic conditions: exploration of associated factors. J Adolesc 
Health 2011;48:295-302. 
27. ATLAS.ti 6 [computer program]. Berlin: 2011. 
28. Braun V CV. Using thematic analysis in psychology. Qualitative Research in Psychology 
2006;3:77–101. 
29. WHO WHO. International Classification of Functioning, Disability and Health (ICF) [online]. 
Available at: http://www.who.int/classifications/icf/en/. Accessed 22 December 2016. 
30. Gilboa Y, Rosenblum S, Fattal-Valevski A, Josman N. Application of the International 
Classification of Functioning, Disability and Health in children with neurofibromatosis type 1: a 
review. Dev Med Child Neurol 2010;52:612-619. 
31. UNESCO Ifs. International Standard Classification of Education; ISCED 2011. Montreal, 
Quebec, Canada2012. 
32. Afridi SK, Leschziner GD, Ferner RE. Prevalence and clinical presentation of headache in a 
National Neurofibromatosis 1 Service and impact on quality of life. Am J Med Genet A 
2015;167A:2282-2285. 
33. Wolters PL, Burns KM, Martin S, et al. Pain interference in youth with neurofibromatosis 
type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, 
and quality of life. Am J Med Genet A 2015;167A:2103-2113. 
34. Johnson H, Wiggs L, Stores G, Huson SM. Psychological disturbance and sleep disorders in 
children with neurofibromatosis type 1. Dev Med Child Neurol 2005;47:237-242. 
35. Cohen JS, Levy HP, Sloan J, Dariotis J, Biesecker BB. Depression Among Adults with 
Neurofibromatosis Type 1: Prevalence and Impact on Quality of Life. Clin Genet 2014. 
36. Pasini A, Lo-Castro A, Di Carlo L, et al. Detecting anxiety symptoms in children and youths 
with neurofibromatosis type I. Am J Med Genet B Neuropsychiatr Genet 2012;159B:869-873. 
37. Lindberg NM, Wellisch D. Anxiety and compliance among women at high risk for breast 
cancer. Annals of behavioral medicine : a publication of the Society of Behavioral Medicine 
2001;23:298-303. 
Chapter 8
194
  
 
 
198 
38. Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kaariainen H. Psychological consequences 
of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective 
follow-up study. International journal of cancer 2001;93:608-611. 
39. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral 
nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311-314. 
40. Barton B, North K. Social skills of children with neurofibromatosis type 1. Dev Med Child 
Neurol 2004;46:553-563. 
41. Pride NA, Crawford H, Payne JM, North KN. Social functioning in adults with 
neurofibromatosis type 1. Res Dev Disabil 2013;34:3393-3399. 
42. Ejerskov C, Lasgaard M, Ostergaard JR. Teenagers and young adults with neurofibromatosis 
type 1 are more likely to experience loneliness than siblings without the illness. Acta Paediatr 
2015;104:604-609. 
43. Hummelvoll G, Antonsen KM. Young adults' experience of living with neurofibromatosis 
type 1. J Genet Couns 2013;22:188-199. 
44. Crawford HA, Barton B, Wilson MJ, et al. The Impact of Neurofibromatosis Type 1 on the 
Health and Wellbeing of Australian Adults. J Genet Couns 2015;24:931-944. 
45. Barke J, Coad J, Harcourt D. Parents' experiences of caring for a young person with 
neurofibromatosis type 1 (NF1): a qualitative study. Journal of community genetics 2016;7:33-39. 
46. Hartley SL, Seltzer MM, Head L, Abbeduto L. Psychological Well-being in Fathers of 
Adolescents and Young Adults with Down Syndrome, Fragile X Syndrome, and Autism. Family 
relations 2012;61:327-342. 
47. Briegel W, Schneider M, Schwab KO. 22q11.2 deletion syndrome: behaviour problems of 
children and adolescents and parental stress. Child: care, health and development 2008;34:795-
800. 
48. Pozo P, Sarria E. Still stressed but feeling better: Well-being in autism spectrum disorder 
families as children become adults. Autism 2015;19:805-813. 
49. Esposito M, Marotta R, Roccella M, et al. Pediatric neurofibromatosis 1 and parental stress: 
a multicenter study. Neuropsychiatr Dis Treat 2014;10:141-146. 
50. Reiss JG, Gibson RW, Walker LR. Health care transition: youth, family, and provider 
perspectives. Pediatrics 2005;115:112-120. 
51. Bindels-de Heus KG, van Staa A, van Vliet I, Ewals FV, Hilberink SR. Transferring young 
people with profound intellectual and multiple disabilities from pediatric to adult medical care: 
parents' experiences and recommendations. Intellect Dev Disabil 2013;51:176-189. 
Worries and needs of adults with NF1 and parents
195
8
  
 
 
199 
52. Fegran L, Hall EO, Uhrenfeldt L, Aagaard H, Ludvigsen MS. Adolescents' and young adults' 
transition experiences when transferring from paediatric to adult care: a qualitative 
metasynthesis. Int J Nurs Stud 2014;51:123-135. 
53. Lotstein DS, Ghandour R, Cash A, McGuire E, Strickland B, Newacheck P. Planning for health 
care transitions: results from the 2005-2006 National Survey of Children With Special Health Care 
Needs. Pediatrics 2009;123:e145-152. 
54. NICE. Transition from children’s to adults’ services. In: Excellence NIfHaC, ed.2016. 
55. Schor EL. Transition: changing old habits. Pediatrics 2015;135:958-960. 
56. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of 
individuals with neurofibromatosis 1. J Med Genet 2007;44:81-88. 
57. Mautner VF, Granstrom S, Leark RA. Impact of ADHD in Adults With Neurofibromatosis 
Type 1: Associated Psychological and Social Problems. J Atten Disord 2012. 
58. WHO Who. Mental health: strengthening our response [online]. Available at: 
http://www.who.int/mediacentre/factsheets/fs220/en/. Accessed October 21, 2016. 
59. Riccardi VM. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. 2nd ed. 
Baltimore, MD: Johns Hopkins University Press, 1992. 
60. Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A. Quality-of-life impairment in 
neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol 2001;137:1421-
1425. 
61. Upadhyaya MaC, D.N. Neurofibromatosis Type 1. Berlin Heidelberg: Springer-Verlag, 2012. 
62. van der Vaart T, Plasschaert E, Rietman AB, et al. Simvastatin for cognitive deficits and 
behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, 
placebo-controlled trial. Lancet Neurol 2013;12:1076-1083. 
63. de Vries PJ, Whittemore VH, Leclezio L, et al. Tuberous sclerosis associated 
neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol 2015;52:25-35. 
 
  
Chapter 8
196
  
 
 
200 
  
Worries and needs of adults with NF1 and parents
197
8
Chapter 8
198
General discussion
199
9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 9.
General discussion
Chapter 9
200
  
 
 
202 
Neurofibromatosis type 1 (NF1) is a neurogenetic disorder with a highly variable behavioral 
phenotype. Compared to former research, the main contribution of this thesis to the behavioral 
phenotype of NF1 is due to larger sample sizes, broader outcome measures, the longitudinal 
design, or the associations between phenotype and quality of life and participation. In this 
chapter, overarching conclusions will be drawn regarding all studies described in Chapters 2 to 8. 
In addition to the conclusions already drawn in previous chapters, clinical implications, 
recommendations for assessment and treatment of individuals with NF1, and suggestions for 
future research are formulated. This information is underlined in the text below.  
 
Behavioral phenotype of NF1  
 
Chapters 2 to 5 focus on clarifying the behavioral phenotype of NF1 on the different levels of the 
ICF.   Motor, emotional, and behavioral problems in children and adolescents are common in NF1, 
probably even more than was thought before.  
 
Motor problems in children with NF1  
We found that almost half of the children of 4 to 16 years with NF1 have severe motor problems, 
independent from age or intelligence. In the general population, this is about 5-6% of school-aged 
children.1 The prevalence of severe motor problems is comparable to or even larger than the 
prevalence of ADHD in NF1.2-4 In addition, ADHD, ASD, and externalizing problem behaviors are 
often associated with motor problems in NF1.5 Compared to former studies, our study used a 
larger group of children and a broader test-battery: the Movement-ABC6, 7, which is regarded as an 
important part of the assessment needed for diagnosing developmental motor problems in 
children.8  
Although the DSM-59, the psychiatric classification system for mental disorders, started as 
a descriptive system, in some classifications there are causal elements referring to the cause of a 
disorder. In the description of developmental coordination disorder (DCD), one of the criteria 
states: “the motor skills deficits are not attributable to a neurologic condition affecting movement 
(e.g., cerebral palsy, muscular dystrophy, degenerative disorder)”. The question is how ‘neurologic 
conditions’ are defined and whether NF1 needs to be regarded as such. Since NF1 can affect 
bones, muscles, and other structures of the musculoskeletal system, this needs to be addressed 
first in clinical assessment. Despite the high prevalence, DCD is probably underrecognized by 
health care professionals.1 Many of these motor difficulties continue into adulthood and 
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evidence-based interventions for children with DCD are known and often available.10 Not 
diagnosing DCD could impede referral to the providers of these interventions, which may have a 
negative effect on the well-being and participation of individuals with NF1. When developmental 
motor problems are this severe, the professionals who have expertise in motor development (i.e. 
rehabilitation doctors, physiotherapists, pediatricians, neurologists, psychiatrists, or healthcare 
psychologists), may consider diagnosing DCD in NF1. 
Children with NF1 can have decreased mineral density, bone strength, and muscle mass,11 
and may have reduced muscle force.12 Future longitudinal and treatment studies may clarify to 
what extent these symptoms contribute to the development of motor problems in NF1. This could 
also provide an answer to questions regarding the musculoskeletal or neurodevelopmental origin 
of motor problems in NF1.  
 
Emotional and behavioral problems in NF1 
Chapter 3 describes the increase of internalizing behavioral problems (also: ‘emotional problems’) 
in children between 4 and 8  years of age. Interestingly, no association was found between these 
emotional problems and intelligence or language development. This lack of association was also 
found in Chapter 7, describing a factor analysis resulting in one component with cognitive 
outcome measures and a relatively independent second component with emotional and 
behavioral problems and psychosocial quality of life. Since the correlation between cognition and 
quality of life appear to be low according to these studies, it can be disputed whether cognitive 
problems in children with NF1 should be a priority in treatment. Possibly the educational system in 
the Netherlands and Belgium (Flanders) provides the opportunity to adapt education to fit the 
capacities of children. In general, quality of life is higher in people with higher educational levels. 
They are less often unemployed, better paid, have better homes and a better appreciation of their 
own health. People with a lower level of education are more vulnerable in times of economic 
downturn.13 Since both cognition and behavior are important features of the behavioral 
phenotype of NF1, psychological assessment should include both aspects. 
 Another relationship that emerges in different studies in this thesis is the association 
between physical and behavioral aspects of NF1. The severity of NF 1 in adults as defined by the 
Riccardi scale,14 appears to be associated with quality of life in some studies.15 Using a self-
constructed scale for severity and a measure for total tumor burden, Martin et al.16 found an 
association between severity and social-emotional outcomes. We did find an association between 
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emotional and behavioral problems and quality of life but not with NF1 severity. Different 
definitions of severity and different behavioral outcome measures may be the reason for the 
differences between these findings. There is a wide variety of NF1 symptoms that can contribute 
to the perceived severity of NF1. For this reason, it is debatable whether a single scale or rating 
can reflect this diversity when it reduces severity to a limited classification in four levels or when it 
defines severity as the sum of a number of symptoms. Somatic symptoms include tumor burden, 
malignancy, neurological symptoms, musculoskeletal symptoms, dermatological symptoms, and 
more. In addition, cognitive, emotional, social, and behavioral symptoms known to affect quality 
of life and participation must be assessed in order to get a complete impression of the severity of 
NF1. It would be better not to add or combine these somatic, cognitive, emotional, social, and 
behavioral symptoms in future research, but to consider them as separate predictors of quality of 
life and participation. 
Having a parent with NF1 can also be a factor that influences outcome in children with NF1. 
Comparing children with a familial mutation to children with a sporadic mutation, the study in 
Chapter 3 did not find a difference in intelligence or behavioral problems but children with a 
familial mutation seemed to score lower on all language tests at kindergarten age. Future research 
may explore genetic or sociocultural transmission as explanations of language problems in young 
children with familial NF1. Interestingly, having a parent with NF1 can possibly be a beneficial 
factor, since more children with familial mutations return for follow-up at a later age in this 
longitudinal study.  
In all three studies from chapters 3 to 5, the emphasis on internalizing behavioral problems 
in NF1 in children, adolescents, and young adults is clear. The only average scores (on a group 
level) in a broad screening of emotional and behavioral problems are the scores on scales for 
externalizing and in particular aggressive behavior. The internalizing domain, also called the 
domain of emotional rather than behavioral problems, includes anxiety, depression, social 
withdrawal, and somatic complaints. Although scores for somatic symptoms in NF1 are showing 
the largest deviation from the scores of children in the normative population, also anxious, 
depressed and withdrawn behavior is clearly present in NF1. These behaviors may remain 
unnoticed at home, at school, or at work for a long time, risking more severe psychopathology.17-19 
Early recognition of anxiety and depression and easy access to mental health care is necessary to 
prevent lower quality of life and late or even too late treatment of these serious disorders.  
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Attention problems and social problems are probably the most prevalent and most serious 
neurobehavioral problem in NF1. In the study described in chapter 3, 33% of the children had an 
ADHD diagnosis and in a recent study from our ENCORE group, about 11% have an autism 
spectrum disorder.20 This problem is even greater in NF1 than these percentages can express, 
since they only refer to children and adolescents with problems in the clinical range, whereas a 
larger group has problems in the borderline of subclinical range. Attentional and social problems 
should be a focus of attention in the follow-up of NF1 since these problems interact and can 
reinforce each other.21, 22 Children with one or two of these problems are at risk of learning 
problems, social isolation, and other comorbid psychopathology.  Early and regular screening and 
intervention into adulthood can reduce the risk of these consequences.  
 
Quality of life and participation in daily life 
Chapter 5 and 8 illustrate determinants of quality of life and the worries of adults about their daily 
activities and participation. Adolescents and young adults with NF1 have lower mental and 
physical quality of life (QoL) and important determinants were sex, fatigue, and internalizing and 
social problems. Until now, fatigue was not a recurring topic in NF1 research. In clinical practice, 
however, fatigue is very often an important point of concern in consultations of adolescents and 
adults with NF1. Now that we know fatigue is such a strong determinant of quality of daily life, this 
needs to be reflected in assessments, care, outcome measures, and research in the near future. In 
a consultation of adult patients with NF1 in the Netherlands during the drafting of the Dutch 
standard for NF1 care, chronic fatigue was the second most prevalent complaint, after cutaneous 
neurofibroma. People with NF1 often complain about reduced physical and mental resilience. The 
recently developed INF1-QOL-Questionnaire23 could be extended with the question:  
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In literature and standards of care, fatigue is being associated with stress, sleeping 
problems, headache, attention/concentration problems, pain, scoliosis, pulmonary (valve) 
stenosis, (brain) tumors, and depressed mood. At present, it is unclear which of these problems 
play a part in causing or increasing fatigue and which of these complaints are consequences of 
fatigue. Future research needs to focus on the emergence of fatigue in the natural history of NF1 
and on the position of fatigue within this field of complaints. Whether severe fatigue symptoms or 
their predictors also occur in children may be answered in such studies. Next to this, current 
successful methods aiming at symptomatic treatment of chronic fatigue24 may well be effective in 
NF1 in the same way that medication effective in the symptomatic treatment of ADHD is also 
effective in treating ADHD-symptoms in NF1.3 
 In our qualitative study, focusing on worries and care needs (Chapter 8), it again became 
apparent that adults with neurofibromatosis type 1 and their parents need a broad scope of care 
and support from their care providers. Comparing this study with a comparable study we 
conducted in adults with TSC and their parents, 25 patients with NF1 experience a lack of routine 
assessment of mental health issues. In TSC, the Tuberous Sclerosis-Associated Neuropsychiatric 
Disorders (TAND) 26 – screening already addresses this need in the TSC-population. A 
‘Neurofibromatosis 1 – associated neuropsychiatric disorders’- screening tool could assist NF1 
patients and professionals, especially those working outside NF1 centers for expertise, to also 
focus on this important part of NF1 care. A concept version of an adaptation and extension of the 
TAND into a ‘NAND’, can be found as an appendix at the end of this chapter.  
Both patients with NF1 and TSC indicate they need to focus not only on complaints about 
somatic or mental health problems but also on daily activities and participation. The ICF model is a 
‘Does fatigue interfere with studying, work, daily living activities or social activities? (e.g. 
increased concentration problems due to fatigue, not being able to attend a full day at 
school or work, not being able to have a family life or social life due to fatigue).’ 
 
No problems due to fatigue         □0 
Mild problems due to fatigue but able to perform activities     □1 
Moderate problems due to fatigue cause me some difficulty in performing activities  □2 
Severe problems due to fatigue stop my activities       □3 
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useful framework to also incorporate socioeconomic, personal, and environmental issues in a 
broad assessment of the needs of people with NF1 and their families. Future initiatives to develop 
these ‘patient-reported outcome measures’ (so-called PROM’s) may be supported by the USA 
National Institutes of Health (NIH), which started the PROMIS initiative, that currently also 
comprises local initiatives such as the Dutch-Flemish PROMIS group.27 This also fits well with the 
current tendency to focus on ‘Value-based healthcare’ (VBHC) aiming to improve ‘patient value’ 
via patient outcomes and cost-effectiveness.  
Also in other neurobehavioral syndromes such as TSC,25 Angelman syndrome, and Fragile X 
syndrome,28 there is a growing interest in daily living challenges and family impact of these 
syndromes, also to find whether and how presently available as well as future treatment options 
can impact on the lives of these individuals. Outcomes of qualitative studies are useful raw 
material for constructing syndrome-specific instruments with known psychometric properties. 
With these instruments, larger groups of patients and their families from various countries and 
cultures can be asked to contribute to the knowledge of associations between a behavioral 
phenotype, quality of life, and participation in daily life.  
Due to the large variation in domains that are affected by NF1, the care for people with 
NF1 is per definition a team effort. Clinical geneticists, neurologists, pediatricians, dermatologists, 
ophthalmologists, and surgeons each contribute to a part of the somatic care. In the Dutch 
standard of care,29 next to the contribution of somatic specialists, also the contribution of parents, 
teachers, psychologists, psychiatrists, physical therapists, occupational therapists, 
speech/language therapists, nurses, and social workers is described. In addition to cooperation 
between all these specialists, a well-organized, government-supported patients’ association is an 
important, low-threshold means to inform patients, parents, and other professionals, and to 
facilitate the exchange of experiences and ideas.  
 
Strengths & weaknesses 
The NF1 outpatient clinic in Rotterdam has been active for almost 35 years. In a growing number 
of countries, systematic follow-up of NF1 is organized. In these years, the knowledge about NF1 
and the experience in care and research is growing, together with the amount of data collected on 
genetic, somatic, cognitive, and behavioral factors in people with NF1. This facilitates research into 
NF1 with a growing number of patients, a longitudinal perspective, and increasing data quality. A 
major effect on research of this growing population in follow-up is the large number of patients 
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that now can be included in cross-sectional studies and be prepared for future trials, contributing 
to the ‘trial readiness’ of our expertise center. If the care that the center provides is valued by 
patients and parents, people return for re-evaluation after a predetermined period of time. This 
enables data collection on the natural history of NF1 and the study of the acquisition of skills and 
the emergence of problems in longitudinal research. At this moment, longitudinal studies in NF1 
are scarce and also the study described in Chapter 3 suffered from a small sample size. There is a 
need for future research in larger populations to confirm or differentiate the findings of 
underpowered studies.  
Recruitment of patients for trials is easier with more than 500 patients in active care. 
However, NF1 is a rare disease and the number of participants necessary for sufficient power can 
still be more than a national reference center can provide. For this reason, an international 
collaboration of national or regional reference centers is crucial, as was also the case during the 
recruitment of participants for the SIMCODA study. Partly for this reason, ENCORE participates in 
the European reference network (ERN) GENTURIS for patients with one of the rare genetic tumor 
risk syndromes (www.genturis.eu). 
A drawback of performing research in an academic, tertiary hospital is the risk of ‘academic 
bias’: since mainly the people with more serious complaints may visit national reference centers. 
Trials evaluating the treatment of NF1-related symptoms may suffer from a bias towards the more 
severely affected individuals. On the other hand, particularly the more severely affected patients 
have the greatest need for this type of specialized care and for the results of future therapeutic 
research. The current development of regional treatment centers in the Netherlands in addition to 
one central expertise center could make care more accessible to all patients and may reduce this 
bias.  
 
Longitudinal studies and trials in NF1 
Both longitudinal studies and trials are costly projects requiring funding for care and research and 
time from patients, families, care providers, and researchers. This requires a thorough 
consideration of criteria for the selection of outcome measures in advance. The information that is 
collected in follow-up needs to contribute to the knowledge about the individuals with a 
neurogenetic disorder and their families. Next to this, it can also give valuable information about 
the disorder in general. At a micro-level, this information needs to enable the healthcare 
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professional to answer questions from his or her clients about their daily lives. At a macro-level, it 
may help to answer questions regarding the behavioral phenotype.  
Selection of outcome measures 
Most criteria for the quality of psychological outcome measures are widely accepted. A 
commission of the Dutch Institute for Psychology (NIP) formulated these criteria in the COTAN 
guidelines (Commissie Testaangelegenheden Nederland: Commission of Assessment Issues in the 
Netherlands). This commission evaluates all submitted instruments using criteria for principles of 
test construction, norms, reliability, content validity, and criterion validity. Although knowledge 
about these criteria is part of the general training of most psychologists, a critical evaluation by an 
expert team is a valuable additional tool for the practicing psychologist. However, not all 
instruments are evaluated by COTAN and evaluation of outcome measures by the psychologist 
who is available for the project will be necessary on many occasions. This is all the more necessary 
when it comes to the usefulness of instruments for a specific target group, such as NF1. 
 International initiatives to aid in the selection of outcome measures are the COnsensus-
based Standards for the selection of health Measurement INstruments (COSMIN) initiative30 and 
the Core Outcome Measures in Effectiveness Trials (COMET) initiative.31 In 2016, this led to the 
development of a guideline for selecting outcome measurement instruments.32 
Outcome measures in follow-up 
A structured follow-up administering preset instruments at preset ages could facilitate a 
longitudinal view on the natural history of the disorder. The VOLG project (Dutch acronym for 
‘Early recognition of problems in learning and behavior’), as described in the Introduction of this 
thesis, is such a follow-up program.  The VOLG follow-up is conducted at our center of expertise 
and at several NF1 treatment centers in the Netherlands and is offered to all children and 
adolescents. A major concern for the VOLG program, which also aims at good data integrity, is 
whether children return to follow-up, years after their first assessment. Referral by a physician 
specialized in NF1 may contribute to long-term compliance. Apart from this, psychologists need to 
listen and respond to the concerns of parents, and they need to provide a thorough evaluation in 
this assessment and state useful recommendations for parents and children. 
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Recommendations regarding the instruments a thorough evaluation should consist of: 
 associated with NF1-related deficits  
 good psychometric properties (e.g. recent, national norms, test-retest, and interrater 
reliability, construct validity)  
 measure a construct over a long period of time to facilitate long-term comparisons and 
longitudinal research 
 internationally used in NF1-research to facilitate comparison in research or comparison with 
other NF1 populations 
 sensitive for changes in time or changes caused by the intervention 
Following the present knowledge about the behavioral phenotype of NF1, Table 1 provides an 
overview of the core constructs and (as an example) instruments that are frequently used in the 
field of NF1 research.  
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Outcome measures in trials 
Trials require large efforts from patients, parents, and professionals and funding from clinical 
institutions, funding organizations, and society before they can inform us about the effectivity of 
the target intervention. For this reason, ample time needs to be paid to the process of selecting 
outcome measures. Chapters 5, 6, and 7 are all associated with trials aiming at treating NF1. 
Chapter 5 describes the starting point of a trial focusing mainly on psychosocial complaints. Like 
many other studies, this ‘SPOT trial’ addresses the symptomatic treatment of the effects of NF1. In 
the near future, the results of this SPOT study and the effects of a psychosocial intervention on 
mental quality of life will be published. 
In the last twenty years translational research has added a more causal approach to 
treatment.  The cooperation of fundamental research with clinical research facilitated translating 
preclinical trials into clinical trials targeting cognitive and behavioral problems. This type of 
research has only just started and more trials are running at this very moment (e.g. the EXCEL trial 
to evaluate the effect of lamotrigine on cognition and behavior in NF1; EudraCT Number: 2013-
003405-26). During and after these trials, lessons are learned every day from current trials to 
contribute to better future trials.  One of these lessons concerns the selection of outcome 
measures. Critical evaluation of the outcome measures can make a valuable contribution to the 
interpretation of current trials and the selection of outcomes in future trials. Chapter 7 illustrates 
how running or past trials can provide information about the value of generally used instruments.  
Evaluation of the outcome measures themselves and the relationship between these measures 
provides useful information for future trials. This paper itself kindled a discussion in the field of 
NF1 trials as to the selection of broad outcome measures (i.e. quality of life surveys or intelligence 
test batteries) or specific outcome measures (i.e. more explanatory outcomes tapping specific 
neuropsychological functions). Walsh et al. argued that researchers should select hypothesis-
driven domains for a trial. We responded that a clinically relevant outcome measure is needed 
when deciding whether a certain treatment should be given to children with learning difficulties.35 
The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International 
Collaboration aims to reach a consensus on clinical trials endpoints in NF1 research. Future 
initiatives should focus first on accumulating and integrating knowledge about outcome measures 
to finally harmonize the selection of neuropsychological outcome measures in NF1.  
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Conclusion 
Behavioral phenotyping in NF1 has shown to be a powerful approach to understanding the natural 
history of a syndrome and its frequently associated co-morbid problems. Also, NF1 is a common 
neurocognitive disorder that can serve as a model for many other monogenetic syndromes. This 
thesis not only extends the knowledge about the phenotype but also provides guidance for the 
diagnosis and treatment of children, adolescents, and adults with NF1. 
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APPENDIX TO DISCUSSION 
CONCEPT 
NAND- Checklist (Neurofibromatosis type 1-Associated-Neuropsychiatric-Disorders) 
 
1. Developmental milestones 
a. First smiled 
b. Sat without support 
c. Walked without holding on 
d. Used single words other than mama/dada 
e. Used two words/short phrases 
f. Toilet trained during the day 
g. Toilet trained at night 
 
2. Current level of functioning 
a. Language 
b. Self-care 
c. Mobility 
d. Speech 
e. Ability to attend school/work 
 
3. Behavioral concerns 
a. Anxiety 
b. Depressed mood 
c. Withdrawn/Extreme shyness 
d. Mood swings 
e. Aggression 
f. Temper tantrums 
g. Self-injury  
h. Absent or delayed onset of language to communicate 
i. Repeating words and phrases over and over again 
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j. Poor eye contact 
k. Difficulties getting on with people of the same age  
l. Repetitive and ritualistic behaviors 
m. Rigidity/inflexibility 
n. Overactivity/hyperactivity 
o. Difficulty paying attention or concentrating 
p. Restlessness/fidgetiness 
q. Impulsivity 
r. Difficulties with eating 
s. Difficulties with fine motor skills 
t. Difficulties with gross motor skills 
u. Feelings of loneliness 
v. Substance abuse (alcohol, tobacco, other) 
 
4. Sleep difficulties and fatigue 
a. Insomnia: difficulty falling asleep 
b. Insomnia: difficulty staying asleep 
c. Sleep apnea 
d. Restless legs syndrome 
e. Extremely tired after normal effort 
 
5. Psychiatric disorders diagnosed 
a. Attention deficit and hyperactivity disorders 
b. Autism spectrum disorders 
c. Anxiety disorders (panic attacks, phobias, obsessive-compulsive disorder) 
d. Depressive disorders 
e. Obsessive-compulsive disorders 
f. Psychotic disorders (incl. schizophrenia, hallucinations and/or delusions) 
g. Developmental coordination disorder 
h. Eating disorders 
i. Dementia and other cognitive regression 
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6. Intellectual ability 
a. Conceptual skills (intellectual functioning, language, academic) 
b. Practical skills (Adaptive behaviors such as daily living skills, communication, personal 
independence, school or work functioning) 
c. Social skills (interpersonal skills, friendships) 
 
7. Academic skills- difficulties in: 
a. Reading  
b. Writing 
c. Spelling 
d. Mathematics/arithmetic  
e. Reading comprehension 
 
8. Neuropsychological skills- difficulties in: 
a. Executive functions: 
i. Inhibition 
ii. Planning 
iii. Organizing 
iv. Flexibility/ shifting attention/dual tasking/multitasking 
v. Working memory 
b. Attentional skills 
i. Focusing attention 
ii. Sustaining attention 
iii. Dividing attention 
c. Language skills:  
i. Language comprehension(receptive language)  
ii. Language expression (expressive language) 
d. Memory skills (recognition and recall) 
e. Visuospatial skills (navigation, drawing, constructing) 
f. Disorientation (time, place, person) 
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9. Psychosocial functioning 
a. Self-esteem 
b. High levels of stress 
c. High levels of stress of parents 
d. Family functioning 
e. Relationship difficulties 
 
10. Impact of NAND: Taken these difficulties together, how much have these bothered, 
troubled, or distressed you/your child/your family? (Scale from 0-Not at all to 10-Extremely) 
 
11. Prioritizing: top priorities to work on next  
 
12. Additional concerns 
 
13. Strengths and protective factors 
 
14. Health-care professional rating of the impact of NAND  
(Scale from 0-Not at all to 10- Extremely ) 
 
15. Current medication 
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Questions 3 to 9 end with: 
 Evaluation, support or treatment in the past  
 Wishing further evaluation, support or treatment 
 
Cursive: NF1- related changes and additions to the TAND 
 
 
This list is an adaptation of the TAND:  
de Vries PJ, Whittemore VH, Leclezio L, et al. Tuberous sclerosis-associated neuropsychiatric 
disorders (TAND) and the TAND Checklist. Pediatr Neurol 2015;52:25-35. 
Rietman AB, 2019 
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I. Summary 
Neurofibromatosis type 1 (NF1) is a genetic disorder or syndrome caused by changes in the NF1 
gene on chromosome 17q11.2. NF1 occurs in 1:2,000 to 4,000 people, of whom about half are 
‘new mutations’ meaning parents do not have NF1. NF1 leads to symptoms in the appearance of 
people, such as light brown spots on the skin (so-called café-au-lait macules), lumps on or in the 
skin but also to an increased risk of having benign and malignant tumors. There is a 7-13% lifetime 
risk of developing malignant peripheral nervesheath tumors. Most symptoms occur in the nervous
system, the skin, and the bones. This leads to unpredictable and variable complications. In adults, 
sex and age do not seem to be associated with NF1 severity, but there appears to be an association 
with general quality of life. Although the diagnostic criteria are largely somatic and the physical  
symptoms are serious and impressive, cognitive deficits and behavioral problems are the most  
common complications of NF1 in children.  
 Genotype is the genetic makeup or code of cells or of an organism. The genotype, together 
with other genetic and environmental factors determines one's phenotype. The phenotype of an 
organism is the combination of characteristics, including the physical appearance and properties, 
development, and behavior. A behavioral phenotype includes cognitive, personality, and 
behavioral patterns. Some behavioral phenotypes may be psychiatric disorders or syndromes. 
Neurocognitive and psychosocial assessments can provide a profile of strengths and weaknesses, a 
behavioral phenotype of the cognitive, sensory, motor, educational, behavioral, social, and 
emotional characteristics of people with NF1.  
Behavioral phenotype of NF1 
The average full-scale intelligence quotient (IQ) of children with NF1 is about 10 to 15 points lower 
than the IQ in the general population and also compared to siblings without NF1. Intellectual 
disability is twice as common in NF1 and there are more individuals with NF1 who have an IQ 
below 70. Other cognitive problems in NF1 are associated with speech and language, visuospatial 
skills, executive functions (inhibition, planning, and flexibility), attention, and motor performance. 
The majority of the behavioral problems found in NF1 are emotional problems such as anxiety, 
depression, and social withdrawal. The most common behavioral disorder in NF1 is ADHD 
(attention-deficit/hyperactivity disorder):  ADHD occurs in 30 to 50% of the children with NF1 
(compared to 5% of children in the general population). They also have poorer social skills and 
there is an increased risk of autism spectrum disorders (ASD).  
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 Effects of NF1 in daily life consist of sleeping problems, learning problems, and a need for 
additional support and treatment. Both the people with NF1 themselves and their parents and 
families experience higher levels of stress, also due to difficulty coping with the uncertainty about 
the course of NF1. Health-related quality of life (QoL) is lower in children and parents, particularly 
when bodily pain is involved.  
This thesis aims to contribute to the knowledge about NF1 on cognitive, behavioral, 
emotional, and social domains of the behavioral phenotype and the effects of this phenotype on 
daily life. By improving assessment and treatment, the care for and the quality of life of individuals 
with NF1 can be improved.  The first five chapters deal with motor, emotional, behavioral, and 
cognitive problems, fatigue, and participation. Following, this knowledge is applied in three 
studies, the SPOT study, the SIMCODA study, and a qualitative study into worries and care needs.  
Chapter 2 focuses on motor problems of children with NF1 and possible predictors. This study 
uses a broad motor performance test battery with a relatively large group of children with NF1. 
Sixty-nine children with NF1, aged 4 to 16 years had a motor, psychological, and neurological 
evaluation. Motor performance was measured with the M-ABC: Movement Assessment Battery 
for Children. Sixty-one percent of these children scored within the clinical range of the M-ABC. In 
analyses, motor problems were associated with ADHD, ASD, and externalizing behavioral problems 
(rule-breaking behavior and aggression). Motor outcome was not predicted by age, intelligence, 
scoliosis, hypotonia, nor hypermobility. The study concludes that motor problems are among the 
most common comorbid developmental problems in children with NF1, and these problems do 
not diminish with age. Because of their impact on daily functioning, motor problems need to be 
specifically addressed in diagnosis, follow-up, and treatment of NF1. 
 
Chapter 3 is a longitudinal study about the development of emotional and behavioral problems in 
young children with NF1 in association with their intellectual and language development. At the 
first assessment at preschool age, we evaluated language skills, intelligence, and emotional and 
behavioral problems as reported by parents. The second assessment at school-age evaluated 
intelligence, and emotional and behavioral problems as reported by parents and teachers. Of the 
61 children (mean age 4½ years) with NF1 who had a first assessment, 38 children had a second 
assessment after 3½ years (mean age 8 years). Parent-rated internalizing behavioral problems 
(anxious, withdrawn, and depressed behavior and/or somatic complaints) significantly increased 
with age in this group. Intelligence and language development were not associated with these 
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internalizing problems. The study concludes that internalizing problems at pre-school age may be 
predictive of internalizing problems at school age. 
 
Chapter 4 is a study describing the emotional and behavioral problems of a large group of children 
and adolescents with NF1. Parents of 183 children and adolescents with an average age of 11 
years (range 6-17) completed the Child Behavior Checklist (CBCL). In addition, 173 teachers 
completed the Teacher's Report Form (TRF) and 88 adolescents (children from 11 to 17 years) 
completed the Youth Self-Report (YSR). According to parents, 32% had behavioral and emotional 
problems (compared to 10% in the general population). This percentage was much lower when 
rated by teachers or adolescents themselves. The most striking scores from all informants were on 
scales for Somatic complaints, Social problems, and Attention problems. Attention problems were 
associated with lower verbal IQ, male gender, younger age, and ADHD symptoms. NF1-related 
somatic factors did not predict behavioral problems scores. Because the rating of behavioral 
problems by adolescents with NF1 are so different from parent and teacher ratings, the study 
recommends considering all these three views.  
 
Chapter 5 describes the baseline measurement of the SPOT NF1 study (Dutch acronym for ‘Social 
and Psychological support of people with NF1 in their Teens or twenties’), aiming at finding 
predictors of mental quality of life of adolescents and young adults with NF1. From 2013 to 2015, 
in the Netherlands and Belgium, 102 adolescents and young adults (16 to 30 years) with NF1 
joined this study. Mental quality of life (MQoL) was measured with the Short-Form Health Survey 
(SF-36). Vitality, coping with NF1, concentration, physical activity, and internalizing problems had a 
strong association with MQoL. Women reported a lower MQoL and more fatigue than men did. 
Mental quality of life was affected more than physical quality of life was. Determinants of mental 
quality of life were role functioning in physical activities, fatigue, internalizing, and social 
problems. Next to this, fatigue severely affected quality of life, in women more than in men.  
Chapter 6 describes the results of the randomized placebo-controlled NF1-SIMCODA-trial 
(Simvastatin for cognitive deficits and daily life functioning), in which the efficacy and safety of 
specific medication (simvastatin) were assessed in a group of school-aged children and 
adolescents with NF1. In previous research, statins were shown to reduce learning deficits in mice 
with NF1, but results of a previous trial in children were not clear. We recruited children with NF1 
aged 8–16 years from two national referral centers in the Netherlands and Belgium. Children were 
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randomly assigned to simvastatin treatment or placebo for 12 months. Investigators, participants, 
and parents did not know in which group the children were placed. Primary outcome measures 
were full-scale intelligence, attention problems (measured with the CBCL), and internalizing 
behavioral problems (CBCL). We randomly assigned 84 children to a treatment group (43 to 
simvastatin, 41 to placebo) between 2010 and 2012. Simvastatin for 12 months had no effect on 
full-scale intelligence, attention problems, and internalizing behavioral problems. Children on 
simvastatin or on placebo reported adverse events, which were serious in two and four patients, 
respectively. Simvastatin treatment during 12 months did not reduce cognitive deficits or 
behavioral problems in children with NF1. The use of simvastatin for cognitive enhancement in 
children with NF1 was not recommended. 
Chapter 7 evaluates the cognitive and behavioral outcome measures used in the former study in 
order to find how appropriate the selection of these measures was. We did this by analyzing the 
degree of deficits compared to reference groups, test-retest reliability, and how scores correlate 
between outcome measures. Outcome measures were compared with age-specific reference 
groups to identify domains of dysfunction. The strongest deviations from the reference groups 
were observed for full-scale intelligence, Rey Complex Figure Test delayed recall, attention 
problems, and social problems. Test-retest reliability over the 1-year trial period was excellent for 
intelligence scales, but poor to moderate for other neuropsychological tests and CBCL subscales. 
The correlation structure revealed two strong components in the outcome measures behavior and 
cognition, with no correlation between these components. Scores on psychosocial quality of life 
correlated strongly with behavioral problems and less with cognitive deficits, indicating cognitive 
and behavioral outcomes are complementary. This analysis demonstrates the need to include 
reliable outcome measures on a variety of cognitive and behavioral domains in clinical trials for 
NF1. 
Chapter 8 describes the worries in daily life and the needs for care of adults with NF1, using a 
qualitative design. Follow-up of adults with NF1 often focuses on tumor growth, but follow-up of 
cognitive or social problems and other NF1-related problems is rarely a part of standardized care. 
In order to provide optimal care services for these patients, we explored needs for care in adults 
with NF1. A qualitative study was performed using group interviews, exploring worries and care 
needs in medical, psychological, and socioeconomic domains, also focusing on the transition from 
pediatric to adult care. Four focus groups were conducted, including young adult patients, patients 
over age 30, and parents of young adult patients. In total, 30 patients and 12 parents participated. 
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The interviews were taken down literally and analyzed by a computer program. Themes were 
organized using the World Health Organization International Classification of Functioning, 
disability, and health (ICF). Results indicated many and diverse worries and care needs both during 
the transitional period and in adulthood in medical, mental health, and socioeconomic domains. 
Worries could be categorized into 13 themes. Parents reported high stress levels and difficulties 
with their parental role. Participants expressed the need for more information, access to NF1 
experts, daily living support, care for mental health and socioeconomic participation, and closer 
communication between health-care providers. In conclusion, worries and needs of patients and 
parents underline the importance of multidisciplinary follow-up and continuity of care during and 
after the transitional period. Additionally, parental stress requires more attention from care 
providers. 
Discussion and recommendations 
This thesis is concluded with a discussion, summarizing and critically interpreting the findings, 
formulating implications and recommendations for future follow-up, treatment, and research. The 
main contribution of this thesis to the behavioral phenotype of NF1 is due to larger sample sizes, 
broader outcome measures, the longitudinal study design, and the associations between 
phenotype and quality of life and participation.  
The main recommendations for clinical assessment and treatment are: 
 When developmental motor problems are severe, professionals should consider 
diagnosing DCD (developmental coordination disorder) in NF1.  
 Since both cognition and behavior are important features of the behavioral phenotype of 
NF1, psychological assessment in NF1 should include both aspects. 
 Early recognition of anxiety and depression and easy access to mental health care are 
necessary to prevent lower quality of life and to prevent late or even too late treatment of 
these serious disorders. 
 Attentional and social problems should be a focus of attention in the follow-up of NF1 
since these problems interact and can reinforce each other. Children with one or two of 
these problems are at risk of learning problems, social isolation, and other comorbid 
psychopathology.  Early and regular screening into adulthood can reduce the risk of these 
consequences. 
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 Because fatigue is a strong determinant of quality of daily life, this needs to be reflected in 
assessments and care.  
 Current successful symptomatic treatment methods used to treat chronic fatigue may be 
effective in NF1 and the usefulness of these treatments for NF1 needs to be evaluated. 
 The ICF model (the International Classification of Functioning, disability, and health, a way 
to look at function, activity and participation devised by the World Health Organization) is a 
useful framework to also look at socioeconomic, personal, and environmental issues in a 
broad assessment of the needs of people with NF1 and their families. 
Suggestions for future research are: 
 Future longitudinal and intervention studies may clarify to what extent musculoskeletal or 
neurodevelopmental problems contribute to the development of motor problems in NF1. 
 Future research may explore the reason why language problems occur in both young 
children with familial NF1 and their parents with NF1. 
 To express the severity of NF1 for future research, it would be better not to add or 
combine somatic, cognitive, emotional, social, and behavioral symptoms into one score, 
but to consider them as separate predictors of quality of life and participation. 
 The recently developed INF1-QOL-Questionnaire could be extended with a question about 
the effects of fatigue on daily life. 
 Future research needs to focus on the development of fatigue in the natural history of NF1.  
 Since fatigue is a strong determinant of quality of daily life, future research needs to focus 
on predictors of fatigue and on trials evaluating the treatment of fatigue in children and 
adults.  
 Syndrome-specific patient reported outcome measures (questionnaires), completed by 
larger groups of patients and their families from various countries and cultures, can 
contribute to the knowledge about the relations between behavioral phenotype, quality of 
life, and participation in daily life.  
 Clinically relevant outcome measures are needed when deciding whether a treatment 
should be given to children with learning difficulties. In a schematic overview, 
recommendations are formulated regarding instruments that can be used in follow-up and 
future trials. Research should also focus on accumulating and integrating knowledge about 
 
outcome measures to harmonize the selection of neuropsychological outcome measures in 
research on NF1. 
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II. Samenvatting (Dutch Summary) 
Neurofibromatose type 1 (NF1) is een genetische aandoening of syndroom veroorzaakt door 
veranderingen in het NF1-gen op chromosoom 17q11.2. NF1 komt voor bij 1: 2000 tot 4000 
mensen, waarbij ongeveer de helft ‘nieuwe mutaties’ zijn, wat betekent dat de ouders geen NF1 
hebben. NF1 leidt tot symptomen in het uiterlijk van mensen, zoals lichtbruine vlekken op de huid 
(ook wel café-au-lait-vlekken genoemd), knobbeltjes op of in de huid, maar ook tot een verhoogd 
risico op goedaardige en kwaadaardige tumoren. Er is een levenslange kans van 7-13% om 
kwaadaardige tumoren te ontwikkelen kwaadaardige perifere zenuwschade-tumoren te
Dit leidt tot veel onvoorspelbare en variabele complicaties. Bij volwassenen 
lijken geslacht en leeftijd niet samen te hangen met de fysieke ernst van NF1, maar er lijkt wel een 
verband te bestaan met de algemene kwaliteit van leven. Hoewel de diagnostische criteria 
grotendeels fysiek zijn en de lichamelijke symptomen ernstig en indrukwekkend zijn, zijn 
cognitieve en gedragsproblemen de meest voorkomende complicaties van NF1 bij kinderen.
              Genotype is een ander woord voor de genetische samenstelling van cellen of van een 
organisme. Het genotype, samen met andere genetische factoren en omgevingsfactoren, bepaalt 
iemands fenotype. Het fenotype van een organisme is de combinatie van kenmerken, waaronder 
uiterlijk en eigenschappen, ontwikkeling en gedrag. Met een gedragsfenotype wordt gedoeld op 
cognitie, persoonlijkheid en gedrag. Sommige gedragsfenotypes kunnen psychische stoornissen of 
syndromen zijn. Neurocognitieve en psychosociale diagnostiek kan een profiel van sterke en 
zwakke punten opleveren, een gedragsfenotype van de cognitieve, zintuiglijke, motorische, 
educatieve, gedrags-, sociale en emotionele kenmerken van mensen met NF1. 
Gedragsfenotype van NF1 
Het gemiddelde totale intelligentiequotiënt (IQ) van kinderen met NF1 is ongeveer 10 tot 15 
punten lager dan het IQ in de algemene populatie en is ook lager als wordt vergeleken met broers 
en zussen zonder NF1. Verstandelijke beperking komt tweemaal zo vaak voor bij NF1 en er zijn dus 
meer mensen met NF1 die een IQ onder 70 hebben. Andere cognitieve problemen bij NF1 hebben 
te maken met spraak en taal, visueel-ruimtelijke vaardigheden, uitvoerende of ‘executieve’ 
functies (inhibitie, planning en flexibiliteit), aandacht en motorische vaardigheden. De 
meerderheid van de gedragsproblemen bij NF1 betreft emotionele problemen zoals angst, 
depressie en teruggetrokken gedrag. De meest voorkomende psychische stoornis bij NF1 is ADHD 
(aandachtsdeficiëntie-/ hyperactiviteitsstoornis): ADHD komt voor bij 30 tot 50% van de kinderen 
ontwikkelen. De meeste symptomen komen voor in het zenuwstelsel, de huid en de botten.
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met NF1 (in vergelijking met 3 tot 5% van de kinderen in de algemene bevolking). Kinderen met 
NF1 hebben vaak ook minder goede sociale vaardigheden en er is een verhoogd risico op 
autismespectrumstoornis (ASS). 
              Gevolgen van NF1 in het dagelijks leven bestaan uit slaapproblemen, leerproblemen en 
een behoefte aan ondersteuning en behandeling. Zowel de mensen met NF1 zelf als hun ouders 
en families ervaren hogere niveaus van stress, ook als gevolg van de onzekerheid over het beloop 
van NF1. Gezondheidsgerelateerde kwaliteit van leven (Quality of Life: QoL) is lager bij kinderen en 
ouders, vooral als het gaat om (lichamelijke) pijn. 
              Dit proefschrift heeft tot doel bij te dragen aan de kennis over het gedragsfenotype van 
NF1 op cognitief, gedragsmatig, emotioneel en sociaal gebied en de gevolgen van dit fenotype op 
het dagelijkse leven. Door diagnostiek en behandeling te verbeteren kunnen de zorg voor en de 
kwaliteit van leven van kinderen en volwassenen met NF1 worden verbeterd. De eerste vijf 
hoofdstukken gaan over motorische, emotionele, gedrags- en cognitieve problemen, 
vermoeidheid, kwaliteit van leven en participatie (deelname aan het dagelijks leven).  Vervolgens 
wordt deze kennis toegepast in drie studies, de SPOT-studie, de SIMCODA-studie en een 
kwalitatief onderzoek naar zorgen en zorgbehoeften. 
Hoofdstuk 2 richt zich op motorische problemen van kinderen met NF1 en mogelijke voorspellers 
van die problemen. Deze studie maakt gebruik van een uitgebreide testbatterij van de motorische 
vaardigheden bij een relatief grote groep kinderen met NF1. Negenenzestig kinderen met NF1, in 
de leeftijd van 4 tot 16 jaar, kregen een motorisch, psychologisch en neurologisch onderzoek. 
Motorische prestaties werden gemeten met de M-ABC: Movement Assessment Battery for 
Children. Eenenzestig procent van deze kinderen scoorde in het klinische bereik van de M-ABC en 
had dus ernstige motorische problemen. Motorische problemen bleken samen te hangen met 
ADHD, ASS en externaliserende problemen (regeloverschrijdend gedrag en agressie). Motorische 
vaardigheid werd niet voorspeld door leeftijd, intelligentie, scoliose, hypotonie of hypermobiliteit. 
De studie concludeert dat motorische problemen een van de meest voorkomende comorbide 
ontwikkelingsproblemen bij kinderen met NF1 zijn en deze problemen nemen niet af met de 
leeftijd. Vanwege hun impact op het dagelijks functioneren moeten motorische problemen 
specifiek worden aangepakt bij de diagnose, follow-up en behandeling van NF1. 
Hoofdstuk 3 is een longitudinale studie van de ontwikkeling van emotionele en gedragsproblemen 
bij jonge kinderen met NF1 in samenhang met hun intellectuele en taalontwikkeling. Bij het eerste 
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onderzoek op de peuterleeftijd werd gekeken naar taalvaardigheden, intelligentie en emotionele 
en gedragsproblemen zoals gerapporteerd door ouders. Het tweede onderzoek op schoolleeftijd 
keek naar intelligentie en emotionele en gedragsproblemen zoals gerapporteerd door ouders en 
leraren. Van de 61 kinderen met NF1 (gemiddelde leeftijd 4½ jaar) die meededen aan het eerste 
onderzoek, kregen 38 kinderen een tweede onderzoek bij een gemiddelde leeftijd van 8 jaar. 
Psychische problemen die door de ouders werden gezien (angstig, teruggetrokken en depressief 
gedrag en/of lichamelijke klachten, zogenaamde ‘internaliserende problemen’) namen significant 
toe met de leeftijd bij deze groep. Intelligentie en taalvaardigheid hingen niet samen met deze 
problemen. De studie concludeert dat internaliserende problemen op kleuterleeftijd mogelijk 
voorspellend zijn voor het zelfde type problemen op schoolleeftijd. 
Hoofdstuk 4 is een studie die de emotionele en gedragsproblemen van een grote groep van 
kinderen en jongeren met NF1 beschrijft. Ouders van 183 kinderen en jongeren met een 
gemiddelde leeftijd van 11 jaar (van 6 tot 17 jaar) vulden de oudergedragsvragenlijst CBCL in (Child 
Behavior Checklist). Ook vulden 173 leraren de leerkrachtvragenlijst TRF in (Teacher's Report 
Form) en 88 jongeren (11 tot 17 jaar) een zelfbeoordelingsvragenlijst (Youth Self Report, YSR). 
Volgens de ouders had 32% van de kinderen gedrags- en emotionele problemen (vergeleken met 
10% in de algemene bevolking). Dit percentage was veel lager volgens de beoordeling door 
leerkrachten of jongeren zelf. Volgens zowel ouders, leerkrachten en jongeren zelf waren de 
meeste problemen te zien op de schalen voor lichamelijke klachten, sociale problemen en 
aandachtsproblemen. Aandachtsproblemen hingen samen met lager verbaal IQ, mannelijk 
geslacht, jongere leeftijd en ADHD-symptomen. NF1-gerelateerde lichamelijke factoren waren niet 
voorspellend voor psychische problemen. Omdat de beoordelingen van psychische problemen bij 
jongeren met NF1 door ouders, leerkrachten en jongeren zelf zulke verschillende resultaten 
oplevert wordt aanbevolen om steeds informatie in te winnen bij alle drie de informanten.  
Hoofdstuk 5 beschrijft de nulmeting van het SPOT NF1-onderzoek ('Sociale en Psychologische 
Ondersteuning van Tieners en twintigers met NF1’), gericht op het vinden van voorspellers voor de 
mentale kwaliteit van leven van jongeren en jongvolwassenen met NF1. Vanaf 2013 tot 2015 
deden in Nederland en België 102 jongeren en jonge volwassenen (16 tot 30 jaar) met NF1 mee 
aan dit onderzoek. Mentale levenskwaliteit (MQoL) werd gemeten met de Short-Form Health 
Survey (SF-36). Vitaliteit, omgaan met NF1, concentratie, fysieke activiteit en internaliserende 
problemen hingen sterk samen met MQoL. Vrouwen rapporteerden een lagere MQoL en meer 
vermoeidheid dan mannen. Mentale kwaliteit van leven bleek meer aangedaan dan fysieke 
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kwaliteit van leven. Voorspellers van mentale kwaliteit van leven zijn rol-functioneren bij fysieke 
activiteiten (het kunnen uitvoeren van taken die men bij zijn rol vindt horen), vermoeidheid, 
internaliserende en sociale problemen. Vermoeidheid heeft grote invloed op de kwaliteit van 
leven, bij vrouwen meer dan bij mannen. 
Hoofdstuk 6 beschrijft de resultaten van de gerandomiseerde placebo-gecontroleerde NF1-
SIMCODA-studie (Simvastatine voor cognitieve problemen en het functioneren in het dagelijks 
leven), waarin de werkzaamheid en veiligheid van specifieke medicatie (simvastatine) werd 
beoordeeld bij een groep schoolgaande kinderen en jongeren met NF1. In eerder onderzoek werd 
aangetoond dat statines de leerproblemen van muizen met NF1 verminderen, maar de resultaten 
van een onderzoek bij kinderen waren niet duidelijk. Deelnemers waren kinderen met NF1 in de 
leeftijd van 8-16 jaar uit twee nationale centra in Nederland en België. Kinderen werden 
willekeurig toegewezen aan simvastatine-behandeling of placebo gedurende 12 maanden. 
Onderzoekers, deelnemers en ouders wisten niet in welke groep de kinderen werden geplaatst. 
Primaire uitkomstmaten waren totale intelligentie (gemeten met een intelligentietest), 
aandachtsproblemen en internaliserende problemen (beide gemeten met de CBCL). Tussen 2010 
en 2012 werden 84 kinderen voor deze trial willekeurig verdeeld over de beide behandelgroepen 
(43 simvastatine, 41 placebo). Het toedienen van simvastatine gedurende 12 maanden had geen 
effect op totale intelligentie, aandachtsproblemen of internaliserende problemen. Kinderen in de 
simvastatine- of de placebogroep hadden beide bijwerkingen, die respectievelijk ernstig waren bij 
twee en vier kinderen. Simvastatine-behandeling gedurende 12 maanden vermindert niet de 
cognitieve tekorten of psychische problemen bij kinderen met NF1. Het gebruik van simvastatine 
voor verbetering van de cognitie bij kinderen met NF1 wordt niet aanbevolen. 
Hoofdstuk 7 evalueert de cognitieve en gedragsmatige uitkomstmaten die werden gebruikt in de 
vorige studie om te bepalen hoe goed de keuze van deze instrumenten was. We deden dit door de 
ernst van de problemen te vergelijken met die van leeftijdsgenoten uit de normgroepen, door te 
bekijken wat de test-hertest-betrouwbaarheid was en hoe de verschillende instrumenten met 
elkaar samenhingen. De sterkste afwijkingen van de normgroep werden gezien op de schaal voor 
totale intelligentie, de Rey Complexe Figuur Test-uitgestelde herinnering, aandachtsproblemen en 
sociale problemen. Test-hertest-betrouwbaarheid over de trial-periode van één jaar was 
uitstekend voor intelligentietests, maar slecht tot matig voor de neuropsychologische tests en de 
CBCL-subschalen. De correlatiestructuur gaf twee sterke componenten in de instrumenten te zien: 
één component voor gedrag en één voor cognitie, zonder correlatie tussen die beide 
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componenten. Scores op psychosociale kwaliteit van leven hingen sterk samen met psychische 
problemen en minder met cognitieve problemen. Instrumenten voor cognitie en psychische 
problemen zijn klaarblijkelijk complementair. Deze analyse geeft aan dat betrouwbare 
instrumenten nodig zijn die een verscheidenheid van cognitieve en psychische problemen in kaart 
brengen bij klinische trials voor NF1. 
Hoofdstuk 8 beschrijft de zorgen in het dagelijks leven en de zorgbehoeften van volwassenen met 
NF1 met behulp van een kwalitatieve studie. Opvolging (follow-up) van volwassenen met NF1 richt 
zich vaak op tumorgroei, maar de follow-up van cognitieve of sociale problemen en andere NF1-
gerelateerde problemen is vaak geen standaard-onderdeel van de zorg. Om optimale zorg te 
bieden aan mensen met NF1 hebben we de zorgbehoeften van volwassenen met NF1 onderzocht. 
Er werd kwalitatief onderzoek gedaan met behulp van groepsinterviews waarin zorgen en 
zorgbehoeften in kaart werden gebracht op lichamelijk, psychologisch en sociaal-economisch 
gebied, ook gericht op de overgang (transitie) van pediatrische naar volwassen zorg. Er werden 
sessies gehouden met vier afzonderlijke focusgroepen: jongvolwassen patiënten, patiënten ouder 
dan 30 jaar en ouders van jongvolwassen patiënten. In totaal namen 30 patiënten en 12 ouders 
deel. De interviews werden letterlijk vastgelegd en geanalyseerd met behulp van een 
computerprogramma. Thema's werden georganiseerd met behulp van de World Health 
Organisatie Internationale Classificatie van Functie, beperking en gezondheid (ICF). Er waren veel 
en uiteenlopende zorgen en behoeftes aan zorg zowel tijdens de transitie als op volwassen leeftijd 
op somatisch-, geestelijke gezondheid- en sociaal-economisch gebied. Zorgen kunnen worden 
onderverdeeld in 13 thema's. Ouders rapporteerden hoge stressniveaus en moeilijkheden bij het 
vervullen van hun ouderlijke rol. Deelnemers gaven aan behoefte te hebben aan meer informatie, 
toegang tot NF1-experts, ondersteuning in het dagelijks leven, zorg voor de geestelijke gezondheid 
en sociaal-economische participatie en betere communicatie tussen zorgverleners. De zorgen en 
behoeften van patiënten en ouders onderstrepen het belang van multidisciplinaire follow-up en 
continuïteit van zorg tijdens en na de transitie. Daarnaast verdient ouderlijke stress meer aandacht 
van zorgverleners. 
Discussie en aanbevelingen 
Dit proefschrift wordt afgesloten met een discussie, een samenvatting en een kritische 
interpretatie van de bevindingen, maar ook met implicaties en aanbevelingen voor toekomstige 
follow-up, behandeling en onderzoek. Dit proefschrift draagt bij aan het gedragsfenotype van NF1, 
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wat vooral te danken is aan een grotere omvang van de steekproeven, bredere uitkomstmaten, 
het longitudinale studiedesign en de verbanden tussen fenotype en kwaliteit van leven en 
participatie.  
De belangrijkste aanbevelingen voor diagnostiek en behandeling zijn: 
 Als motorische ontwikkelingsproblemen ernstig zijn, zouden professionals DCD 
(developmental coordination disorder; ontwikkelingscoördinatiestoornis) als comorbide 
probleem moeten diagnosticeren in NF1. 
 Aangezien zowel cognitie als gedrag belangrijke kenmerken zijn van het gedragsfenotype van 
NF1, moet psychologische diagnostiek bij NF1 beide aspecten omvatten. 
 Vroegtijdige onderkenning van angst en depressie en goede toegang tot geestelijke 
gezondheidszorg is noodzakelijk om een lagere kwaliteit van leven en late of zelfs te late 
behandeling van deze ernstige problemen te voorkomen. 
 Aandachts- en sociale problemen moeten een aandachtspunt zijn in de follow-up van NF1 
omdat deze problemen elkaar kunnen versterken. Kinderen met één of twee van deze 
problemen lopen het risico op leerproblemen, sociaal isolement en andere comorbide 
psychopathologie. Vroege en regelmatige screening onderweg naar volwassenheid kan de kans 
op deze gevolgen verminderen. 
 Omdat vermoeidheid een sterke bepalende factor is voor de kwaliteit van het dagelijks leven, 
moet dit tot uiting komen in diagnostiek en zorg voor NF1.  
 Huidige succesvolle symptomatische behandelingsmethoden die worden gebruikt om 
chronische vermoeidheid te behandelen kunnen effectief zijn bij NF1 en de bruikbaarheid van 
deze behandelingen voor NF1 moet worden geëvalueerd. 
 Het ICF-model van de Wereldgezondheidsorganisatie (WHO), een manier om te kijken naar 
functie, activiteit en participatie, is een nuttig kader om ook te kijken naar de sociaal-
economische, persoonlijke en omgevingsinvloeden bij een brede beoordeling van de 
behoeften van mensen met NF1 en hun families. 
Suggesties voor toekomstig onderzoek zijn: 
 Toekomstige longitudinale en interventiestudies kunnen verduidelijken in welke mate 
neurologische ontwikkelingsproblemen en problemen van het houdings- en 
bewegingsapparaat bijdragen tot de ontwikkeling van motorische problemen bij NF1. 
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 In toekomstig onderzoek kan de oorzaak worden gezocht van taalproblemen bij jonge 
kinderen met NF1 van wie de ouders ook NF1 hebben. 
 Om de ernst van NF1 weer te geven, zou het beter zijn om fysieke, cognitieve, emotionele, 
sociale en gedragssymptomen niet in één score samen te vatten of te combineren, maar om ze 
te beschouwen als afzonderlijke voorspellers van kwaliteit van leven en participatie. 
 De recent ontwikkelde INF1-QOL-vragenlijst kan worden uitgebreid met een vraag over de 
effecten van vermoeidheid op het dagelijks leven. 
 Toekomstig onderzoek moet zich richten op de ontwikkeling van vermoeidheid in het 
natuurlijk beloop van NF1 bij kinderen en volwassenen. 
 Aangezien vermoeidheid een sterke bepalende factor is voor de kwaliteit van het dagelijks 
leven, moet toekomstig onderzoek zich richten op voorspellers van vermoeidheid en op 
studies die de behandeling van vermoeidheid evalueren. 
 Syndroom-specifieke door de patiënt zelf in te vullen uitkomstmaten (vragenlijsten, 
zogenaamde PROM’s), ingevuld door grotere groepen patiënten en hun families uit 
verschillende landen en culturen, kunnen bijdragen aan de kennis over de relaties tussen 
gedragsfenotype, kwaliteit van leven en deelname aan het dagelijks leven. 
 Klinisch relevante uitkomstmaten zijn nodig om te beslissen of een behandeling moet worden 
gegeven aan kinderen met leer- en gedragsproblemen. In een schematisch overzicht worden 
aanbevelingen geformuleerd met betrekking tot instrumenten die kunnen worden gebruikt in 
follow-up en toekomstige trials. Onderzoek moet ook gericht zijn op het verzamelen en 
integreren van kennis over uitkomstmaten om de selectie van neuropsychologische 
uitkomstmaten in onderzoek bij NF1 te harmoniseren.  
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III. Abbreviations 
ADHD  Attention-deficit/hyperactivity disorder 
ADOS-G Autism Diagnostic Observation Scale-Generic 
ASD  Autism spectrum disorder 
Aseba  Achenbach System of Empirically Based Assessment 
CBCL  Child behavior checklist 
CHQ-PF50  Child Health Questionnaire CHQ–parent form 50 
CI  Confidence interval 
CNL  Kempenhaeghe Centre for Neurological Learning Disabilities  
CWT  Color-Word interference task 
DCD  Developmental coordination disorder 
DSM-IV Diagnostic and statistical manual of mental disorders 
EF  Executive functions 
ENCORE Erfelijke Neurocognitieve Ontwikkelingsstoornissen Rotterdam Erasmus MC 
Erasmus MC  Erasmus Medical Center 
GP  General practitioner 
HCP  Health-care provider 
HRQoL  Health-related Quality of Life 
ICF  International classification of functioning, disability, and health 
ID  Intellectual disability 
IQ  Intelligence quotient 
ISCED  International classification of education 
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KMO  Kaiser-Meyer-Olkin 
JLO   Judgement of Line Orientation 
LCQ  Language comprehension quotient 
M-ABC-1 or 2 Movement Assessment Battery for Children version 1 or 2 
MEC  Medical and Ethical Review Committee 
MPNST Malignant peripheral nerve sheath tumor 
MQoL   Mental quality of life 
NF1  Neurofibromatosis type 1 
NF1-SIMCODA Simvastatin for cognitive deficits and behavioral problems in patients with  
  neurofibromatosis type 1 
NFVN  Neurofibromatosis patient organization of The Netherlands 
QoL   Quality of life 
PCA  Principal components analysis 
Ras  Rat Sarcoma protein 
RCFT  Rey Complex Figure test  
RDLS  Reynell developmental language scales 
SD  Standard deviation 
SDQ  Sentence development quotient 
SELT  Schlichting expressive language test 
SES  Socioeconomic status 
SF-36  Short-Form Health Survey 
SON-R 2½-7 Snijders Oomen non-verbal revised intelligence scale for young children 
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SPOT-NF1 Sociale en Psychische ondersteuning van Tieners en twintigers met NF1 
SRS  Social Responsiveness Scale 
TRF  Teacher's Report Form 
VOLG  Vroegtijdige Onderkenning Leer- en Gedragsproblemen 
WDQ  Word development quotient 
WISC-III-NL Wechsler intelligence scale for children, third version for the Netherlands 
WHO  World Health Organization 
WPPSI-III-R Wechsler Preschool and Primary Scale of Intelligence-Third version for the  
  Netherlands 
YSR  Youth self-report 
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Rietman. Houten: Bohn, Stafleu en van Loghum.  
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VI. PhD Portfolio 
Summary of PhD training and teaching 
Name PhD student: Andre B. Rietman 
Erasmus MC Department: Pediatric 
Neurology/Child and adolescent 
psychiatry/psychology 
Research School: NIHES 
 PhD period: 2010-2018 
Promotors: Prof. Dr. Y. Elgersma; Prof. Dr. H.A. Moll 
Co-promotors: Dr. P.F.A. de Nijs; Dr. M.C.Y. de Wit 
1. PhD training 
 Year Workload 
Hours 
Workload 
ECTS 
General courses  
- Erasmus Winter Programme: Biostatistics for clinicians and 
Introduction to clinical research 
- The why and how of readable articles 
- Research Integrity- ethics in medical research 
- Biostatistical methods 1 
- BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’) 
- Biomedical English Writing and Communication 
 
2009 
 
2011 
2011 
2013 
2012 
2014 
 
2*25 =50 
 
8 
 
 
20 
 
 
 
 
2 ECTS 
6 ECTS 
 
3 ECTS 
Specific courses (e.g. Research school, Medical Training) 
- Training ADOS 1/2 and ADOS 3/4 (both certified) 
- Consensus meeting ADOS 
 
2013 
2012-2018 
 
3*13 = 39 
8*2.5 = 20 
 
Seminars and workshops 
- Endnote en literatuurzoeken- Bibliotheek Erasmus MC 
- Symposium NVKN 
- CPO-symposium Erasmus MC ‘Methodologie van 
patiëntgebonden onderzoek en voorbereiding 
subsidieaanvragen’ 
- Training transitie, zelfmanagement en participatie 
- Dutch ADHD network 
- Colloquia kinder- en jeugdpsychiatrie- en psychologie 
- Conferentie Ned. Vereniging Neuropsychologie 
- Annual clinical symposium Kempenhaeghe 
- European pediatric psychology conference Gent 
- Courses on supervising  
 
2010 
2010 
 
2011 
2013 
2011-2016 
2012-2018 
2012-2018 
2011; 2012 
2018 
2016-2018 
 
6 
7 
 
3 
11 
8*3 = 24 
8*1 = 8 
4*8= 32 
2*8= 16 
2*8= 16 
2*8= 16 
 
Subtotal education  276 =10 ECTS 11 ECTS 
Presentations in the Netherlands, Dutch meetings 
- Presentations on current research in ENCORE meetings, 
internal research meetings, patient meetings (NFVN, STSN 
and Fragile X association), EAA werkgroepen, 
kinderartsencongres, schoolpsychologencongres, 
autismecongres, etc. 
- Samen Nog Beter Congres- ‘Sensorische informatieverwerking’ 
(oral keynote) 
- Revalidatiecongres Den Haag 
- Nederlands psychiatrie jaarcongres NVVP 
- Nederlands congres prikkelverwerking 
 
2011-2018 
 
 
 
 
2015 
 
2016 
2015&2016 
2017 
 
9*3= 27 
 
 
 
 
 
 
 
1 ECTS 
 
1 ECTS 
2 ECTS 
1 ECTS 
Presentations on (Inter)national conferences 
- European conference on Neurofibromatosis (NF1) Oslo (oral) 
- European workshop on NF1 Leuven (oral) 
 
2010 
2011 
  
1 ECTS 
1 ECTS 
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- European conference on NF1 Istanbul (incl. poster) 
- Conf. Society of behavioral phenotypes (SSBP) Leuven (oral) 
- Behavioral problems in Angelman Syndrome- International 
Angelman congress Erasmus MC Rotterdam (oral) 
- Autism in Fragile X syndrome- Fragile X Association the 
Netherlands (oral) 
- Sensory-motor problems, pediatricians week Erasmus MC 
Sophia Rotterdam (oral) 
- Problems in learning and behavior in NF1, mini-symposium child 
and adolescent psychiatry and psychology, Erasmus MC 
Rotterdam (oral) 
- European conference on Sensory processing Finland (oral and 
poster) 
- European conference on Neurofibromatosis (NF1) Barcelona 
(oral) 
- Pediatric psychology network- conference Amsterdam (oral) 
- SSBP (society of behavioral phenotypes) conference London 
(oral) 
- ICNC 14th International Child Neurology Congress A’dam (oral) 
- European conference on Neurofibromatosis (NF1) Padua (oral) 
- SSBP conference Leiden (oral) 
- Angelman conference Phoenix Arizona (oral) 
- NVKN jaarcongres Rotterdam (oral) 
- Joint global neurofibromatosis conference 2018 Paris (oral) 
2012 
2012 
 
2012 
 
2012 
 
2013 
 
2013 
 
 
2014 
 
2014 
 
2014 
2015 
2016 
2016 
2017 
2017 
2018 
2018 
1 ECTS 
1 ECTS 
 
1 ECTS 
 
1 ECTS 
 
1 ECTS 
 
1 ECTS 
 
 
2 ECTS 
 
1 ECTS 
 
1 ECTS 
1 ECTS 
1 ECTS 
1 ECTS 
1 ECTS 
1 ECTS 
1 ECTS 
1 ECTS 
Subtotal conferences  27 = 1 ECTS 24 ECTS 
2. Teaching  Year Hours ECTS 
Lecturing 
- Yearly lectures, workshops, and courses on 
(neuro)psychological, neurological and therapeutical topics for 
physicians, psychologists, therapists, teachers, parents, etc.  
- Teaching medical students and  psychiatrists in training about 
neuropsychology, neurofibromatosis type1, language- and 
learning disorders, regulation disorders, sensory-motor 
problems, and ADHD 
 
2010-2018 
 
 
2015-2018 
 
Approx.  
50*6= 300 
 
 
Supervising, Tutoring 
- Supervising master’s clinical or research internships (12 
students) 
- Supervising school psychologists and Gz-psychologists in-
training (12 students) 
 
2012-2018 
 
2012-2018 
  
11 ECTS 
 
11 ECTS 
Supervising Master’s theses 
- Supervising master’s theses (8 students) 
 
2012-2018 
  
8 ECTS 
Other 
- Dutch publications on Neurofibromatosis, Tuberous sclerosis, 
Sensory processing and Psychopathology 
- Collaborating in writing Guideline Tuberous Sclerosis, 
Standards of care for Neurofibromatosis type 1 and type 2, 
Brochures for GP’s about Neurofibromatosis type 1 and for 
Fragile X syndrome 
 
2011-2018 
 
2014-2018 
  
4 ECTS 
 
2 ECTS 
Subtotal Teaching  180 hours =  
11 ECTS 
36 ECTS 
TOTAL  22 ECTS 71 ECTS 
(1 ECTS = 28  HOURS)  93 ECTS 
Total: 
 Education  21 ECTS 
 Conferences  25 ECTS 
 Teaching  47 ECTS 
 TOTAL   93 ECTS  
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VII. Dankwoord 
 
In 2009 werkte ik nog bij Kinderhaven toen me werd gevraagd mee te denken bij de aanvang van 
expertisecentrum ENCORE en de trials die werden opgestart. Toen ik in 2010 bij het Erasmus MC 
kwam werken, was nog niet helemaal duidelijk dat er een promotietraject voor me in zou zitten en 
hoe dat vorm zou moeten krijgen, maar wel wat mijn rol binnen de trials zou zijn. Ook werd me 
door de klinisch werkende mensen al snel duidelijk gemaakt dat er meer van me werd verwacht 
dan alleen een bijdrage aan de trials, maar dat mijn meerwaarde moest liggen in het leggen van 
verbanden tussen wetenschap en de (poli)klinische praktijk. In de loop van de tijd werd steeds 
duidelijker dat NF1 en TSC mijn focus moesten zijn en door van alles en nog wat aan te pakken, 
kreeg mijn promotietraject op een nogal organische manier steeds meer vorm. Bij elkaar heeft het 
me (fulltime gerekend) ruim 5 jaar gekost om tot dit eindproduct te komen en hoewel ik blij ben 
deze punt te zetten, ben ik voor mijn gevoel nog maar net begonnen met onderzoek en voelt het 
meer als een komma.  
Hoewel een promotietraject een soloproject lijkt, zijn er veel mensen die een bijdrage hebben 
geleverd aan dit werk. Met de kans dat ik iemand ga vergeten, wil ik er een paar noemen die ik 
zonder meer dankbaar ben.  
Allereerst alle kinderen, jongeren en volwassenen met Neurofibromatose type 1 (NF1) en 
hun ouders en verzorgers. Niet alleen waren zij op zoek naar ondersteuning of hulp bij alle 
gevolgen van NF1. Ook waren ze geregeld onbaatzuchtig bereid om ‘de wetenschap’ van dienst te 
zijn. ‘Als mijn kind of ik er zelf niet iets aan heb, dan misschien wel een van die andere mensen 
met NF1, nu of later’. De vriendelijkheid waar in het begin van dit boek wordt gesproken is 
geregeld zonder meer van toepassing op mensen met NF1. Aan alle mensen met NF1 en aan de 
mensen om hen heen is dit boek in de eerste plaats opgedragen.  
En dan de mensen die aan de start van dit project stonden: Ype Elgersma, mijn promotor 
van het eerste uur. Hoewel je zo bescheiden was om je terug te trekken uit een aantal van mijn 
projecten, heb je toch flinke invloed gehad door je duidelijke uitleg, je rustige leiderschap en je 
inhoudelijke inbreng in vele projecten. Henriëtte Moll, wij hadden al flink wat met elkaar te maken 
gehad bij het op poten zetten van de VOLG en de SPOT-projecten. Daarom ben ik blij dat je 
uiteindelijk ook mijn promotor hebt willen zijn. En Willem Frans Arts: helaas was ik niet zo snel dat 
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je mijn promotor kon blijven, maar je vertrouwen bij de aanvang van ENCORE heeft er mede voor 
gezorgd dat ik dit werk kon gaan doen. Daarom vind ik het erg leuk dat je de rector wilt vervangen 
bij mijn promotieplechtigheid.  
Aan mijn copromotoren heb ik minstens zo veel te danken. Pieter, mijn directe collega 
binnen de KJPP (kinder- en jeugdpsychologie/psychiatrie), aan jou heb ik veel gehad tijdens onze 
(on)geregelde gesprekken, je krabbels in de zijlijn, maar ook door je oog voor detail. Dank voor je 
beschikbaarheid, je relativeringsvermogen en de gesprekken in welke taal dan ook. Dankzij jou 
hoeft niemand zich zorgen te maken over een gebrek aan weetjes en verhalen tijdens lunches en 
borrels. Marie-Claire, van mijn start in de kinderneurologie tot nu was je ondanks je drukke werk 
steeds in staat om mij te spreken of van commentaar te voorzien met je gevoel voor ‘de grote lijn’. 
Alle mensen van wie ik binnen ENCORE veel heb geleerd. Als psycholoog had ik 
aanvankelijk sterk het gevoel dat de wereld van fundamenteel onderzoek ver van mijn bed is. 
Inmiddels staat (in ieder geval voor mij) de wereld van muizen, genen en moleculen een stuk 
minder ver af van de wereld van kinderen en kwaliteit van leven.  
Mijn collega promovendi, hoewel ik een beetje ouder ben dan jullie, heb ik me bij jullie 
altijd thuis gevoeld. Thijs, dank voor al onze discussies, je scepsis (door sommigen aangezien voor 
arrogantie;) en je persoonlijke betrokkenheid en dank voor de eer om je paranimf te mogen zijn! 
Lieve Iris, geweldig om met jou samen te werken aan de RATE en de RAPIT studies. Ondanks jouw 
bescheidenheid en je zachtmoedigheid was ik niet verrast door jouw briljante verdediging bij je 
promotie. Myrthe, je onzekerheid bij de aanvang van jouw promotietraject was zo onterecht, dat 
heb je wel bewezen door jouw slimme en consciëntieuze manier van werken. Met jouw 
gedrevenheid gaat het je zeker lukken om ook ver van hier jouw promotie af te ronden.  
Alle coauteurs en collega’s die hebben meegedacht en meegeschreven aan de artikelen in 
dit boek. Het is geen onverdeeld genoegen om jullie commentaar binnen te krijgen, omdat het 
daarna weer veel werk is om dat te verwerken, zowel emotioneel, cognitief als in letters. 
Allereerst moet ik Rianne Oostenbrink noemen, die altijd snel en ongezouten mijn teksten 
retourneerde, die me wees op mijn verantwoordelijkheden, een logische opbouw van een betoog 
en wat waar hoort volgens de ongeschreven afspraken van de wetenschappelijke wereld. 
Dankjewel Rianne, je bent een soort schaduw-co-promotor voor me geweest. Agnies van Eeghen, 
‘onze’ gedreven AVG-arts die al heel wat voor elkaar krijgt binnen en buiten ENCORE- dank dat ik 
mocht aansluiten bij het kwalitatieve onderzoek, dat heeft me inmiddels al heel wat gebracht. De 
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harde werkers van de kinderneurologie hebben het gezicht bepaald van mijn start binnen 
ENCORE, vooral dank aan Coriene, Femke, Marie-Claire en Margreet voor jullie welkom tijdens 
mijn eerste jaren in dit werk. ENCORE is inmiddels een respectabele denktank van fundamenteel 
tot klinisch onderzoek waarbij ik onder andere heb kunnen profiteren van de inbreng van mensen 
als Cindy Navis, Karen de Heus, Maartje Radstaake, Mariëlle Caspers, Rick van Minkelen, Shimriet 
Zeidler en Suzanne Pasmans. 
Veel van onze grotere onderzoeksprojecten waren niet zo goed geweest zonder de bijdrage 
van de afdeling humane genetica van het universiteitsziekenhuis Leuven: Eric Legius (dank voor al 
je vriendelijke uitleg en dat je in mijn commissie wilt plaatsnemen!), Ellen Plasschaert (mijn 
Leuvense evenknie), Mie Jef Descheemaeker, Annick Vogels en Marleen Renard.  Een speciale 
vermelding voor de collega’s van CNL Kempenhaeghe die in Oosterhout meehelpen en denken om 
zorg en onderzoek rond NF1 vorm te geven: Sandra van Abeelen (mijn VOLG-maatje), Annick 
Laridon, Alma Weber, Eddy Gaukema, Jos Hendriksen en Katrijn Verdyck.  
Mijn ENCORE-KJPP-collega’s Jeroen, Leontine, Bram, Sabine, Gwen en Pieter. Goed dat we 
elkaar proberen scherp te houden om de psychologische en psychiatrische kant een plek te geven 
binnen het ENCORE-onderzoek.  
Philip Hopman en Katinka Krijgsman, dank voor jullie werk aan de illustraties, de omslag en 
d
d
 Andere co-auteurs, meedenkers en collega’s waarmee ik helaas soms meer digitaal dan in 
levende lijve communiceer: AnneLoes van Staa (leuk dat je aan de commissie wilt deelnemen!),  
Cootje Donkersloot (ja, ook echte ‘clinici’ horen in dit lijstje!), Coriene Catsman, Frank Verhulst 
(zonder dat te weten inspirator van mijn laatste stelling), Jan van de Ende, Lisbeth Utens (wat 
jammer dat je niet kon opponeren, maar wat ﬁjn dat je ook nog bij ons blijft!), Badies Manai 
(mister GCP-himself!), Hanneke IJsselstijn, Hanneke van Helden, Marie-Christine Franken, Femke 
Aarsen, Francis van Veelen, Lianne Krab, Pauline Both, Caspar Loomen, Walter Taal en Yvonne 
Vergouwe. Belangrijke meedenkers waren ook mijn collega promovendi, zoals Luuk Stapersma, 
Raisa Schiller, Mireille Hermans, Annelieke Hijkoop en Chantal  ten Kate.
Ook de Nederlandse patiëntenvereniging voor neurofib o atose (NFVN) h eft een onmisbare 
bijdrage gel v rd aan verschillende proj cten van ENCORE en van di  proefschrift. Het bes uur, 
de leden en de voorzitter Ton Akkermans zijn erg succesvol in het ondersteunen van nieuwe 
initiatieven en het delen van de resultaten met de leden.
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vermelding voor de collega’s van CNL Kempenhaeghe die in Oosterhout meehelpen en denken om 
zorg en onderzoek rond NF1 vorm te geven: Sandra van Abeelen (mijn VOLG-maatje), Annick 
Laridon, Alma Weber, Eddy Gaukema, Jos Hendriksen en Katrijn Verdyck.  
Mijn ENCORE-KJPP-collega’s Jeroen, Leontine, Bram, Sabine, Gwen en Pieter. Goed dat we 
elkaar proberen scherp te houden om de psychologische en psychiatrische kant een plek te geven 
binnen het ENCORE-onderzoek.  
Philip Hopman en Katinka Krijgsman, dank voor jullie werk aan de illustraties, de omslag en 
de vormgeving- jullie hebben me geholpen om dit boek een gezicht te geven.  
Manon Hillegers en Martha Grootenhuis, dank voor jullie deelname in de 
promotiecommissie en voor het werk dat we zowel tijdens als na mijn promotie samen zullen 
doen. 
  
maar ook van/met PhD studenten, Gz-psychologen, schoolpsychologen en basispsychologen vind 
ik een van de leukste kanten van dit werk.  Speciaal dank aan de meeschrijvende studenten en 
collega’s: mijn SPOT-maatje Charlotte Bouman, Sanne Bongers, Dora Csermak, Kimberley van 
Noort, Eline Pols, Jay-Dee Troost, Jessica Smid, Daniela Gawehns, and my dear colleagues abroad: 
Alanna Jacobs and Beth Nicholson.  
Ten slotte zij die mij lief zijn en zijn gebleven, ook al is dat soms niet gemakkelijk (van jullie 
kant, niet van de mijne;). Mijn ouders voor alles wat ze tot hun einde hebben gegeven aan mij, 
mijn lieve (schoon)ouders Hielke en Lidia Ploeg, andere lieve familieleden en vrienden. In het 
bijzonder natuurlijk mijn beide paranimfen Ron Rietman en Jannemieke van Wolferen, ook al 
verschillen jullie nog zo van elkaar, dit is wat jullie bindt: dank voor jullie vriendelijkheid, 
betrokkenheid en alle regelwerk dat jullie zomaar voor mij willen doen. En lest best, de mensen 
die elke dag kleur aan mijn leven geven: mijn beste vriendin, mijn klankbord en grote liefde 
Monique en de mooiste en liefste kinderen van de wereld: Kjeld, Sybe en Ymkje. Ik kan niet in 
woorden zeggen wat het betekent om jullie in mijn leven te hebben.  
 
 
 
Studenten hebben voor mij een flinke plek ingenomen in de afgelopen jaren, ook in het 
denk- en schrijfwerk. Begeleiden van en samenwerken met masterstudenten, research of klinisch, 
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VIII. Curriculum vitae  
André Bernard Rietman was born as the second son of Bernard 
Rietman (1938-2015) and Sophia Geertruida Wilhelmina van der 
Spek (1933-2010) on the 7th of July in 1964 in Warnsveld, the 
Netherlands, where he was raised as well. After primary education 
in Warnsveld and secondary education in Zutphen, he studied at 
the HBO Occupational Therapy in Amsterdam. He got his bachelor 
degree in 1986 and started working as an occupational therapist in 
adult psychiatry, child psychiatry, a private practice, and in child 
rehabilitation. In 1988 he started the department of occupational therapy in Curium, a center for 
child psychiatry in Oegstgeest. During his work as an occupational therapist he started studying 
psychology in the evenings (from 1992) and he obtained his master’s degree (Cum laude) in 1997. 
In that same year, he started working as a psychologist at the ‘Pedologisch Instituut’ (Centre for 
Child studies) in The Hague).  
In 1999 André completed the European graduate school for child neuropsychology at the 
Free University Amsterdam (Cum laude). In 2004 he was registered as a Healthcare psychologist 
(Gz-psycholoog). In 2008, together with pediatric neurologist Liesl Rehbock, he started the 
neurology outpatient clinic of Kinderhaven in Rotterdam. When ENCORE (Expertise Center for 
Neurodevelopmental Disorders, Erasmus Medical Center, Rotterdam) was started in 2010, he 
started working at the Erasmus Medical Centre Sophia Children’s Hospital in Rotterdam, the 
Netherlands. First for the department of pediatric neurology, from 2015 for the department for 
child and adolescent psychiatry/psychology and for the department of surgery (outpatient clinic 
for long-term follow-up of children that had surgery early in life (CHIL)). From 2010, as part of the 
ENCORE-team he started the VOLG program (Vroegtijdige Onderkenning Leer- en 
Gedragsproblemen: early recognition of problems in learning and behavior), first for children with 
Neurofibromatosis type 1 (NF1), Tuberous Sclerosis Complex (TSC), or Angelman syndrome, later 
also for other syndromes within ENCORE. He was the psychologist for various trials examining the 
effect of medication on epilepsy, behavior, and learning of children with NF1 or TSC working 
together with PhD students Thijs van der Vaart, Iris Overwater and Myrthe Ottenhof. He led the 
SPOT-NF1 trial for Social and Psychosocial support for people with NF1 in their Teens or Twenties, 
together with Charlotte Bouman.  
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André did courses and had supervision on sensory processing, neurodevelopmental 
therapy, traumatic brain injury, cognitive behavioral therapy, solution focused therapy, system-
oriented psychotherapy, statistics, biomedical English writing and communication, regulations in 
research (BROK), etc. From 1992 he teaches at several institutions, gives lectures and courses in 
the Netherlands and Belgium, and writes books and papers about various subjects: sensory 
processing, language- and learning disorders, regulation disorders, sensory-motor problems, 
neuropsychology, attention, ADHD, autism, parental guidance, psychopathology, and child 
development. He presented his research in NF1 at several national and international conferences. 
He supervises and supports master students in clinical work and research, starting psychologists, 
Healthcare (Gz-) psychologists and School psychologists in training, and PhD students. 
André is the partner of Monique Ploeg, who is also the mother of their sons Kjeld (1994) 
and Sybe (1997) and their daughter Ymkje (2004). They live in Delft with their cats and rats.  
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Neurofibromatosis type 1 (NF1) is a genetic 
disorder leading to symptoms in the skin, 
the bones, and the nervous system, 
but also to an increased risk of having 
benign and malignant tumors. NF1 leads to 
unpredictable and variable complications 
and a lower quality of life. Cognitive deficits 
and behavioral problems are among 
the most common complications of NF1 
in children. This thesis focuses on the 
behavioral phenotype including the most 
frequent cognitive, behavioral, emotional 
and social problems of NF1.
